

Average Risks of Breast and Ovarian Cancer Associated Detected in Case Series Unselected for Family History: A

American Journal of Human Genetics

72, 1117-1130

DOI: 10.1086/375033

Citation Report

#	ARTICLE	IF	CITATIONS
1	21. Risk-reducing bilateral salpingo-oophorectomy in BRCA mutations career. , 0, , .		0
3	FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell, 2003, 3, 417-420.	16.8	72
4	Ovarian surface epithelium: family history and early events in ovarian cancer. Reproductive Biology and Endocrinology, 2003, 1, 70.	3.3	52
5	Breast and Ovarian Cancer Risks Due to Inherited Mutations in <i>BRCA1</i> and <i>BRCA2</i>. Science, 2003, 302, 643-646.	12.6	2,032
6	Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Research, 2003, 5, R175-86.	5.0	37
7	Long-Term Psychological Impact of Carrying a BRCA1/2 Mutation and Prophylactic Surgery: A 5-Year Follow-Up Study. Journal of Clinical Oncology, 2003, 21, 3867-3874.	1.6	268
8	CANCER: Enhanced: A Risky Business--Assessing Breast Cancer Risk. Science, 2003, 302, 574-575.	12.6	22
9	Re: Gynecologic Surgeries and Risk of Ovarian Cancer in Women with BRCA1 and BRCA2 Ashkenazi Founder Mutations: An Israeli Population-Based Case-Control Study. Journal of the National Cancer Institute, 2003, 95, 1640-1640.	6.3	5
10	The Role of Estrogens in BRCA1/2 Mutation Carriers. Cancer Nursing, 2003, 26, 421-430.	1.5	3
12	BayesMendel: an R Environment for Mendelian Risk Prediction. Statistical Applications in Genetics and Molecular Biology, 2004, 3, 1-19.	0.6	74
13	Cancer Risk Assessment. , 2004, , 127-134.		0
14	The Family History " More Important Than Ever. New England Journal of Medicine, 2004, 351, 2333-2336.	27.0	451
15	Prophylactic Oophorectomy and Hormone Replacement Therapy: Protection at What Price?. Journal of Clinical Oncology, 2004, 22, 978-980.	1.6	19
16	Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk. Journal of Clinical Oncology, 2004, 22, 1315-1327.	1.6	140
18	Breast Cancer Risks for <i>BRCA1/2</i> Carriers. Science, 2004, 306, 2187-2191.	12.6	44
19	Heterozygote excess is repeatedly observed in females at the BRCA2 locus N372H. Journal of Medical Genetics, 2004, 41, 523-528.	3.2	8
20	Intensive radiologic surveillance: a focus on the psychological issues. Annals of Oncology, 2004, 15, i43-i47.	1.2	19
21	Sex Ratio Among the Offspring of BRCA Mutation Carriers. JAMA - Journal of the American Medical Association, 2004, 292, 687-688.	7.4	8

#	ARTICLE	IF	CITATIONS
22	Genetic alterations in hereditary breast cancer. <i>Annals of Oncology</i> , 2004, 15, i7-i13.	1.2	45
23	Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. <i>Clinical Cancer Research</i> , 2004, 10, 2473-2481.	7.0	224
24	BRCA1 functions as a breast stem cell regulator. <i>Journal of Medical Genetics</i> , 2004, 41, 1-5.	3.2	146
25	Aggregation of Ovarian Cancer with Breast, Ovarian, Colorectal, and Prostate Cancer in First-degree Relatives. <i>American Journal of Epidemiology</i> , 2004, 159, 750-758.	3.4	27
26	Breast MRI for Women With Hereditary Cancer Risk. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 1368.	7.4	45
27	Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. <i>Annals of Oncology</i> , 2004, 15, 1834-1841.	1.2	60
28	Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. <i>British Journal of Cancer</i> , 2004, 91, 1911-1915.	6.4	138
29	GENETIC TESTING IN PRIMARY CARE. <i>Annual Review of Genomics and Human Genetics</i> , 2004, 5, 1-14.	6.2	64
30	Haplotype and cancer risk analysis of two common mutations, BRCA1 4184del4 and BRCA2 2157delG, in high risk northwest England breast/ovarian families. <i>Journal of Medical Genetics</i> , 2004, 41, 21e-21.	3.2	17
31	Common risk factors of breast and ovarian cancer: recent view. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 721-740.	2.5	50
32	Tracing the network connecting brca and fanconi anaemia proteins. <i>Nature Reviews Cancer</i> , 2004, 4, 266-276.	28.4	195
33	BRCA1 and BRCA2: 1994 and beyond. <i>Nature Reviews Cancer</i> , 2004, 4, 665-676.	28.4	824
34	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. <i>European Journal of Human Genetics</i> , 2004, 12, 899-906.	2.8	55
35	CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. <i>Oncogene</i> , 2004, 23, 1474-1480.	5.9	61
36	Highly penetrant hereditary cancer syndromes. <i>Oncogene</i> , 2004, 23, 6445-6470.	5.9	302
37	The BOADICEA model of genetic susceptibility to breast and ovarian cancer. <i>British Journal of Cancer</i> , 2004, 91, 1580-1590.	6.4	411
38	BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. <i>British Journal of Cancer</i> , 2004, 91, 1829-1834.	6.4	43
39	Genetic testing for breast and ovarian cancer susceptibility: a family experience. <i>Journal of Midwifery and Women's Health</i> , 2004, 49, 210-219.	1.3	17

#	ARTICLE	IF	CITATIONS
40	Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2004, 94, 796-802.	1.4	11
41	Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance. <i>Annals of Surgical Oncology</i> , 2004, 11, 1030-1034.	1.5	78
42	Short- and Long-Term Impact of Receiving Genetic Mutation Results in Women at Increased Risk for Hereditary Breast Cancer. <i>Journal of Genetic Counseling</i> , 2004, 13, 115-133.	1.6	49
43	The Genetic Epidemiology of Breast Cancer Genes. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2004, 9, 221-236.	2.7	210
44	Familial breast and ovarian cancers. <i>International Journal of Clinical Oncology</i> , 2004, 9, 270-282.	2.2	27
45	Hereditary breast cancer in Jews. <i>Familial Cancer</i> , 2004, 3, 249-257.	1.9	57
46	Hereditary ovarian cancer in Ashkenazi Jews. <i>Familial Cancer</i> , 2004, 3, 259-264.	1.9	36
47	Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. <i>Familial Cancer</i> , 2004, 3, 265-281.	1.9	35
48	Breast cancer genetics: Unsolved questions and open perspectives in an expanding clinical practice. <i>American Journal of Medical Genetics Part A</i> , 2004, 129C, 56-64.	2.4	13
49	Estimating penetrance from family data using a retrospective likelihood when ascertainment depends on genotype and age of onset. <i>Genetic Epidemiology</i> , 2004, 27, 109-117.	1.3	35
50	Prevention of breast cancer in women who carry <i>BRCA1</i> or <i>BRCA2</i> mutations: A critical review of the literature. <i>International Journal of Cancer</i> , 2004, 112, 357-364.	5.1	98
51	Variants of Uncertain Clinical Significance as a Result of BRCA1/2 Testing: Impact of an Ambiguous Breast Cancer Risk Message. <i>Genetic Testing and Molecular Biomarkers</i> , 2004, 8, 235-239.	1.7	42
52	Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With <i>BRCA1/2</i> Mutations: A Decision Analysis. <i>Journal of Clinical Oncology</i> , 2004, 22, 1045-1054.	1.6	150
53	BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. <i>Annals of Oncology</i> , 2004, 15, 1373-1376.	1.2	33
54	Progress and Challenges in Screening for Early Detection of Ovarian Cancer. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 355-366.	3.8	375
55	Prédispositions familiales aux cancers du sein. <i>Imagerie De La Femme</i> , 2004, 14, 141-144.	0.0	0
56	Relative frequency and morphology of cancers in STK11 mutation carriers. <i>Gastroenterology</i> , 2004, 126, 1788-1794.	1.3	228
57	Mechanisms of breast cancer. <i>Drug Discovery Today Disease Mechanisms</i> , 2004, 1, 235-245.	0.8	14

#	ARTICLE	IF	CITATIONS
58	Breast Cancer Surveillance in Women with Hereditary Risk Due to BRCA1 or BRCA2 Mutations. <i>Clinical Breast Cancer</i> , 2004, 5, 260-268.	2.4	27
59	Impact of Genetic Testing for Breast and Ovarian Cancer Susceptibility. <i>Genetic Testing and Molecular Biomarkers</i> , 2004, 8, 1-12.	1.7	28
60	Cancer genetics in primary care. <i>Primary Care - Clinics in Office Practice</i> , 2004, 31, 649-683.	1.6	8
61	BRCA mutations and pathology in the female genital tract. <i>Current Diagnostic Pathology</i> , 2004, 10, 326-335.	0.4	3
62	Epidemiology of breast cancer among BRCA mutation carriers: an overview. <i>Cancer Letters</i> , 2004, 205, 1-8.	7.2	35
63	One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations. <i>European Journal of Cancer</i> , 2004, 40, 422-428.	2.8	85
64	Psychological distress in women at increased risk for breast cancer: the role of risk perception. <i>European Journal of Cancer</i> , 2004, 40, 2056-2063.	2.8	56
65	BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. <i>European Journal of Cancer</i> , 2004, 40, 2788-2793.	2.8	50
66	E18. Management of high-risk women; assessing the risk. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 38-39.	2.2	0
67	Integrated Evaluation of DNA Sequence Variants of Unknown Clinical Significance: Application to BRCA1 and BRCA2. <i>American Journal of Human Genetics</i> , 2004, 75, 535-544.	6.2	351
68	Clinical Validity and Clinical Utility of Genetic Tests. <i>Current Protocols in Human Genetics</i> , 2004, 42, Unit9.15.	3.5	1
69	BRCA1/2 Mutation Carriers. <i>Journal of Psychosocial Oncology</i> , 2004, 22, 93-106.	1.2	15
70	The dawn of genetic testing for glaucoma. <i>Current Opinion in Ophthalmology</i> , 2004, 15, 75-79.	2.9	9
71	The family history of cancer – a common concern in palliative care. <i>Progress in Palliative Care</i> , 2004, 12, 59-66.	1.2	9
72	Towards Evidence-Based Management of Inherited Breast and Breast-Ovarian Cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2004, 2, 11.	1.5	1
73	A Counselling Model for BRCA1/2 Genetic Susceptibility Testing. <i>Hereditary Cancer in Clinical Practice</i> , 2004, 2, 19.	1.5	16
74	Contribution of the Defective BRCA1, BRCA2 and CHEK2 Genes to the Familial Aggregation of Breast Cancer: a Simulation Study Based on the Swedish Family-Cancer Database. <i>Hereditary Cancer in Clinical Practice</i> , 2004, 2, 185.	1.5	8
75	Cost-effectiveness of predictive genetic tests for familial breast and ovarian cancer. <i>Genomics Society and Policy</i> , 2005, 1, 1.	0.2	6

#	ARTICLE	IF	CITATIONS
76	Effect of Prior Bilateral Oophorectomy on the Presentation of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>Hereditary Cancer in Clinical Practice</i> , 2005, 3, 53.	1.5	2
77	Clinical, Molecular and Geographical Features of Hereditary Breast/Ovarian Cancer in Latvia. <i>Hereditary Cancer in Clinical Practice</i> , 2005, 3, 71-6.	1.5	9
78	Hereditary Breast-Ovarian Cancer Team of the University Medical Centre Groningen (UMCG) - a Report. <i>Hereditary Cancer in Clinical Practice</i> , 2005, 3, 179-80.	1.5	0
79	What's the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. <i>Genetics in Medicine</i> , 2005, 7, 239-245.	2.4	55
80	5 Role of BRCA1/BRCA2 in Ovarian, Fallopian Tube, and Peritoneal Papillary Serous Carcinoma. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, , 347-356.	0.0	0
81	Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: Public health implications. <i>Genetics in Medicine</i> , 2005, 7, 28-33.	2.4	70
82	Polygenic Inherited Predisposition to Breast Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 35-41.	1.1	27
83	Endometrial Cancer With Concurrent Ovarian Malignancy: Assessing the Risks. <i>Obstetrics and Gynecology</i> , 2005, 106, 680-681.	2.4	3
84	Genetic Risk Assessment and <i>BRCA</i> Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2005, 143, 362.	3.9	314
85	Genetic Risk Assessment and <i>BRCA</i> Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement. <i>Annals of Internal Medicine</i> , 2005, 143, 355.	3.9	383
86	Cowden Syndrome: A Rare, but Recognisable Cancer Predisposition Disorder. <i>Clinical Oncology</i> , 2005, 17, 393.	1.4	2
87	Epithelial Ovarian Cancer: A Review of Current Management. <i>Clinical Oncology</i> , 2005, 17, 399-411.	1.4	83
88	The role of prophylactic salpingo-oophorectomy in women who carry mutations of the BRCA genes. <i>The Obstetrician and Gynaecologist</i> , 2005, 7, 23-27.	0.4	4
89	Psychological functioning in African American women at an increased risk of hereditary breast and ovarian cancer. <i>Clinical Genetics</i> , 2005, 68, 222-227.	2.0	23
90	Reply: Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian Cancer Research UK. <i>British Journal of Cancer</i> , 2005, 92, 1337-1338.	6.4	1
91	Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian cancer. <i>British Journal of Cancer</i> , 2005, 92, 1336-1337.	6.4	0
92	Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2005, 93, 287-292.	6.4	307
93	Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. <i>Oncogene</i> , 2005, 24, 8343-8348.	5.9	79

#	ARTICLE	IF	CITATIONS
94	Nursing Leadership in Genomics for Health and Society. Journal of Nursing Scholarship, 2005, 37, 102-110.	2.4	28
95	MRI Screening for Breast Cancer in Women with a Familial or Genetic Predisposition. Imaging Decisions (Berlin, Germany), 2005, 9, 11-18.	0.2	5
96	BRCA1 Genetic Mutation and Its Link to Ovarian Cancer: Implications for Advanced Practice Nurses. Journal of the American Academy of Nurse Practitioners, 2005, 17, 518-526.	1.4	6
97	Management of women at high risk for breast cancer: New imaging beyond mammography. Breast, 2005, 14, 480-486.	2.2	42
98	Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?. Gynecologic Oncology, 2005, 96, 439-443.	1.4	13
99	Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecologic Oncology, 2005, 97, 457-467.	1.4	95
100	Adult granulosa cell tumors of the ovary in two first-degree relatives. Gynecologic Oncology, 2005, 98, 502-505.	1.4	7
101	Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: Results from a prospective population-based study in France. Genes Chromosomes and Cancer, 2005, 43, 404-413.	2.8	39
102	A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genetic Epidemiology, 2005, 29, 1-11.	1.3	136
103	Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers. Human Mutation, 2005, 26, 583-589.	2.5	20
104	Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. International Journal of Cancer, 2005, 117, 230-233.	5.1	27
105	Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. International Journal of Cancer, 2005, 117, 988-991.	5.1	152
106	Ovarian carcinoma screening in women at intermediate risk. Cancer, 2005, 104, 314-320.	4.1	23
107	Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?. Cancer, 2005, 104, 1567-1574.	4.1	36
108	Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer, 2005, 104, 1849-1853.	4.1	18
109	The impact of receiving genetic test results on general and cancer-specific psychologic distress among members of an African-American kindred with a BRCA1 mutation. Cancer, 2005, 104, 2508-2516.	4.1	37
110	Genetic Testing and the Family. Journal of Midwifery and Women's Health, 2005, 50, 227-233.	1.3	31
111	Oligogenic combinations associated with breast cancer risk in women under 53½ years of age. Human Genetics, 2005, 116, 208-221.	3.8	44

#	ARTICLE	IF	CITATIONS
113	Predictive Genetic Testing for Hereditary Breast and Ovarian Cancer: Psychological Distress and Illness Representations 1 Year Following Disclosure. <i>Journal of Genetic Counseling</i> , 2005, 14, 349-363.	1.6	63
114	A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. <i>Familial Cancer</i> , 2005, 4, 89-96.	1.9	23
115	The "portrait" of hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 297-304.	2.5	48
116	High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 111-113.	2.5	21
117	Brief Report: Towards a dietary prevention of hereditary breast cancer. <i>Cancer Causes and Control</i> , 2005, 16, 125-138.	1.8	37
118	Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer. <i>Journal of Pathology</i> , 2005, 206, 220-223.	4.5	32
120	Should we use MRI to screen women at high-risk of breast cancer?. <i>Cancer Imaging</i> , 2005, 5, 32-38.	2.8	3
121	Clinical Implications of the Breast Cancer Susceptibility Genes BRCA1 and BRCA2. <i>Women's Health</i> , 2005, 1, 27-34.	1.5	0
123	Breast Cancer Prevention. , 2005, , 255-276.		5
124	Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation-Negative Hereditary Breast Cancer Families. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1382-1384.	6.3	80
125	Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6890-6898.	1.6	214
126	Surgical Prevention of Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 324-332.	1.6	16
127	Non-random transmission of mutant alleles to female offspring in BRCA carriers. <i>Journal of Medical Genetics</i> , 2005, 42, e6-e6.	3.2	5
128	Enhanced Counseling for Women Undergoing BRCA1/2 Testing: Impact on Subsequent Decision Making About Risk Reduction Behaviors. <i>Health Education and Behavior</i> , 2005, 32, 654-667.	2.5	47
129	Prevention and Management of Hereditary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1656-1663.	1.6	152
130	Reproductive Issues for Women With BRCA Mutations. <i>Journal of the National Cancer Institute Monographs</i> , 2005, 2005, 83-86.	2.1	47
131	Cancer Prevention: The Importance of Accurate Risk Assessment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1357-1358.	2.5	1
132	Prevalence of <EMPH TYPE="ITAL">BRCA1</EMPH> and <EMPH TYPE="ITAL">BRCA2</EMPH> Mutations in Women Diagnosed With Ductal Carcinoma In Situ. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 964.	7.4	94

#	ARTICLE	IF	CITATIONS
133	BRCA Patients and Clinical Collectives. <i>Social Studies of Science</i> , 2005, 35, 41-68.	2.5	72
135	Clinical implications of the breast cancer susceptibility genes BRCA1 and BRCA2. <i>Women's Health</i> , 2005, 1, 27-34.	1.5	4
136	BRCA1 and BRCA2 as ovarian cancer susceptibility genes. <i>Carcinogenesis</i> , 2005, 26, 1651-1656.	2.8	72
137	Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. <i>British Journal of Cancer</i> , 2005, 92, 857-866.	6.4	35
138	Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application. <i>Journal of the National Cancer Institute</i> , 2005, 97, 715-723.	6.3	228
139	Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 350-356.	2.5	133
140	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. <i>Journal of Medical Genetics</i> , 2005, 42, 602-603.	3.2	121
141	Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. <i>Journal of Medical Genetics</i> , 2005, 43, 424-428.	3.2	19
142	Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2005, 23, 8629-8635.	1.6	138
143	Breast Cancer Risk Following Bilateral Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: An International Case-Control Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 7491-7496.	1.6	408
144	Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1507-1515.	6.3	200
145	Quality or Quantity in the Management of Hereditary Ovarian Cancer Risk: Is It Really a Trade-Off?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6817-6819.	1.6	1
146	Realizing the Promise of Genomics in Biomedical Research. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1399.	7.4	127
147	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. <i>Journal of Medical Genetics</i> , 2005, 42, 711-719.	3.2	360
148	A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations. <i>Annals of Oncology</i> , 2005, 16, 322-329.	1.2	10
149	Ductal Lavage of Fluid-Yielding and Non-Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1082-1089.	2.5	27
150	Population-based family studies in genetic epidemiology. <i>Lancet, The</i> , 2005, 366, 1397-1406.	13.7	148
151	Genetic epidemiology and public health: hope, hype, and future prospects. <i>Lancet, The</i> , 2005, 366, 1484-1498.	13.7	279

#	ARTICLE	IF	CITATIONS
152	Mammographic breast density as an intermediate phenotype for breast cancer. <i>Lancet Oncology</i> , The, 2005, 6, 798-808.	10.7	548
153	Breast Cancer and Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2005, 32, 547-558.	1.9	17
154	Mammography, Breast Ultrasound, and Magnetic Resonance Imaging for Surveillance of Women at High Familial Risk for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8469-8476.	1.6	997
155	Genetic Testing for Inherited Breast Cancer Risk in African Americans. <i>Cancer Investigation</i> , 2005, 23, 285-295.	1.3	51
156	Benign Breast Disorders. <i>New England Journal of Medicine</i> , 2005, 353, 275-285.	27.0	268
157	BRCA1 in hormonal carcinogenesis: basic and clinical research. <i>Endocrine-Related Cancer</i> , 2005, 12, 533-548.	3.1	79
158	Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. <i>Journal of Medical Genetics</i> , 2005, 43, 295-305.	3.2	583
159	BRCA2: breaks, mistakes and failed separations. <i>Trends in Molecular Medicine</i> , 2005, 11, 145-148.	6.7	20
161	Early detection of breast and ovarian cancer in families with BRCA mutations. <i>European Journal of Cancer</i> , 2005, 41, 549-554.	2.8	63
162	Hereditary breast cancer growth rates and its impact on screening policy. <i>European Journal of Cancer</i> , 2005, 41, 1610-1617.	2.8	74
163	Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. <i>European Journal of Cancer</i> , 2005, 41, 2312-2320.	2.8	57
164	Chemoprevention: From research to clinical oncology. <i>European Journal of Cancer</i> , 2005, 41, 1833-1841.	2.8	7
165	Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. <i>European Journal of Surgical Oncology</i> , 2005, 31, 1112-1118.	1.0	41
166	High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: Implications for breast and ovarian cancer risk. <i>Molecular Genetics and Metabolism</i> , 2005, 86, 320-327.	1.1	9
168	Breast cancer: The challenges facing surgeons in the next two decades. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2005, 3, 206-209.	1.8	0
169	247 Minority Recruitment in Hereditary Breast Cancer Research. <i>Breast Diseases</i> , 2005, 16, 204.	0.0	18
170	Hereditary Cancer Predisposition Syndromes. <i>Journal of Clinical Oncology</i> , 2005, 23, 276-292.	1.6	534
171	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. <i>Breast Cancer Research</i> , 2005, 8, R3.	5.0	75

#	ARTICLE	IF	CITATIONS
172	Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation. Breast Cancer Research, 2005, 7, R1122-31.	5.0	23
173	Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2005, 7, R833-43.	5.0	103
174	CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Research, 2005, 7, R513-21.	5.0	24
175	Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Research, 2005, 7, R465-9.	5.0	57
176	The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2005, 7, R176.	5.0	45
177	Breast cancer susceptibility testing: past, present and future. Expert Review of Anticancer Therapy, 2006, 6, 1205-1214.	2.4	39
178	Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2006, 8, R72.	5.0	66
179	Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Research, 2006, 8, R15.	5.0	44
180	Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncology, The, 2006, 7, 223-229.	10.7	333
181	Risk factors and epidemiology of breast cancer. Women's Health Medicine, 2006, 3, 8-14.	0.0	27
182	MR Imaging for Surveillance of Women at High Familial Risk for Breast Cancer. Magnetic Resonance Imaging Clinics of North America, 2006, 14, 391-402.	1.1	23
183	Plaidoyer pour une utilisation raisonnée de l'IRM dans le dépistage du cancer du sein. Imagerie De La Femme, 2006, 16, 229-231.	0.0	0
185	Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. European Journal of Cancer, 2006, 42, 621-628.	2.8	43
186	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. European Journal of Cancer, 2006, 42, 1143-1150.	2.8	139
187	Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 and epithelial ovarian cancers. European Journal of Cancer, 2006, 42, 1475-1483.	2.8	28
188	Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. European Journal of Cancer, 2006, 42, 2722-2728.	2.8	38
189	Gynaecological oncology perspective on management of the menopause. European Journal of Surgical Oncology, 2006, 32, 892-897.	1.0	16
190	Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Molecular and Cellular Endocrinology, 2006, 247, 4-21.	3.2	162

#	ARTICLE	IF	CITATIONS
192	Hereditary Breast and Ovarian Cancer – Current Clinical Guidelines in Germany. Breast Care, 2006, 1, 8-14.	1.4	1
193	Ethical Obligations and Counseling Challenges in Cancer Genetics. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 185-191.	4.9	9
194	Prophylaxis and Screening Options: Recommendations for Young Women with BRCA Mutations. Breast Disease, 2006, 23, 31-35.	0.8	15
195	Familial Breast Cancer – What are the Choices, What Are the Questions?. Breast Care, 2006, 1, 6-7.	1.4	1
196	MRI in the Early Detection of Breast Cancer in Women with High Genetic Risk. Tumori, 2006, 92, 517-523.	1.1	37
197	Age and Geographical Distribution in Families with BRCA1/BRCA2 Mutations in the Slovak Republic. Hereditary Cancer in Clinical Practice, 2006, 4, 7-11.	1.5	2
198	Low rates of acceptance of BRCA1 and BRCA2 test results among African American women at increased risk for hereditary breast-ovarian cancer. Genetics in Medicine, 2006, 8, 576-582.	2.4	68
199	Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions. American Journal of Surgical Pathology, 2006, 30, 1222-1230.	3.7	130
200	Satisfaction with Prophylactic Mastectomy and Breast Reconstruction in Genetically Predisposed Women. Plastic and Reconstructive Surgery, 2006, 117, 1675-1682.	1.4	103
201	BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1863-1870.	2.5	115
202	Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers. European Journal of Cancer Prevention, 2006, 15, 474-479.	1.3	7
203	Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer. European Journal of Cancer Prevention, 2006, 15, 483-489.	1.3	42
204	Ashkenazi Jews and Breast Cancer: The Consequences of Linking Ethnic Identity to Genetic Disease. American Journal of Public Health, 2006, 96, 1979-1988.	2.7	19
205	Magnetic Resonance Imaging of Adnexal Masses. Topics in Magnetic Resonance Imaging, 2006, 17, 379-397.	1.2	19
206	Differences in IGFBP-3 regulation between young healthy women from BRCA families and those belonging to BRCA1/2 families. European Journal of Cancer Prevention, 2006, 15, 233-241.	1.3	7
207	Risk communication in completed series of breast cancer genetic counseling visits. Genetics in Medicine, 2006, 8, 688-696.	2.4	21
208	Fertility Sparing Options for Breast Cancer Patients. Breast Disease, 2006, 23, 73-80.	0.8	6
209	Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Medical Genetics, 2006, 7, 75.	2.1	72

#	ARTICLE	IF	CITATIONS
210	Evaluation of the needs and concerns of partners of women at high risk of developing breast/ovarian cancer. <i>Psycho-Oncology</i> , 2006, 15, 96-108.	2.3	26
211	Tests de pr��disposition g��n��tique aux cancers du sein. <i>Revue Francophone Des Laboratoires</i> , 2006, 6-11.	0.0	0
212	Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 183-188.	2.5	28
213	Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 54-59.	2.5	53
214	Screening for familial ovarian cancer-management and outcome of women with moderate to high risk of developing ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 86-91.	2.5	1
215	Genetics as a tool to improve cancer outcomes: ethics and policy. <i>Nature Reviews Cancer</i> , 2006, 6, 476-482.	28.4	20
216	Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. <i>European Journal of Human Genetics</i> , 2006, 14, 49-54.	2.8	16
217	Modifiers of risk of hereditary breast cancer. <i>Oncogene</i> , 2006, 25, 5832-5836.	5.9	102
218	Basal-like breast cancer and the BRCA1 phenotype. <i>Oncogene</i> , 2006, 25, 5846-5853.	5.9	414
219	Models of genetic susceptibility to breast cancer. <i>Oncogene</i> , 2006, 25, 5898-5905.	5.9	246
220	Clinical management of BRCA1 and BRCA2 mutation carriers. <i>Oncogene</i> , 2006, 25, 5825-5831.	5.9	79
221	BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 1-23.	4.4	54
222	Satisfaction with genetic counseling for BRCA1 and BRCA2 mutations among African American women. <i>Patient Education and Counseling</i> , 2006, 63, 196-204.	2.2	53
223	Genetic mutations in gynaecological cancers. <i>Reviews in Gynaecological and Perinatal Practice</i> , 2006, 6, 115-125.	0.3	4
224	Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2006, 85, 93-105.	2.8	45
225	Partnering in Oncogenetic Research â�� The INHERIT BRCAs Experience: Opportunities and Challenges. <i>Familial Cancer</i> , 2006, 5, 3-13.	1.9	12
226	Screening behavior in women at increased familial risk for breast cancer. <i>Familial Cancer</i> , 2006, 5, 359-368.	1.9	38
227	Risk Reduction Behaviors and Provider Communication Following Genetic Counseling and BRCA1 Mutation Testing in an African American Kindred. <i>Journal of Genetic Counseling</i> , 2006, 15, 293-305.	1.6	43

#	ARTICLE	IF	CITATIONS
228	491-503.	1.6	18
229	A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. Breast Cancer Research and Treatment, 2006, 96, 97-100.	2.5	8
230	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Research and Treatment, 2006, 95, 105-109.	2.5	82
231	Premature Menopause in Patients with BRCA1 Gene Mutation. Breast Cancer Research and Treatment, 2006, 100, 59-63.	2.5	98
232	Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Breast Cancer Research and Treatment, 2006, 100, 83-91.	2.5	21
236	A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Education and Counseling, 2006, 62, 13-20.	2.2	94
237	Update on hereditary breast cancer. Current Oncology Reports, 2006, 8, 14-21.	4.0	8
238	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecologic Oncology, 2006, 100, 58-64.	1.4	349
239	Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecologic Oncology, 2006, 100, 83-88.	1.4	43
240	CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecologic Oncology, 2006, 100, 20-26.	1.4	170
241	Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy. Gynecologic Oncology, 2006, 100, 1-2.	1.4	13
242	Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study. Gynecologic Oncology, 2006, 103, 1077-1082.	1.4	53
243	Twenty-three novel BRCA1 and BRCA2 sequence variations identified in a cohort of Swiss breast and ovarian cancer families. Cancer Genetics and Cytogenetics, 2006, 169, 62-68.	1.0	9
244	Prevention of ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 339-362.	2.8	42
245	Familial ovarian cancer screening. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2006, 20, 321-338.	2.8	16
246	Chemoprevention of Breast Cancer for Women at High Risk. Seminars in Oncology, 2006, 33, 642-646.	2.2	23
247	A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 2006, 45, 646-655.	2.8	111
248	Characterization of the breast cancer associated ATM7271T>G (V2424G) mutation by gene expression profiling. Genes Chromosomes and Cancer, 2006, 45, 1169-1181.	2.8	17

#	ARTICLE	IF	CITATIONS
249	Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. <i>Cancer</i> , 2006, 107, 1769-1776.	4.1	80
250	Association between clinical characteristics and risk-reduction interventions in women who underwent <i>BRCA1</i> and <i>BRCA2</i> testing. <i>Cancer</i> , 2006, 107, 2745-2751.	4.1	61
251	A haplotype containing the <i>p53</i> polymorphisms Ins16bp and Arg72Pro modifies cancer risk in <i>BRCA2</i> mutation carriers. <i>Human Mutation</i> , 2006, 27, 242-248.	2.5	35
252	Population-based estimates of breast cancer risks associated with <i>ATM</i> gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. <i>Human Mutation</i> , 2006, 27, 1122-1128.	2.5	88
253	Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. <i>International Journal of Cancer</i> , 2006, 119, 1412-1418.	5.1	33
254	Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With <i>BRCA</i> Mutations. <i>Obstetrics and Gynecology</i> , 2006, 108, 515-520.	2.4	55
255	On the difference of micronucleus frequencies in peripheral blood lymphocytes between breast cancer patients and controls. <i>Mutagenesis</i> , 2006, 21, 313-320.	2.6	53
256	Current breast cancer risks of hormone replacement therapy in postmenopausal women. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2455-2463.	1.8	13
258	Optimal Selection of Individuals for <i>BRCA</i> Mutation Testing. <i>Journal of Clinical Oncology</i> , 2006, 24, 3311-3311.	1.6	4
259	<i>BRCA1</i> and <i>BRCA2</i> genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. <i>Annals of Oncology</i> , 2006, 17, vii34-vii40.	1.2	31
260	Population-Based Study of Changing Breast Cancer Risk in Icelandic <i>BRCA2</i> Mutation Carriers, 1920-2000. <i>Journal of the National Cancer Institute</i> , 2006, 98, 116-122.	6.3	108
261	Screening in women's health, with emphasis on fetal Down's syndrome, breast cancer and osteoporosis. <i>Human Reproduction Update</i> , 2006, 12, 499-512.	10.8	10
262	Breast Cancer Screening, Outside the Population-Screening Program, of Women from Breast Cancer Families without Proven <i>BRCA1/BRCA2</i> Mutations: a Simulation Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 429-436.	2.5	11
263	Effect of Mammography on Breast Cancer Risk in Women with Mutations in <i>BRCA1</i> or <i>BRCA2</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2311-2313.	2.5	60
264	Application of a Polygenic Model of Breast and Ovarian Cancer to Critical Illness Insurance. <i>Annals of Actuarial Science</i> , 2006, 1, 319-343.	1.5	5
265	Hormonosensibilit� des cancers ovariens �pith�liaux. , 2006, , 57-70.		1
266	The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 76-79.	2.5	26
267	Pr�dispositions g�n�tiques aux cancers de l�ovaire. , 2006, , 31-44.		1

#	ARTICLE	IF	CITATIONS
268	Common Genetic Variants for Breast Cancer: 32 Largely Refuted Candidates and Larger Prospects. Journal of the National Cancer Institute, 2006, 98, 1350-1353.	6.3	37
269	BRCA1 and BRCA2 Cancer Risks. Journal of Clinical Oncology, 2006, 24, 3312-3313.	1.6	26
270	Loss of Heterozygosity Analysis in Ductal Lavage Samples from BRCA1 and BRCA2 Carriers: A Cautionary Tale. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1396-1398.	2.5	5
271	Genetic and Histopathologic Evaluation of BRCA1 and BRCA2 DNA Sequence Variants of Unknown Clinical Significance. Cancer Research, 2006, 66, 2019-2027.	0.9	153
272	Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Research, 2006, 66, 1866-1872.	0.9	119
273	Commentary: Grading the credibility of molecular evidence for complex diseases. International Journal of Epidemiology, 2006, 35, 572-578.	1.9	61
274	Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample. Journal of Clinical Oncology, 2006, 24, 863-871.	1.6	298
275	Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA - Journal of the American Medical Association, 2006, 295, 2374.	7.4	240
276	Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 359-363.	2.5	37
277	Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation. JAMA - Journal of the American Medical Association, 2006, 296, 185.	7.4	544
278	Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. Journal of Clinical Oncology, 2006, 24, 3361-3366.	1.6	188
279	Genetic Testing for Hereditary Breast and Ovarian Cancer: Responsibility and Choice. Qualitative Health Research, 2006, 16, 97-118.	2.1	67
280	Pregnancies, Breast-Feeding, and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). Journal of the National Cancer Institute, 2006, 98, 535-544.	6.3	191
281	Screening for ovarian cancer: progress and challenges. Journal of Family Planning and Reproductive Health Care, 2006, 32, 173-175.	0.8	0
282	Improving Outcomes in Bilateral Breast Reconstruction Using Autogenous Tissue. Annals of Plastic Surgery, 2006, 56, 487-491.	0.9	34
283	The Genetics of Breast and Ovarian Cancer III: A new model of family history with insurance applications. Scandinavian Actuarial Journal, 2006, 2006, 338-367.	1.7	5
284	Risk perceptions, worry, and attitudes about genetic testing for breast cancer susceptibility. Psychology and Health, 2006, 21, 211-230.	2.2	77
286	Risk prediction models for familial breast cancer. Future Oncology, 2006, 2, 257-274.	2.4	78

#	ARTICLE	IF	CITATIONS
287	Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert Review of Molecular Diagnostics, 2006, 6, 627-637.	3.1	8
288	Surveillance of women at high risk for hereditary ovarian cancer is inefficient. British Journal of Cancer, 2006, 94, 814-819.	6.4	90
289	Evaluation of models to predict BRCA germline mutations. British Journal of Cancer, 2006, 95, 914-920.	6.4	60
290	Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening?. British Journal of Cancer, 2006, 95, 1126-1127.	6.4	1
291	Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of "easy to apply" probability models. British Journal of Cancer, 2006, 95, 757-762.	6.4	13
292	Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kinâ€œCohort Study in Ontario, Canada. Journal of the National Cancer Institute, 2006, 98, 1694-1706.	6.3	571
293	Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years. Cancer Research, 2006, 66, 8297-8308.	0.9	317
294	BRCA Mutation Frequency and Penetrance: New Data, Old Debate. Journal of the National Cancer Institute, 2006, 98, 1675-1677.	6.3	39
295	Optimal Selection of Individuals for BRCA Mutation Testing: A Comparison of Available Methods. Journal of Clinical Oncology, 2006, 24, 707-715.	1.6	112
296	MRI for breast cancer screening. Annals of Oncology, 2006, 17, x325-x331.	1.2	7
297	Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3770-3774.	7.1	81
298	Risk of Colorectal Cancer in Monoallelic and Biallelic Carriers of MYH Mutations: A Population-Based Case-Family Study. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 312-314.	2.5	172
299	Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. Journal of Medical Genetics, 2006, 44, 107-121.	3.2	72
300	X Inactiveâ€œSpecific Transcript RNA Coating and Genetic Instability of the X Chromosome in BRCA1 Breast Tumors. Cancer Research, 2007, 67, 5134-5140.	0.9	95
301	Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. Genetics in Medicine, 2007, 9, 173-179.	2.4	17
302	Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nature Clinical Practice Oncology, 2007, 4, 578-590.	4.3	113
303	No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. British Journal of Cancer, 2007, 96, 1335-1342.	6.4	134
304	Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. British Journal of Cancer, 2007, 96, 296-305.	6.4	107

#	ARTICLE	IF	CITATIONS
305	Cancer risks among BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2007, 96, 11-15.	6.4	296
306	Predicting the Performance of a Genetic Testing Service for Cancer Susceptibility. Genetic Testing and Molecular Biomarkers, 2007, 11, 381-386.	1.7	1
307	BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials. Clinical Cancer Research, 2007, 13, 7357-7362.	7.0	97
308	Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Human Reproduction, 2007, 22, 1573-1577.	0.9	118
309	Familial Effects of BRCA1 Genetic Mutation Testing: Changes in Perceived Family Functioning. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 135-141.	2.5	19
310	Assessing Environmental Modifiers of Disease Risk Associated with Rare Mutations. Human Heredity, 2007, 63, 134-143.	0.8	8
311	Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2587.	7.4	164
312	Current Status of Breast MR Imaging Part 2. Clinical Applications. Radiology, 2007, 244, 672-691.	7.3	367
313	Breast Cancers Detected with Imaging Screening in the BRCA Population: Emphasis on MR Imaging with Histopathologic Correlation. Radiographics, 2007, 27, S165-S182.	3.3	19
314	Mammography screening and genetic disposition to radiation risk. British Journal of Radiology, 2007, 80, 591-592.	2.2	3
315	The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 270-275.	2.5	59
316	Factors Associated with an Individual's Decision to Withdraw from Genetic Testing for Breast And Ovarian Cancer Susceptibility: Implications for Counseling. Genetic Testing and Molecular Biomarkers, 2007, 11, 45-54.	1.7	48
317	A Mutation in the 5' Untranslated Region of the BRCA1 Gene in Sporadic Breast Cancer Causes Downregulation of Translation Efficiency. Journal of International Medical Research, 2007, 35, 564-573.	1.0	16
318	Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in <i>BRCA1</i> or <i>BRCA2</i> . Journal of Clinical Oncology, 2007, 25, 2921-2927.	1.6	126
319	Prophylactic mastectomy: ethical issues. British Medical Bulletin, 2007, 81-82, 7-19.	6.9	19
320	BRCA1 Regulates IFN- γ Signaling through a Mechanism Involving the Type I IFNs. Molecular Cancer Research, 2007, 5, 261-270.	3.4	44
321	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 740-746.	2.5	63
322	Oral Contraceptives and Breast Cancer Risk in the International <i>BRCA1/2</i> Carrier Cohort Study: A Report From EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. Journal of Clinical Oncology, 2007, 25, 3831-3836.	1.6	137

#	ARTICLE	IF	CITATIONS
324	Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups. JAMA - Journal of the American Medical Association, 2007, 298, 2869.	7.4	280
325	Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer. Clinical Cancer Research, 2007, 13, 7305-7313.	7.0	31
326	LOC387715/HTRA1 and Complement Factor H Variants in Patients with Age-Related Macular Degeneration Seen at the Mayo Clinic. Ophthalmic Genetics, 2007, 28, 203-207.	1.2	16
327	Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers. Journal of Clinical Oncology, 2007, 25, 301-307.	1.6	73
328	Validity of Models for Predicting BRCA1 and BRCA2 Mutations. Annals of Internal Medicine, 2007, 147, 441.	3.9	106
329	Maimon M. Cohen, PhD. Genetics in Medicine, 2007, 9, 321-322.	2.4	0
330	Psychological adjustment among partners of women at high risk of developing breast/ovarian cancer. Genetics in Medicine, 2007, 9, 311-320.	2.4	16
331	Susceptibility to Breast Cancer: Hereditary Syndromes and Low Penetrance Genes. Breast Disease, 2007, 27, 21-50.	0.8	36
332	Identifying Transcription Regulatory Elements in the Human and Mouse Genomes Using Tissue-specific Gene Expression Profiles. Journal of Integrative Bioinformatics, 2007, 4, 1-23.	1.5	0
333	Management Options after Prophylactic Surgeries in Women with BRCA Mutations: A Review. Cancer Control, 2007, 14, 330-337.	1.8	11
334	Screening and Follow-up of the Patient at High Risk for Breast Cancer. Obstetrics and Gynecology, 2007, 110, 1404-1416.	2.4	21
335	Mixed Ovarian Germ Cell Tumor in a BRCA2 Mutation Carrier. International Journal of Gynecological Pathology, 2007, 26, 160-164.	1.4	11
336	Elective oophorectomy in the gynecological patient: when is it desirable?. Current Opinion in Obstetrics and Gynecology, 2007, 19, 350-354.	2.0	23
337	Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours. Current Signal Transduction Therapy, 2007, 2, 165-173.	0.5	0
338	Lifestyle Behaviors in Women With a BRCA1 or BRCA2 Genetic Mutation. Cancer Nursing, 2007, 30, E1-E10.	1.5	15
339	Current Management Strategies for Ovarian Cancer. Mayo Clinic Proceedings, 2007, 82, 751-770.	3.0	127
340	Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006. European Journal of Cancer, 2007, 43, 238-257.	2.8	66
341	A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. European Journal of Cancer, 2007, 43, 1905-1917.	2.8	232

#	ARTICLE	IF	CITATIONS
342	BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. <i>Cancer Letters</i> , 2007, 248, 308-320.	7.2	17
343	Implementation of Genetics to Personalize Medicine. <i>Gender Medicine</i> , 2007, 4, 248-265.	1.4	21
345	A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer Predisposition Genes. <i>American Journal of Human Genetics</i> , 2007, 81, 873-883.	6.2	416
346	RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. <i>American Journal of Human Genetics</i> , 2007, 81, 1186-1200.	6.2	217
347	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. <i>Lancet Oncology</i> , 2007, 8, 26-34.	10.7	220
348	Personalized Medicine in the Era of Genomics. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1682.	7.4	174
349	Breast cancer risk-assessment models. <i>Breast Cancer Research</i> , 2007, 9, 213.	5.0	142
350	An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). <i>Breast Cancer Research</i> , 2007, 9, 104.	5.0	136
351	Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. <i>Breast Cancer Research</i> , 2007, 9, R26.	5.0	76
352	Impact of the US Patent System on the Promise of Personalized Medicine. <i>Gender Medicine</i> , 2007, 4, 187-192.	1.4	4
353	Founder mutations in BRCA1 and BRCA2 genes. <i>Annals of Oncology</i> , 2007, 18, vi93-vi98.	1.2	216
354	Management Updates for Women with a BRCA1 or BRCA2 Mutation. <i>Molecular Diagnosis and Therapy</i> , 2007, 11, 133-144.	3.8	32
355	Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2293-2305.	1.8	22
356	Nutritional Factors in Ovarian Cancer Prevention: What Have We Learned in the Past 5 Years?. <i>Nutrition and Cancer</i> , 2007, 59, 142-151.	2.0	9
357	Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-oophorectomy?. <i>Annals of Oncology</i> , 2007, 18, 1641-1645.	1.2	13
358	Current Management Strategies for Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 751-770.	3.0	156
360	Strategies for Ovarian Cancer Prevention. <i>Obstetrics and Gynecology Clinics of North America</i> , 2007, 34, 667-686.	1.9	8
361	Management of an Inherited Predisposition to Breast Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 154-162.	27.0	222

#	ARTICLE	IF	CITATIONS
362	Prophylactic Mastectomy. Surgical Clinics of North America, 2007, 87, 317-331.	1.5	19
364	Epithelial Ovarian Cancer: Disease Etiology, Treatment, Detection, and Investigational Gene, Metabolite, and Protein Biomarkers. Journal of Proteome Research, 2007, 6, 2936-2962.	3.7	102
366	The Genetics of Breast and Gynecologic Cancers. , 2007, , 43-71.		0
367	Genetic Counseling for Breast Cancer Risk: General Concepts, Challenging Themes and Future Directions. Breast Disease, 2007, 27, 69-96.	0.8	16
368	The Korean Hereditary Breast Cancer (KOHBRA) Study: Protocol Review. Journal of Breast Cancer, 2007, 10, 241.	1.9	18
369	Contribution of <i>BRCA1</i> and <i>BRCA2</i> mutations to inherited ovarian cancer. Human Mutation, 2007, 28, 1207-1215.	2.5	76
370	Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain: A population-based study. International Journal of Cancer, 2007, 120, 384-391.	5.1	57
371	Effectiveness of preventive interventions in <i>BRCA1/2</i> gene mutation carriers: A systematic review. International Journal of Cancer, 2007, 121, 225-231.	5.1	61
372	Prophylactic salpingo-oophorectomy in a series of 89 women carrying a <i>BRCA1</i> or a <i>BRCA2</i> mutation. Cancer, 2007, 109, 1784-1790.	4.1	48
373	Genetic susceptibility for breast cancer: How many more genes to be found?. Critical Reviews in Oncology/Hematology, 2007, 63, 125-149.	4.4	104
374	The <i>BRCA1</i> Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies. BMC Genetics, 2007, 8, 68.	2.7	8
375	Estimating risk of breast cancer in carriers of <i>BRCA1</i> and <i>BRCA2</i> mutations: a meta-analytic approach. Statistics in Medicine, 2007, 26, 1775-1787.	1.6	12
376	Biochip analysis of <i>BRCA1/2</i> and <i>CHEK2</i> common mutations in ovarian cancer and primary multiple tumors involving the ovaries (Russian population). Molecular Biology, 2007, 41, 32-36.	1.3	11
377	A genome-wide association study identifies alleles in <i>FGFR2</i> associated with risk of sporadic postmenopausal breast cancer. Nature Genetics, 2007, 39, 870-874.	21.4	1,370
378	Cancer phenomics: <i>RET</i> and <i>PTEN</i> as illustrative models. Nature Reviews Cancer, 2007, 7, 35-45.	28.4	231
379	Breast cancer risk associated with <i>BRCA1</i> and <i>BRCA2</i> in diverse populations. Nature Reviews Cancer, 2007, 7, 937-948.	28.4	400
380	Risk estimation for familial breast cancer: improving the system of counselling. European Journal of Human Genetics, 2007, 15, 1139-1144.	2.8	4
381	DNA repair capacity as a possible biomarker of breast cancer risk in female <i>BRCA1</i> mutation carriers. British Journal of Cancer, 2007, 96, 118-125.	6.4	41

#	ARTICLE	IF	CITATIONS
382	Genome-wide association study identifies novel breast cancer susceptibility loci. <i>Nature</i> , 2007, 447, 1087-1093.	27.8	2,165
383	A survey of preventive measures among BRCA1 mutation carriers from Poland. <i>Clinical Genetics</i> , 2007, 71, 153-157.	2.0	12
384	Screening for <i>BRCA1</i> and <i>BRCA2</i> mutations in Eastern Finnish breast/ovarian cancer families. <i>Clinical Genetics</i> , 2007, 72, 311-320.	2.0	13
385	The β 1 subunit of the L-type calcium channel is not a predisposition gene for thyrotoxic periodic paralysis. <i>Clinical Endocrinology</i> , 2007, 66, 229-234.	2.4	7
386	Ductal Pattern Enhancement on Magnetic Resonance Imaging of the Breast Due to Ductal Lavage. <i>Breast Journal</i> , 2007, 13, 281-286.	1.0	5
387	Adverse Selection in Term Life Insurance Purchasing due to the BRCA1/2 Genetic Test and Elastic Demand. <i>Journal of Risk and Insurance</i> , 2007, 74, 65-86.	1.6	48
388	American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 75-89.	329.8	2,234
389	Cancer Risk Elicitation and Communication: Lessons from the Psychology of Risk Perception. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 147-167.	329.8	147
390	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2007, 179, 89-92.	1.0	14
391	The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. <i>Gynecologic Oncology</i> , 2007, 104, 7-10.	1.4	135
392	Does a BRCA mutation plus tamoxifen equal hysterectomy?. <i>Gynecologic Oncology</i> , 2007, 104, 3-4.	1.4	16
393	Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions. <i>Gynecologic Oncology</i> , 2007, 107, 159-162.	1.4	257
394	Screening and Prevention of Hereditary Gynecologic Cancers. <i>Seminars in Oncology</i> , 2007, 34, 406-410.	2.2	17
395	The Prevention of Hereditary Breast Cancer. <i>Seminars in Oncology</i> , 2007, 34, 401-405.	2.2	13
396	Meta-Analysis of <i>BRCA1</i> and <i>BRCA2</i> Penetrance. <i>Journal of Clinical Oncology</i> , 2007, 25, 1329-1333.	1.6	1,560
397	Genetic susceptibility to breast cancer. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2007, 8, 255-267.	5.7	78
398	Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred. <i>Familial Cancer</i> , 2007, 6, 63-71.	1.9	4
399	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. <i>Familial Cancer</i> , 2007, 6, 473-482.	1.9	21

#	ARTICLE	IF	CITATIONS
400	Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. <i>Familial Cancer</i> , 2007, 6, 483-490.	1.9	25
401	Results of an Intervention for Individuals and Families with BRCA Mutations: A Model for Providing Medical Updates and Psychosocial Support Following Genetic Testing. <i>Journal of Genetic Counseling</i> , 2007, 16, 433-456.	1.6	47
402	Distress and Family Functioning in Oncogenetic Counselling for Hereditary and Familial Breast and/or Ovarian Cancers. <i>Journal of Genetic Counseling</i> , 2007, 16, 625-634.	1.6	12
403	Predictors of Cancer Worry in Unaffected Women from High Risk Breast Cancer Families: Risk Perception is not the Primary Issue. <i>Journal of Genetic Counseling</i> , 2007, 16, 635-644.	1.6	21
404	Women with BRCA1 or BRCA2 Mutations Renegotiating a Post-Prophylactic Mastectomy Identity: Self-Image and Self-Disclosure.. <i>Journal of Genetic Counseling</i> , 2007, 16, 789-798.	1.6	24
405	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 29-36.	2.5	27
406	High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 225-232.	2.5	86
407	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 349-353.	2.5	71
408	Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. <i>Breast Cancer Research and Treatment</i> , 2007, 104, 299-308.	2.5	47
409	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 221-228.	2.5	45
410	BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 267-276.	2.5	22
411	The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. <i>European Journal of Health Economics</i> , 2007, 8, 137-144.	2.8	34
413	New Insights into Breast Cancer Genetics and Impact on Patient Management. <i>Current Treatment Options in Oncology</i> , 2007, 8, 61-73.	3.0	24
414	Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 79-86.	2.5	16
415	Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 67-75.	2.5	34
416	G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 377-385.	2.5	37
417	Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 165-169.	2.5	5
418	Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 229-236.	2.5	20

#	ARTICLE	IF	CITATIONS
419	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. <i>Cancer Causes and Control</i> , 2008, 19, 1111-1119.	1.8	87
420	Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. <i>Lifetime Data Analysis</i> , 2008, 14, 18-36.	0.9	11
421	“Are You at Risk for Hereditary Breast Cancer?” Development of a Personal Risk Assessment Tool for Hereditary Breast and Ovarian Cancer. <i>Journal of Genetic Counseling</i> , 2008, 17, 64-78.	1.6	12
422	Health Behaviors and Psychological Distress in Women Initiating BRCA1/2 Genetic Testing: Comparison with Control Population. <i>Journal of Genetic Counseling</i> , 2008, 17, 314-326.	1.6	35
423	Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. <i>Familial Cancer</i> , 2008, 7, 119-124.	1.9	21
424	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2008, 7, 179-186.	1.9	63
425	Hereditary diffuse gastric cancer: association with lobular breast cancer. <i>Familial Cancer</i> , 2008, 7, 73-82.	1.9	117
426	Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk. <i>Familial Cancer</i> , 2008, 7, 221-228.	1.9	11
427	Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Familial Cancer</i> , 2008, 7, 233-244.	1.9	17
428	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. <i>Familial Cancer</i> , 2008, 7, 275-279.	1.9	32
429	Predictors of choosing life-long screening or prophylactic surgery in women at high and moderate risk for breast and ovarian cancer. <i>Familial Cancer</i> , 2008, 7, 347-359.	1.9	19
433	The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. <i>Clinical and Translational Oncology</i> , 2008, 10, 78-84.	2.4	32
434	The Trajectory of Psychological Impact in BRCA1/2 Genetic Testing: Does Time Heal?. <i>Annals of Behavioral Medicine</i> , 2008, 36, 107-116.	2.9	76
436	Hereditary breast cancer: new genetic developments, new therapeutic avenues. <i>Human Genetics</i> , 2008, 124, 31-42.	3.8	276
437	The counselees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. <i>Psycho-Oncology</i> , 2008, 17, 822-830.	2.3	112
438	Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth. <i>Prenatal Diagnosis</i> , 2008, 28, 292-298.	2.3	35
439	Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. <i>Human Mutation</i> , 2008, 29, 1292-1303.	2.5	54
440	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2008, 122, 2017-2022.	5.1	306

#	ARTICLE	IF	CITATIONS
441	A compendium of familial relative risks of cancer among first degree relatives: A population-based study. <i>International Journal of Cancer</i> , 2008, 123, 1664-1673.	5.1	11
442	Should genetic testing for <i>BRCA1/2</i> be permitted for minors? Opinions of <i>BRCA</i> mutation carriers and their adult offspring. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2008, 148C, 70-77.	1.6	34
443	Inherited gynaecological cancer syndromes. <i>The Obstetrician and Gynaecologist</i> , 2008, 10, 9-15.	0.4	3
444	The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With <i>BRCA1/2</i> Mutations. <i>Annals of Surgical Oncology</i> , 2008, 15, 21-33.	1.5	108
445	Mechanisms of inherited cancer susceptibility. <i>Journal of Zhejiang University: Science B</i> , 2008, 9, 1-4.	2.8	35
446	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>American Journal of Human Genetics</i> , 2008, 82, 937-948.	6.2	257
447	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. <i>British Journal of Cancer</i> , 2008, 98, 1457-1466.	6.4	461
448	Label-free detection of DNA hybridization based on hydration-induced tension in nucleic acid films. <i>Nature Nanotechnology</i> , 2008, 3, 301-307.	31.5	194
449	The distinctive biology of cancer in adolescents and young adults. <i>Nature Reviews Cancer</i> , 2008, 8, 288-298.	28.4	540
450	Can genes for mammographic density inform cancer aetiology?. <i>Nature Reviews Cancer</i> , 2008, 8, 812-823.	28.4	40
451	Breast and Ovarian Cancer: A New Model For Educating Women. <i>Nursing for Women's Health</i> , 2008, 12, 490-499.	0.8	3
452	The Body's Response to Health Care Provider Communication: The Impact of Dominant Versus Facilitative Styles. <i>Journal of Applied Biobehavioral Research</i> , 2008, 13, 67-85.	2.0	11
453	Magnetic resonance findings in women at high risk for developing breast cancer: An Australian feasibility study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2008, 52, 29-35.	1.8	3
454	<i>BRCA</i> mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the <i>BRCA</i> -negative experience. <i>Health Expectations</i> , 2008, 11, 220-231.	2.6	47
455	Family history as a predictor of uptake of cancer preventive procedures by women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Clinical Genetics</i> , 2008, 73, 474-479.	2.0	48
456	Risk factors for a serous cancer precursor (œp53 signature) in women with inherited <i>BRCA</i> mutations. <i>Gynecologic Oncology</i> , 2008, 111, 226-232.	1.4	77
457	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. <i>BMC Cancer</i> , 2008, 8, 101.	2.6	22
458	Spectrum and characterisation of <i>BRCA1</i> and <i>BRCA2</i> deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. <i>BMC Cancer</i> , 2008, 8, 140.	2.6	64

#	ARTICLE	IF	CITATIONS
459	Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer, 2008, 8, 146.	2.6	42
460	Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer, 2008, 8, 214.	2.6	14
461	Understanding genetic analysis for breast cancer and its implications for plastic surgery. Aesthetic Surgery Journal, 2008, 28, 85-91.	1.6	7
462	Breast Cancer in Young Women. Journal of the American College of Surgeons, 2008, 206, 1193-1203.	0.5	71
463	Brc1 in immunoglobulin gene conversion and somatic hypermutation. DNA Repair, 2008, 7, 253-266.	2.8	18
464	Formal and Informal Support Needs of Young Women with BRCA Mutations. Journal of Psychosocial Oncology, 2008, 26, 111-133.	1.2	45
465	Genetic Predisposition to Breast Cancer: Past, Present, and Future. Annual Review of Genomics and Human Genetics, 2008, 9, 321-345.	6.2	233
466	New sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis in an elderly healthy female population in Croatia. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1376-83.	2.3	18
467	Inherited Susceptibility to Common Cancers. New England Journal of Medicine, 2008, 359, 2143-2153.	27.0	462
468	Fertility preservation in patients with non-oncological conditions. Reproductive BioMedicine Online, 2008, 16, 792-800.	2.4	49
469	Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?. Breast Cancer Research, 2008, 10, 208.	5.0	70
471	Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. British Journal of Cancer, 2008, 98, 2006-2010.	6.4	21
472	Formal Concept Analysis for the Identification of Combinatorial Biomarkers in Breast Cancer. , 2008, , 229-240.		17
473	Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1/2 mutation carriers. Maturitas, 2008, 60, 71-77.	2.4	2
475	Etiologic impact of known cancer susceptibility genes. Mutation Research - Reviews in Mutation Research, 2008, 658, 42-54.	5.5	20
476	Social and Ethical Implications of Genomics, Race, Ethnicity, and Health Inequities. Seminars in Oncology Nursing, 2008, 24, 254-261.	1.5	16
477	Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976-1999. European Journal of Medical Genetics, 2008, 51, 141-147.	1.3	20
478	Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer. European Journal of Surgical Oncology, 2008, 34, 1148-1154.	1.0	26

#	ARTICLE	IF	CITATIONS
479	Absorbed radiation dose of the female breast during diagnostic multidetector chest CT and dose reduction with a tungsten-antimony composite breast shield: preliminary results. <i>Clinical Radiology</i> , 2008, 63, 278-288.	1.1	25
481	Identification of personal risk of breast cancer: genetics. <i>Breast Cancer Research</i> , 2008, 10, S12.	5.0	11
482	Concise Handbook of Familial Cancer Susceptibility Syndromes - Second Edition. <i>Journal of the National Cancer Institute Monographs</i> , 2008, 2008, 3-93.	2.1	185
483	Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 383-395.	2.8	26
484	Telephone Genetic Counseling for High-Risk Women Undergoing BRCA1 and BRCA2 Testing: Rationale and Development of a Randomized Controlled Trial. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 37-52.	1.7	47
486	The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families. <i>Cancer Research</i> , 2008, 68, 7006-7014.	0.9	100
487	BRCA1 p.Val1688del Is a Deleterious Mutation That Recurs in Breast and Ovarian Cancer Families From Northeast Italy. <i>Journal of Clinical Oncology</i> , 2008, 26, 26-31.	1.6	44
488	Performance of BRCA1/2 Mutation Prediction Models in Asian Americans. <i>Journal of Clinical Oncology</i> , 2008, 26, 4752-4758.	1.6	57
489	Loss of Heterozygosity at the BRCA2 Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline BRCA2 Mutation. <i>Clinical Cancer Research</i> , 2008, 14, 2953-2961.	7.0	37
490	Polymorphisms in RAD51, XRCC2, and XRCC3 Are Not Related to Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1016-1019.	2.5	41
491	Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. <i>Human Reproduction</i> , 2008, 24, 1000-1006.	0.9	61
492	Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. <i>Genetics in Medicine</i> , 2008, 10, 161-166.	2.4	81
493	Predominant Ashkenazi BRCA1/2 Mutations in Families with Pancreatic Cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 267-271.	1.7	10
494	Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 1331-1337.	1.6	522
495	Penetrance Analysis of the PALB2 c.1592delT Founder Mutation. <i>Clinical Cancer Research</i> , 2008, 14, 4667-4671.	7.0	90
496	Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1037-1041.	6.3	208
497	Association of Single Nucleotide Polymorphisms in Glycosylation Genes with Risk of Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 397-404.	2.5	46
498	The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain. <i>Clinical Cancer Research</i> , 2008, 14, 2861-2869.	7.0	90

#	ARTICLE	IF	CITATIONS
499	Screening for Breast Cancer in Women with a Familial or Genetic Predisposition. , 2008, , 459-464.		0
500	Variation of Breast Cancer Risk Among BRCA1/2 Carriers. JAMA - Journal of the American Medical Association, 2008, 299, 194-201.	7.4	244
501	The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. Annals of Oncology, 2008, 19, 655-659.	1.2	36
502	Beating the Biological Clock: The Compressed Family Life Cycle of Young Women with BRCA Gene Alterations. Social Work in Health Care, 2008, 47, 416-437.	1.6	54
503	BRCA1 and BRCA2 Missense Variants of High and Low Clinical Significance Influence Lymphoblastoid Cell Line Post-Irradiation Gene Expression. PLoS Genetics, 2008, 4, e1000080.	3.5	12
504	Genetic Variation in the One-Carbon Transfer Pathway and Ovarian Cancer Risk. Cancer Research, 2008, 68, 2498-2506.	0.9	75
505	Cancer Risk Management Practices of Noncarriers Within<i>BRCA1/2</i>Mutationâ€œPositive Families in the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. Journal of Clinical Oncology, 2008, 26, 225-232.	1.6	19
506	<i>BRCA1</i> and <i>BRCA2</i> Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research, 2008, 14, 3761-3767.	7.0	92
507	BRCA1 5083del19 Mutant Allele Selectively Up-Regulates Periostin Expression <i>In vitro</i> and <i>In vivo</i>. Clinical Cancer Research, 2008, 14, 6797-6803.	7.0	12
508	Clinical Classification of<i>BRCA1</i>and<i>BRCA2</i>DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysisâ€œA Report From the kConFab Investigators. Journal of Clinical Oncology, 2008, 26, 1657-1663.	1.6	72
510	Better Life Expectancy in Women with <i>BRCA2</i> Compared with <i>BRCA1</i> Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542.	2.5	15
511	Age of onset in familial cancer. Annals of Oncology, 2008, 19, 2084-2088.	1.2	47
512	Breast Cancer Screening inBRCA1Mutation Carriers: Effectiveness of MR Imagingâ€œMarkov Monte Carlo Decision Analysis. Radiology, 2008, 246, 763-771.	7.3	44
513	Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. Journal of the National Cancer Institute, 2008, 100, 1361-1367.	6.3	179
514	BioSumm: A novel summarizer oriented to biological information. , 2008, , .		1
515	Changes in Diet and Physical Activity Following<i>BRCA1/2</i>Testing. Journal of Psychosocial Oncology, 2008, 26, 63-80.	1.2	29
516	BRCA2 Gene Mutations in Slovenian Male Breast Cancer Patients. Genetic Testing and Molecular Biomarkers, 2008, 12, 203-209.	1.7	15
517	GENETICS: Hereditary breast and ovarian cancers. JAAPA: Official Journal of the American Academy of Physician Assistants, 2008, 21, 18-21.	0.3	2

#	ARTICLE	IF	CITATIONS
518	Disclosure of positive BRCA1/2-mutation status in young couples: The journey from uncertainty to bonding through partner support.. Families, Systems and Health, 2008, 26, 296-316.	0.6	36
519	Interpersonal responses among sibling dyads tested for BRCA1/BRCA2 gene mutations.. Health Psychology, 2008, 27, 100-109.	1.6	20
521	Complete mutation screening and haplotype characterization of BRCA1 gene in Tunisian patients with familial breast cancer. Cancer Biomarkers, 2008, 4, 11-18.	1.7	33
522	Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios. Cancer Informatics, 2008, 6, CIN.S618.	1.9	45
523	Sampling Distributions of Critical Illness Insurance Premium Rates: Breast and Ovarian Cancer. ASTIN Bulletin, 2008, 38, 527-542.	1.0	2
524	Whatâ€™s in a cancer syndrome? Genes, phenotype and pathology. Pathology, 2008, 40, 247-259.	0.6	1
525	Preservation of Female Fertility. Obstetrics and Gynecology, 2008, 112, 1160-1172.	2.4	29
526	Prophylactic Mastectomy and Reconstruction: Clinical Outcomes and Patient Satisfaction. Plastic and Reconstructive Surgery, 2008, 122, 1-9.	1.4	157
527	Ovary. , 0, , 257-266.		0
528	Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. International Journal of Biological Sciences, 2008, 4, 133-142.	6.4	63
529	BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. International Journal of Medical Sciences, 2008, 5, 197-202.	2.5	62
530	Benign and malignant gynaecological disease. , 0, , 85-90.		0
531	BRCA1 and BRCA2 Germline Mutations in Malaysian Women with Early-Onset Breast Cancer without a Family History. PLoS ONE, 2008, 3, e2024.	2.5	41
532	Cancer genetics and reproduction. , 0, , 13-22.		0
533	C��NCER HEREDITARIO DE MAMA. Revista Chilena De Radiologia, 2008, 14, .	0.2	0
535	Preimplantation genetic diagnosis: current practice and future possibilities. , 0, , 35-58.		0
536	The Breast and Ovarian Cancer Risks in Korea Due to Inherited Mutations in BRCA1 and BRCA2: A Preliminary Report. Journal of Breast Cancer, 2009, 12, 92.	1.9	17
538	High Rates of Occult Fallopian Tube Cancer Diagnosed at Prophylactic Bilateral Salpingo-Oophorectomy. International Journal of Gynecological Cancer, 2009, 19, 826-829.	2.5	60

#	ARTICLE	IF	CITATIONS
540	Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma. PLoS ONE, 2009, 4, e4812.	2.5	53
541	Expanding the Public Health Research Agenda for Ovarian Cancer. Journal of Women's Health, 2009, 18, 1299-1305.	3.3	4
542	Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. Journal of the National Cancer Institute, 2009, 101, 1058-1065.	6.3	114
543	Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncology, 2009, 5, 689-701.	2.4	35
544	The Twilight Zone Between Health and Sickness: A Qualitative Exploration with Asymptomatic BRCA1 and 2 Mutation Carriers. Women and Health, 2009, 49, 263-279.	1.0	17
545	Ductal Lavage in Women from <i>BRCA1/2</i> Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer?. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1243-1251.	2.5	25
546	Update on genetic predisposition to breast cancer. Expert Review of Anticancer Therapy, 2009, 9, 1103-1113.	2.4	11
547	BRCA in breast cancer: ESMO Clinical Recommendations. Annals of Oncology, 2009, 20, iv19-iv20.	1.2	43
548	BRCA2 splice site mutations in an Italian breast/ovarian cancer family. Annals of Oncology, 2009, 20, 1285.	1.2	2
549	Modification of Ovarian Cancer Risk by <i>BRCA1/2</i>-Interacting Genes in a Multicenter Cohort of <i>BRCA1/2</i> Mutation Carriers. Cancer Research, 2009, 69, 5801-5810.	0.9	31
550	Oral Contraceptive Use and <i>BRCA</i> Penetrance: A Case-Only Study. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2107-2113.	2.5	18
551	Established and Suspected Risk Factors in Breast Cancer Aetiology. Breast Care, 2009, 4, 82-87.	1.4	18
552	ACOG Practice Bulletin No. 103: Hereditary Breast and Ovarian Cancer Syndrome. Obstetrics and Gynecology, 2009, 113, 957-966.	2.4	249
553	Oophorectomy for Breast Cancer Prevention in Women with Brca1 Or Brca2 Mutations. Women's Health, 2009, 5, 63-68.	1.5	14
554	Verification of consumers' experiences and perceptions of genetic discrimination and its impact on utilization of genetic testing. Genetics in Medicine, 2009, 11, 193-201.	2.4	52
555	Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Annals of Oncology, 2009, 20, 874-878.	1.2	21
556	Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genetics in Medicine, 2009, 11, 783-789.	2.4	92
557	Age-dependent penetrance of different germline mutations in the BRCA1 gene. Journal of Clinical Pathology, 2009, 62, 350-356.	2.0	23

#	ARTICLE	IF	CITATIONS
559	Disentangling the Babylonian speech confusion in genetic counseling: An analysis of the reliability and validity of the nomenclature for BRCA1/2 DNA-test results other than pathogenic. <i>Genetics in Medicine</i> , 2009, 11, 742-749.	2.4	6
560	Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 80-87.	6.3	786
561	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	2.9	99
562	Co-existence of breast and ovarian cancers in BRCA germ-line mutation carriers. <i>Ecantermedicalscience</i> , 2009, 3, 109.	1.1	6
563	Mammographic Density and Breast Cancer Risk: Evaluation of a Novel Method of Measuring Breast Tissue Volumes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1754-1762.	2.5	110
564	Risk of Pancreatic Cancer in Families With Lynch Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1790.	7.4	434
565	Weight History, Smoking, Physical Activity and Breast Cancer Risk among French-Canadian Women Non-Carriers of More Frequent <i>BRCA1/2</i> Mutations. <i>Journal of Cancer Epidemiology</i> , 2009, 2009, 1-11.	1.1	23
566	Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. <i>Journal of Clinical Pathology</i> , 2009, 62, 896-902.	2.0	24
567	Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1365-1372.	2.5	82
568	Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young BRCA Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2009, 101, 205-209.	6.3	108
569	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the International <i>BRCA1/2</i> Carrier Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 601-610.	2.5	130
570	High Frequency of <i>TP53</i> Mutation in <i>BRCA1</i> and Sporadic Basal-like Carcinomas but not in <i>BRCA1</i> Luminal Breast Tumors. <i>Cancer Research</i> , 2009, 69, 663-671.	0.9	136
571	The Breast Cancer Susceptibility Mutation <i>PALB2 1592delT</i> Is Associated with an Aggressive Tumor Phenotype. <i>Clinical Cancer Research</i> , 2009, 15, 3214-3222.	7.0	122
572	Staging and Weighting Evidence in Biomedicine. <i>Social Studies of Science</i> , 2009, 39, 691-715.	2.5	69
573	Low-risk susceptibility alleles in 40 human breast cancer cell lines. <i>BMC Cancer</i> , 2009, 9, 236.	2.6	25
574	A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. <i>Gynecologic Oncology</i> , 2009, 112, 594-600.	1.4	77
575	Hereditary Breast and Ovarian Cancer Syndrome. <i>Gynecologic Oncology</i> , 2009, 113, 6-11.	1.4	42
576	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. <i>Gynecologic Oncology</i> , 2009, 115, 135-137.	1.4	13

#	ARTICLE	IF	CITATIONS
577	Germline mutations in MEN1 and BRCA1 genes in a woman with familial multiple endocrine neoplasia type 1 and inherited breast-ovarian cancer syndromes: a case report. <i>Cancer Genetics and Cytogenetics</i> , 2009, 195, 75-79.	1.0	14
578	Breast Cancer Before Age 40 Years. <i>Seminars in Oncology</i> , 2009, 36, 237-249.	2.2	574
579	PEL: an unbiased method for estimating age-dependent genetic disease risk from pedigree data unselected for family history. <i>Genetic Epidemiology</i> , 2009, 33, 379-385.	1.3	17
580	Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients. <i>Human Mutation</i> , 2009, 30, 564-574.	2.5	38
581	Body mass index and risk of ovarian cancer. <i>Cancer</i> , 2009, 115, 812-822.	4.1	132
582	Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. <i>Cancer</i> , 2009, 115, 1598-1604.	4.1	31
583	Occult fallopian tube carcinoma detected in routine pelvic washing specimens submitted for staging: Another justification for pelvic washing cytology?. <i>Diagnostic Cytopathology</i> , 2009, 37, 923-929.	1.0	10
586	No association of TCFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 185-192.	2.5	12
587	No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 307-313.	2.5	9
588	No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 211-213.	2.5	3
589	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 479-489.	2.5	124
590	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 127-135.	2.5	27
591	Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 539-546.	2.5	31
592	Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. <i>Familial Cancer</i> , 2009, 8, 127-133.	1.9	11
593	Health behaviors among Ashkenazi Jewish individuals receiving counseling for BRCA1 and BRCA2 mutations. <i>Familial Cancer</i> , 2009, 8, 241-250.	1.9	13
594	Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. <i>Familial Cancer</i> , 2009, 8, 277-287.	1.9	33
595	Haplotypes of the 1157T CHEK2 germline mutation in ethnically diverse populations. <i>Familial Cancer</i> , 2009, 8, 473-478.	1.9	6
596	The Effectiveness of Family History Questionnaires in Cancer Genetic Counseling. <i>Journal of Genetic Counseling</i> , 2009, 18, 366-378.	1.6	23

#	ARTICLE	IF	CITATIONS
597	Women's Decision Making about Risk-Reducing Strategies in the Context of Hereditary Breast and Ovarian Cancer: A Systematic Review. <i>Journal of Genetic Counseling</i> , 2009, 18, 578-597.	1.6	61
598	BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation. <i>Journal of Biosciences</i> , 2009, 34, 415-422.	1.1	55
599	Guidelines for Genetic Risk Assessment of Hereditary Breast and Ovarian Cancer: Early Disagreements and Low Utilization. <i>Journal of General Internal Medicine</i> , 2009, 24, 822-828.	2.6	47
600	Refining BRCA1 and BRCA2 penetrance estimates in the clinic. <i>Current Breast Cancer Reports</i> , 2009, 1, 127-130.	1.0	2
601	Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Current Breast Cancer Reports</i> , 2009, 1, 139-147.	1.0	1
602	Prophylactic oophorectomy may differentially reduce breast cancer risk in women with BRCA1 versus BRCA2 mutations. <i>Current Breast Cancer Reports</i> , 2009, 1, 157-161.	1.0	4
605	Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 77, 464-476.	2.6	17
606	Preimplantation genetic diagnosis for BRCA1/2—a novel clinical experience. <i>Prenatal Diagnosis</i> , 2009, 29, 508-513.	2.3	61
607	Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. <i>BMC Women's Health</i> , 2009, 9, 20.	2.0	12
608	Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. <i>European Journal of Human Genetics</i> , 2009, 17, 1471-1480.	2.8	36
609	BRCA1 tumours correlate with a HIF-1 α phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. <i>British Journal of Cancer</i> , 2009, 101, 1168-1174.	6.4	56
610	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). <i>British Journal of Cancer</i> , 2009, 101, 2048-2054.	6.4	15
611	The prevalence of hereditary breast/ovarian cancer risk in patients with a history of breast or ovarian cancer in Japanese subjects. <i>Journal of Obstetrics and Gynaecology Research</i> , 2009, 35, 912-917.	1.3	4
612	Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the <i>BRCA1</i> or <i>BRCA2</i> gene. <i>Clinical Genetics</i> , 2009, 75, 220-224.	2.0	17
613	Identification and Management of Women at High Risk for Hereditary Breast/Ovarian Cancer Syndrome. <i>Breast Journal</i> , 2009, 15, 155-162.	1.0	55
614	Gynaecological cancers in genetically susceptible women: new thoughts on tubal pathology. <i>Diagnostic Histopathology</i> , 2009, 15, 545-553.	0.4	4
615	Hereditary ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 28-44.	4.4	94
616	Linking the Cellular Functions of <i>BRCA</i> Genes to Cancer Pathogenesis and Treatment. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 461-487.	22.4	183

#	ARTICLE	IF	CITATIONS
617	Socioeconomic status and quality of life of women with family history of breast cancer attending an oncogenetic counseling clinic – a comparison with general population. <i>Acta Oncol</i> ³ gica, 2009, 48, 86-92.	1.8	7
618	Genetics: Breast Cancer as an Exemplar. <i>Nursing Clinics of North America</i> , 2009, 44, 327-338.	1.5	10
619	Development and Characterization of Reference Materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 Genetic Testing. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 553-561.	2.8	9
620	Regulatory aspects of genetic research with residual human tissue: Effective and efficient data coding. <i>European Journal of Cancer</i> , 2009, 45, 2376-2382.	2.8	9
621	First case of invasive breast cancer following prophylactic bilateral skin sparing mastectomy in a BRCA1 mutation carrier. <i>European Journal of Surgical Oncology</i> , 2009, 35, 1016-1018.	1.0	8
624	Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. <i>American Journal of Surgery</i> , 2009, 198, 538-543.	1.8	53
625	Hereditary breast cancer syndromes and clinical implications. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2009, 62, 181-189.	1.0	8
626	Role of genetic polymorphisms and ovarian cancer susceptibility. <i>Molecular Oncology</i> , 2009, 3, 171-181.	4.6	69
627	The Contribution of <i>BRCA1</i> and <i>BRCA2</i> to Ovarian Cancer. <i>Molecular Oncology</i> , 2009, 3, 138-150.	4.6	178
628	Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. <i>Molecular Oncology</i> , 2009, 3, 97-137.	4.6	171
629	BRCA1 involvement in toxicological responses and human cancer etiology. <i>Toxicology Letters</i> , 2009, 188, 77-83.	0.8	15
630	Ethical, legal and social implications of prenatal and preimplantation genetic testing for cancer susceptibility. <i>Reproductive BioMedicine Online</i> , 2009, 19, 23-33.	2.4	27
631	Calculation of Risk of Colorectal and Endometrial Cancer Among Patients With Lynch Syndrome. <i>Gastroenterology</i> , 2009, 137, 1621-1627.	1.3	322
632	PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2009, 2, 83-85.	0.2	5
633	Epidemiology of Ovarian Cancer. <i>Methods in Molecular Biology</i> , 2009, 472, 413-437.	0.9	239
634	Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. <i>Breast Cancer Research</i> , 2009, 11, R76.	5.0	44
635	Multiple Primary Malignancies. , 2009, , .		1
636	Evolving Role of MRI in Breast Cancer Imaging. <i>PET Clinics</i> , 2009, 4, 241-253.	3.0	4

#	ARTICLE	IF	CITATIONS
637	Women at High Risk for Breast Cancer--What the Primary Care Provider Needs to Know. Journal of the American Board of Family Medicine, 2009, 22, 43-50.	1.5	23
638	Contralateral Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Journal of Clinical Oncology, 2009, 27, 5887-5892.	1.6	292
639	Risk reducing mastectomy: outcomes in 10 European centres. Journal of Medical Genetics, 2009, 46, 254-258.	3.2	80
640	Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in <i>BRCA</i> Carriers. Genetic Testing and Molecular Biomarkers, 2009, 13, 51-56.	0.7	76
641	Genetic Counseling and the Advanced Practice Oncology Nursing Role in a Hereditary Cancer Prevention Clinic: Hereditary Breast Cancer Focus (Part I). Breast Journal, 2009, 15, S2-S10.	1.0	5
642	Transitional Cell Metaplasia of Fallopian Tube Fimbriae. American Journal of Surgical Pathology, 2009, 33, 111-119.	3.7	50
643	Ovarian Pathology in Risk-reducing Salpingo-oophorectomies From Women With <i>BRCA</i> Mutations, Emphasizing the Differential Diagnosis of Occult Primary and Metastatic Carcinoma. American Journal of Surgical Pathology, 2009, 33, 1125-1136.	3.7	46
644	Multistep Level Sections to Detect Occult Fallopian Tube Carcinoma in Risk-reducing Salpingo-oophorectomies From Women With <i>BRCA</i> Mutations. American Journal of Surgical Pathology, 2009, 33, 1878-1885.	3.7	92
645	Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. European Journal of Cancer Prevention, 2009, 18, 343-348.	1.3	36
646	TNRC9/LOC643714 polymorphisms are not associated with breast cancer risk in Chinese women. European Journal of Cancer Prevention, 2009, 18, 285-290.	1.3	14
647	GENOMICS IN PA PRACTICE. JAAPA: Official Journal of the American Academy of Physician Assistants, 2009, 22, 61-63.	0.3	1
648	Molecular genetics analysis of hereditary breast and ovarian cancer patients in India. Hereditary Cancer in Clinical Practice, 2009, 7, 13.	1.5	19
649	Unraveling the Next Chapter. Cancer Journal (Sudbury, Mass), 2009, 15, 15-18.	2.0	23
651	Hereditary Breast Ovarian Cancer Syndromes in the Maritimes. Journal of Obstetrics and Gynaecology Canada, 2010, 32, 155-159.	0.7	0
652	Safety and Efficacy of Perforator Flap Breast Reconstruction With Combined Intraabdominal Procedures. Annals of Plastic Surgery, 2010, 64, 144-150.	0.9	10
653	Hereditary Gynecologic Cancer Syndromes. Postgraduate Obstetrics & Gynecology, 2010, 30, 8.	0.1	0
654	Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy. Obstetrics and Gynecology, 2010, 116, 733-743.	2.4	89
655	<i>BRCA</i> Gene Structure and Function in Tumor Suppression. Cancer Journal (Sudbury, Mass), 2010, 16, 39-47.	2.0	59

#	ARTICLE	IF	CITATIONS
656	Hereditary Gynecologic Cancer Syndromes. Postgraduate Obstetrics & Gynecology, 2010, 30, 1-7.	0.1	1
657	Breast Cancer Screening and Prevention. Annals of Internal Medicine, 2010, 152, ITC4-1.	3.9	9
658	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	4.9	253
659	Moving Toward Personalized Medicine: Treatment-Focused Genetic Testing of Women Newly Diagnosed With Ovarian Cancer. International Journal of Gynecological Cancer, 2010, 20, 704-716.	2.5	27
660	Building the Cancer Family: Family Planning in the Context of Inherited Breast and Ovarian Cancer Risk. Journal of the Society for Social Work and Research, 2010, 1, 14-27.	1.3	18
661	Breast Cancer Risk Reduction. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1112-1146.	4.9	34
662	Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genetics in Medicine, 2010, 12, 801-807.	2.4	35
663	Prioritizing Candidate Genetic Modifiers of BRCA1 and BRCA2 Using a Combinatorial Analysis of Global Expression and Polymorphism Association Studies of Breast Cancer. Methods in Molecular Biology, 2010, 653, 23-34.	0.9	2
664	Choice of Management of Southern Chinese BRCA Mutation Carriers. World Journal of Surgery, 2010, 34, 1416-1426.	1.6	26
666	Effects of measured susceptibility genes on cancer risk in family studies. Human Genetics, 2010, 127, 349-357.	3.8	11
667	La génétique constitutionnelle peut-elle impacter la prise en charge d'une femme atteinte de cancer du sein aujourd'hui ?. Oncologie, 2010, 12, 248-254.	0.7	1
669	Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2. Journal of Community Genetics, 2010, 1, 91-99.	1.2	3
670	BRCA1 and BRCA1 Genes and Inherited Breast and/or Ovarian Cancer: Benefits of Genetic Testing. Indian Journal of Surgical Oncology, 2010, 1, 245-249.	0.7	7
671	Personalized genomic medicine. Internal and Emergency Medicine, 2010, 5, 81-90.	2.0	21
672	Women's Perceptions of the Personal and Family Impact of Genetic Cancer Risk Assessment: Focus Group Findings. Journal of Genetic Counseling, 2010, 19, 148-160.	1.6	36
673	CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers. Breast Cancer Research and Treatment, 2010, 119, 87-93.	2.5	22
674	The silent mutation nucleotide 744 G→A, Lys172Lys, in exon 6 of BRCA2 results in exon skipping. Breast Cancer Research and Treatment, 2010, 119, 547-550.	2.5	32
675	BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Research and Treatment, 2010, 119, 201-211.	2.5	70

#	ARTICLE	IF	CITATIONS
676	Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2010, 119, 221-232.	2.5	56
677	Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 120, 235-244.	2.5	79
678	Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?. Breast Cancer Research and Treatment, 2010, 121, 133-141.	2.5	16
679	Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Research and Treatment, 2010, 119, 13-24.	2.5	109
680	The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2010, 121, 639-649.	2.5	15
681	Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2010, 122, 281-285.	2.5	8
682	Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Research and Treatment, 2010, 119, 399-407.	2.5	61
683	Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Research and Treatment, 2010, 119, 409-414.	2.5	49
684	Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Research and Treatment, 2010, 123, 491-498.	2.5	57
685	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 124, 195-203.	2.5	58
686	Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment, 2010, 124, 643-651.	2.5	157
687	Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family. Breast Cancer Research and Treatment, 2010, 123, 587-590.	2.5	3
688	Predictors of breast cancer screening behavior in women with a strong family history of the disease. Breast Cancer Research and Treatment, 2010, 124, 509-519.	2.5	46
689	Copy number variations are not modifiers of phenotypic expression in a pair of identical twins carrying a BRCA1 mutation. Breast Cancer Research and Treatment, 2010, 123, 901-905.	2.5	12
690	On the development of a decision support intervention for mothers undergoing BRCA1/2 cancer genetic testing regarding communicating test results to their children. Familial Cancer, 2010, 9, 89-97.	1.9	31
691	Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection. Familial Cancer, 2010, 9, 193-201.	1.9	11
692	Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2Âyears. Familial Cancer, 2010, 9, 213-220.	1.9	15
693	Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence. Familial Cancer, 2010, 9, 291-295.	1.9	2

#	ARTICLE	IF	CITATIONS
694	Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland. <i>Familial Cancer</i> , 2010, 9, 267-274.	1.9	6
695	Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population. <i>Familial Cancer</i> , 2010, 9, 519-523.	1.9	13
696	The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. <i>Familial Cancer</i> , 2010, 9, 545-553.	1.9	18
697	The Role of Surgery in Cancer Prevention. <i>Current Problems in Surgery</i> , 2010, 47, 750-830.	1.1	11
698	Distress in partners of high-risk women undergoing breast cancer surveillance. <i>Journal of Men's Health</i> , 2010, 7, 413-419.	0.3	1
699	Cancer genetics and reproduction. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2010, 24, 3-18.	2.8	2
700	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast</i> , 2010, 19, 479-483.	2.2	24
701	Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?. <i>Gynecologic Oncology</i> , 2010, 117, 27-31.	1.4	21
702	Genomic alterations in histopathologically normal breast tissue from <i>BRCA1</i> mutation carriers may be caused by BRCA1 haploinsufficiency. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 78-90.	2.8	26
703	Estimating gene penetrance from family data. <i>Genetic Epidemiology</i> , 2010, 34, 373-381.	1.3	22
704	Are we overestimating the penetrance of mutations in SDHB?. <i>Human Mutation</i> , 2010, 31, 761-762.	2.5	64
705	A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. <i>BMC Medical Genetics</i> , 2010, 11, 20.	2.1	96
706	Women's constructions of the 'right time' to consider decisions about risk-reducing mastectomy and risk-reducing oophorectomy. <i>BMC Women's Health</i> , 2010, 10, 24.	2.0	30
707	Risk-reducing strategies for women carrying <i>brca1/2</i> mutations with a focus on prophylactic surgery. <i>BMC Women's Health</i> , 2010, 10, 28.	2.0	58
708	The detection, treatment, and biology of epithelial ovarian cancer. <i>Journal of Ovarian Research</i> , 2010, 3, 8.	3.0	58
709	High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series. <i>Hereditary Cancer in Clinical Practice</i> , 2010, 8, 2.	1.5	8
710	Psychological adjustment among male partners in response to women's breast/ovarian cancer risk: a theoretical review of the literature. <i>Psycho-Oncology</i> , 2010, 19, 1-11.	2.3	31
711	Androgen receptor expression in breast cancer patients tested for <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Histopathology</i> , 2010, 57, 877-884.	2.9	29

#	ARTICLE	IF	CITATIONS
712	Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women. <i>European Journal of Cancer Care</i> , 2010, 19, 360-368.	1.5	14
713	Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. <i>British Journal of Cancer</i> , 2010, 103, 693-700.	6.4	171
714	Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. <i>British Journal of Cancer</i> , 2010, 103, 1103-1108.	6.4	30
715	Methylation profiles of hereditary and sporadic ovarian cancer. <i>Histopathology</i> , 2010, 57, 363-370.	2.9	38
716	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	21.4	309
717	Does family history predict the age at onset of new breast cancers in <i>BRCA1</i> and <i>BRCA2</i> mutation-positive families?. <i>Clinical Genetics</i> , 2010, 77, 273-279.	2.0	14
718	Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing*. <i>Clinical Genetics</i> , 2010, 77, 342-349.	2.0	102
719	Inflammation targets specific organs for cancer in carriers of BRCA1/2 pathway mutations. <i>Nature Precedings</i> , 2010, , .	0.1	1
721	Do Alterations in Mitochondrial DNA Play a Role in Breast Carcinogenesis?. <i>Journal of Oncology</i> , 2010, 2010, 1-11.	1.3	31
722	BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-9.	1.3	20
723	Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations. <i>South African Medical Journal</i> , 2010, 100, 113.	0.6	16
724	Management of the asymptomatic BRCA mutation carrier. <i>The Application of Clinical Genetics</i> , 2010, 3, 121.	3.0	6
725	The Change of Practice Patterns of the Hereditary Breast Cancer Management in Korea after the Korean Hereditary Breast Cancer Study. <i>Journal of Breast Cancer</i> , 2010, 13, 418.	1.9	8
726	Search for Cancer Risk Factors with Microarray-Based Genome-Wide Association Studies. <i>Technology in Cancer Research and Treatment</i> , 2010, 9, 107-121.	1.9	7
727	Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1874-1878.	6.3	89
728	BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. <i>Carcinogenesis</i> , 2010, 31, 961-967.	2.8	240
729	Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. <i>Genetics in Medicine</i> , 2010, 12, 245-259.	2.4	259
730	<i>BRCA1</i> -Associated Breast Cancers Present Differently From <i>BRCA2</i> -Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5265-5273.	1.6	166

#	ARTICLE	IF	CITATIONS
731	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.9	169
732	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Human Molecular Genetics</i> , 2010, 19, 2886-2897.	2.9	60
733	Improving Surveillance and Quality of Life of <i>BRCA</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, e376-e377.	1.6	2
734	Cost-effective analysis of genotyping using oral cells in the geriatric population. <i>Genetics and Molecular Research</i> , 2010, 9, 1886-1895.	0.2	6
735	Changes in the Mouse Estrus Cycle in Response to <i>Brca1</i> Inactivation Suggest a Potential Link between Risk Factors for Familial and Sporadic Ovarian Cancer. <i>Cancer Research</i> , 2010, 70, 221-228.	0.9	40
736	Survival Analysis of Cancer Risk Reduction Strategies for <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2010, 28, 222-231.	1.6	217
737	Gene Methylation in Breast Ductal Fluid from <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 265-274.	2.5	26
738	Variation at 8q24 and 9p24 and Risk of Epithelial Ovarian Cancer. <i>Twin Research and Human Genetics</i> , 2010, 13, 43-56.	0.6	17
739	The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of <i>BRCA1</i> and <i>BRCA2</i> carriers—implications for oncogenetics practice. <i>Journal of Medical Genetics</i> , 2010, 47, 486-491.	3.2	13
740	Association of the Variants <i>CASP8</i> D302H and <i>CASP10</i> V410I with Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2859-2868.	2.5	37
741	Prevención en cáncer. <i>Revista Médica Clínica Las Condes</i> , 2010, 21, 771-778.	0.2	1
742	<i>MLH1</i> Founder Mutations with Moderate Penetrance in Spanish Lynch Syndrome Families. <i>Cancer Research</i> , 2010, 70, 7379-7391.	0.9	29
743	Application of Screening Principles to the Reconstructed Breast. <i>Journal of Clinical Oncology</i> , 2010, 28, 173-180.	1.6	55
744	Population-Based Study of the Risk of Second Primary Contralateral Breast Cancer Associated With Carrying a Mutation in <i>BRCA1</i> or <i>BRCA2</i> . <i>Journal of Clinical Oncology</i> , 2010, 28, 2404-2410.	1.6	166
745	Clinical application of breast cancer risk assessment models. <i>Future Oncology</i> , 2010, 6, 355-365.	2.4	11
746	Genetic counselling for hereditary predisposition to ovarian and breast cancer. <i>Annals of Oncology</i> , 2010, 21, vii334-vii338.	1.2	7
747	Common Genetic Variants and Modification of Penetrance of <i>BRCA2</i> -Associated Breast Cancer. <i>PLoS Genetics</i> , 2010, 6, e1001183.	3.5	85
748	Role of traditional and new biomarkers in breast carcinogenesis. <i>Ecancermedicalscience</i> , 2010, 3, 157.	1.1	1

#	ARTICLE	IF	CITATIONS
749	Clinical Decision Making Using Ovarian Cancer Risk Assessment. American Journal of Roentgenology, 2010, 194, 337-342.	2.2	12
751	Cost-effectiveness of Breast MR Imaging and Screen-Film Mammography for Screening <i>BRCA1</i> Gene Mutation Carriers. Radiology, 2010, 254, 793-800.	7.3	65
752	<i>BRCA1</i> gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer – a population based study from the Western Sweden Health Care region. Acta Oncologica, 2010, 49, 361-367.	1.8	9
753	Toward Classification of <i>BRCA1</i> Missense Variants Using a Biophysical Approach. Journal of Biological Chemistry, 2010, 285, 20080-20087.	3.4	39
754	Breast MR Imaging: Current Indications and Advanced Imaging Techniques. Radiologic Clinics of North America, 2010, 48, 1013-1042.	1.8	55
755	Breast Cancer Predisposition Syndromes. Hematology/Oncology Clinics of North America, 2010, 24, 799-814.	2.2	23
756	The Use of Breast Imaging to Screen Women at High Risk for Cancer. Radiologic Clinics of North America, 2010, 48, 859-878.	1.8	80
757	Evaluation of the Contribution of the Three Breast Cancer Susceptibility Genes <i>CHEK2</i> , <i>STK11</i> , and <i>PALB2</i> in Non- <i>BRCA1/2</i> French Canadian Families with High Risk of Breast Cancer. Genetic Testing and Molecular Biomarkers, 2010, 14, 515-526.	0.7	26
758	<i>BRCA</i> mutations in the management of breast cancer: the state of the art. Nature Reviews Clinical Oncology, 2010, 7, 702-707.	27.6	140
759	A One-Step Prescreening for Point Mutations and Large Rearrangement in <i>BRCA1</i> and <i>BRCA2</i> Genes Using Quantitative Polymerase Chain Reaction and High-Resolution Melting Curve Analysis. Genetic Testing and Molecular Biomarkers, 2010, 14, 677-690.	0.7	17
760	Identification and Management of Women With <i>BRCA</i> Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clinic Proceedings, 2010, 85, 1111-1120.	3.0	137
761	The role of <i>BRCA</i> mutation testing in determining breast cancer therapy. Nature Reviews Clinical Oncology, 2010, 7, 708-717.	27.6	85
762	Genetic susceptibility to breast cancer. Molecular Oncology, 2010, 4, 174-191.	4.6	291
763	Breast cancer in young women. Breast Cancer Research, 2010, 12, 212.	5.0	131
764	Evidence for <i>SMAD3</i> as a modifier of breast cancer risk in <i>BRCA2</i> mutation carriers. Breast Cancer Research, 2010, 12, R102.	5.0	25
765	268 Breast cancer risk-reducing surgery in Helsinki. European Journal of Cancer, Supplement, 2010, 8, 136-137.	2.2	0
766	269 Influence of factors affecting response to neoadjuvant chemotherapy in the design of the surgical approach to T2 and T3 breast tumours. European Journal of Cancer, Supplement, 2010, 8, 137.	2.2	0
769	<i>BRCA</i> in breast cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 2010, 21, v20-v22.	1.2	91

#	ARTICLE	IF	CITATIONS
770	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Current Opinion in Obstetrics and Gynecology, 2010, 22, 72-78.	2.0	170
771	Tumeurs rares et prÃ©disposition gÃ©nÃ©tique. , 2010, , 15-23.		0
772	Hereditary Breast and Ovarian Cancer Syndrome and Issues inÂPediatric and Adolescent Practice. Journal of Pediatric and Adolescent Gynecology, 2010, 23, 253-258.	0.7	6
773	Discovering moderate-risk breast cancer susceptibility genes. Current Opinion in Genetics and Development, 2010, 20, 268-276.	3.3	96
774	The inherited genetics of ovarian and endometrial cancer. Current Opinion in Genetics and Development, 2010, 20, 231-238.	3.3	64
775	Common genetic variants and cancer risk in Mendelian cancer syndromes. Current Opinion in Genetics and Development, 2010, 20, 299-307.	3.3	25
777	Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: A meta-analysis. European Journal of Cancer, 2010, 46, 2275-2284.	2.8	222
778	53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks. Cell, 2010, 141, 243-254.	28.9	1,406
779	Metastasizing patent claims on BRCA1. Genomics, 2010, 95, 312-314.	2.9	16
780	A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Research, 2010, 12, R109.	5.0	102
781	Hereditary breast and ovarian cancer testing: integration and outcomes within community oncology practices. Community Oncology, 2010, 7, 75-81.	0.2	4
782	Expanding the Criteria for <i>BRCA</i> Mutation Testing in Breast Cancer Survivors. Journal of Clinical Oncology, 2010, 28, 4214-4220.	1.6	120
783	Preventing Future Cancers by Testing Women With Ovarian Cancer for<i>BRCA</i>Mutations. Journal of Clinical Oncology, 2010, 28, 675-682.	1.6	78
784	Global Patterns of Cancer Incidence and Mortality Rates and Trends. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1893-1907.	2.5	2,266
785	Clinical Implementation of Translational Genomics. , 2010, , 191-200.		1
786	Update on Screening Breast MRI in High-Risk Women. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 241-247.	1.1	4
787	Breast Cancer Epidemiology. , 2010, , .		34
788	Principles of Clinical Cancer Genetics. , 2010, , .		3

#	ARTICLE	IF	CITATIONS
789	Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecological Endocrinology, 2010, 26, 568-577.	1.7	31
790	Interactive Animated Visualizations of Breast, Ovarian Cancer and Other Health Indicator Data Using Weave, an Interactive Web – based Analysis and Visualization Environment. , 2011, , .		5
791	Ethical Tensions in Genetic Counselling Research. Monash Bioethics Review, 2011, 29, 31-42.	0.8	1
792	Predictors of relationship adjustment among couples coping with a high risk of developing breast/ovarian cancer. Psychology and Health, 2011, 26, 21-39.	2.2	12
793	Diagnosis of Early Stage Ovarian Cancer by ¹ H NMR Metabonomics of Serum Explored by Use of a Microflow NMR Probe. Journal of Proteome Research, 2011, 10, 1765-1771.	3.7	70
794	Preserving the Self: The Process of Decision Making About Hereditary Breast Cancer and Ovarian Cancer Risk Reduction. Qualitative Health Research, 2011, 21, 502-519.	2.1	47
795	Attitudes Toward Direct-to-Consumer Advertisements and Online Genetic Testing Among High-Risk Women Participating in a Hereditary Cancer Clinic. Journal of Health Communication, 2011, 16, 607-628.	2.4	19
797	A Decade of Advances in Treatment for Advanced Nonâ€Small Cell Lung Cancer. Clinics in Chest Medicine, 2011, 32, 839-851.	2.1	58
798	PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening. Clinical Ovarian Cancer & Other Gynecologic Malignancies, 2011, 4, 83-85.	0.2	0
799	Clinical Approach to Diagnosis and Management of Ovarian, Fallopian Tube, and Peritoneal Carcinoma. Surgical Pathology Clinics, 2011, 4, 261-274.	1.7	3
800	The Role of PARP Inhibitors in Breast Cancer. Breast Diseases, 2011, 22, 341-343.	0.0	0
801	Candidate Gene Association Studies. Methods in Molecular Biology, 2011, 713, 105-117.	0.9	6
802	Molecular Pathology of Ovarian Carcinomas. Surgical Pathology Clinics, 2011, 4, 275-296.	1.7	1
803	High Risk of Colorectal and Endometrial Cancer in Ashkenazi Families With the MSH2 A636P Founder Mutation. Gastroenterology, 2011, 140, 1919-1926.	1.3	11
804	Public health in the genomic era: will Public Health Genomics contribute to major changes in the prevention of common diseases?. Archives of Public Health, 2011, 69, 8.	2.4	18
805	Modification of <i>BRCA1</i>-Associated Breast and Ovarian Cancer Risk by <i>BRCA1</i>-Interacting Genes. Cancer Research, 2011, 71, 5792-5805.	0.9	49
806	Methods in Biobanking. Methods in Molecular Biology, 2011, , .	0.9	26
808	Therapeutic Approaches for Women Predisposed to Breast Cancer. Annual Review of Medicine, 2011, 62, 295-306.	12.2	33

#	ARTICLE	IF	CITATIONS
809	Genetic Epidemiology. Methods in Molecular Biology, 2011, , .	0.9	3
810	Update on Screening Breast MRI in High-Risk Women. Obstetrics and Gynecology Clinics of North America, 2011, 38, 149-158.	1.9	10
811	Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations. American Journal of Surgery, 2011, 202, 298-302.	1.8	23
812	Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. Human Pathology, 2011, 42, 153-165.	2.0	6
813	Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review. Maturitas, 2011, 70, 261-265.	2.4	67
816	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncology, The, 2011, 12, 852-861.	10.7	1,028
817	The tubal hypothesis of ovarian cancer: caution needed. Lancet Oncology, The, 2011, 12, 1089-1091.	10.7	24
818	Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Research, 2011, 13, R73.	5.0	188
819	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	5.0	71
820	Genetic architecture of cancer and other complex diseases: lessons learned and future directions. Carcinogenesis, 2011, 32, 945-954.	2.8	96
821	Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer. JAMA - Journal of the American Medical Association, 2011, 306, 1557.	7.4	466
822	Early Diagnosis of Breast Cancer using Molecular, Biochemical and Pathological Markers. American Journal of Applied Sciences, 2011, 8, 1-8.	0.2	0
823	Ovarian cancer: symptoms, treatment and long-term patient management. Cancer Nursing Practice, 2011, 10, 29-37.	0.0	0
824	An unusual presentation of breast cancer in a very young woman. BMJ Case Reports, 2011, 2011, bcr1220103590-bcr1220103590.	0.5	1
825	Earlier Age of Onset in BRCA Carriers—Anticipation or Cohort Effect?. Current Oncology, 2011, 18, 257-258.	2.2	8
826	Biology of BRCA1 and BRCA2 genes and implications for cancer management. , 0, , 57-74.		0
828	Breast cancer therapy and reproduction. , 0, , 62-72.		0
829	Gynecologic Malignancies. , 0, , 440-455.		0

#	ARTICLE	IF	CITATIONS
830	High-risk screening using breast MRI. , 0, , 112-134.		0
831	Usage Patterns of Surveillance, Chemoprevention and Risk-Reducing Surgery in KoreanBRCAMutation Carriers: 5 Years of Experience at a Single Institution. Journal of Breast Cancer, 2011, 14, S17.	1.9	7
832	The Prevalence of Ovarian Cancer in Korean Women at High-Risk for Hereditary Breast-Ovarian Cancer. Journal of Breast Cancer, 2011, 14, S24.	1.9	2
833	BRCA2 (breast cancer 2, early onset). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
834	Inherited and acquired alterations in development of breast cancer. The Application of Clinical Genetics, 2011, 4, 145.	3.0	35
835	Gerosuppressant Metformin: less is more. Aging, 2011, 3, 348-362.	3.1	56
836	Clinical Considerations ofBRCA1- andBRCA2-Mutation Carriers: A Review. International Journal of Surgical Oncology, 2011, 2011, 1-11.	0.6	28
837	The Changing Face of Mastectomy (from Mutilation to Aid to Breast Reconstruction). International Journal of Surgical Oncology, 2011, 2011, 1-7.	0.6	18
838	Screening for Ovarian Cancer. Cancer Control, 2011, 18, 16-21.	1.8	38
839	Economic evaluation of targeted cancer interventions: Critical review and recommendations. Genetics in Medicine, 2011, 13, 853-860.	2.4	19
840	Bilateral Prophylactic Mastectomy in Swedish Women at High Risk of Breast Cancer. Annals of Surgery, 2011, 253, 1147-1154.	4.2	54
841	Reconstructive Outcomes in Patients Undergoing Contralateral Prophylactic Mastectomy. Plastic and Reconstructive Surgery, 2011, 128, 1025-1033.	1.4	68
842	Management of the Adnexal Mass. Obstetrics and Gynecology, 2011, 117, 1413-1428.	2.4	50
843	Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention. Current Drug Targets, 2011, 12, 1974-1982.	2.1	2
844	Hereditary ovarian cancer. Current Opinion in Oncology, 2011, 23, 526-530.	2.4	19
845	Genetics. Clinical Obstetrics and Gynecology, 2011, 54, 180-190.	1.1	1
846	Psychological Sequelae of Ovarian Cancer Screening and Genetic Testing for Ovarian Cancer Susceptibility. Current Women's Health Reviews, 2011, 7, 358-366.	0.2	2
847	Hereditary Breast and Ovarian Cancer. Deutsches Ärztblatt International, 2011, 108, 323-30.	0.9	119

#	ARTICLE	IF	CITATIONS
848	Genetic testing and first presymptomatic diagnosis in Moroccan families at high risk for breast/ovarian cancer. <i>Oncology Letters</i> , 2011, 2, 389-393.	1.8	21
849	Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 1163-1170.	1.8	6
850	Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: Variant reclassification and surgical decisions. <i>Genetics in Medicine</i> , 2011, 13, 998-1005.	2.4	115
851	Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer. <i>Oncology Letters</i> , 2011, 2, 1287-1289.	1.8	9
852	Breast cancer after bilateral risk-reducing mastectomy. <i>Clinical Genetics</i> , 2011, 79, 431-437.	2.0	49
853	Practicalities of developing a breast magnetic resonance imaging screening service for women at high risk for breast cancer. <i>ANZ Journal of Surgery</i> , 2011, 81, 688-693.	0.7	3
854	The role of micronucleus scoring in fine needle aspirates of ductal carcinoma of the breast. <i>Cytopathology</i> , 2011, 22, 111-114.	0.7	16
855	Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2011, 118, 814-824.	2.3	114
856	Breast Cancer Risk in Relation to Alcohol Consumption and BRCA Gene Mutations - A Case-Only Study of Gene-Environment Interaction. <i>Breast Journal</i> , 2011, 17, 477-484.	1.0	19
857	Identification of BRCA1-deficient ovarian cancers. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 593-599.	2.8	15
858	A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor. <i>Oncogene</i> , 2011, 30, 3360-3369.	5.9	30
859	Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study. <i>British Journal of Cancer</i> , 2011, 104, 578-586.	6.4	22
860	Morphological predictors of BRCA1 germline mutations in young women with breast cancer. <i>British Journal of Cancer</i> , 2011, 104, 903-909.	6.4	40
861	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. <i>British Journal of Cancer</i> , 2011, 104, 1356-1361.	6.4	7
862	Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance. <i>Seminars in Cancer Biology</i> , 2011, 21, 72-82.	9.6	94
863	Longer-term influence of breast cancer genetic counseling on cognitions and distress: Smaller benefits for affected versus unaffected women. <i>Patient Education and Counseling</i> , 2011, 85, 425-431.	2.2	33
864	Variants of Uncertain Significance in Breast Cancer-Related Genes: Real-World Implications for a Clinical Conundrum. Part One: Clinical Genetics Recommendations. <i>Seminars in Oncology</i> , 2011, 38, 469-480.	2.2	14
865	Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. <i>BMC Pharmacology</i> , 2011, 11, 7.	0.4	43

#	ARTICLE	IF	CITATIONS
866	Genetic susceptibility to sporadic ovarian cancer: A systematic review. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1816, 132-146.	7.4	26
867	Development of Breast Cancer in a 21-Year-Old Childhood Wilms' Tumor Survivor With a BRCA1 2634delC Mutation. <i>Clinical Breast Cancer</i> , 2011, 11, 268-269.	2.4	2
868	Ileal metastasis of breast cancer in a patient with a BRCA2 gene mutation: Report of a case. <i>Surgery Today</i> , 2011, 41, 1665-1669.	1.5	5
869	Risk Prediction of Complex Diseases from Family History and Known Susceptibility Loci, with Applications for Cancer Screening. <i>American Journal of Human Genetics</i> , 2011, 88, 548-565.	6.2	80
870	An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations. <i>Familial Cancer</i> , 2011, 10, 97-105.	1.9	30
871	What I wish I™d known before surgery: BRCA carriers™ perspectives after bilateral salpingo-oophorectomy. <i>Familial Cancer</i> , 2011, 10, 79-85.	1.9	57
872	A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. <i>Familial Cancer</i> , 2011, 10, 193-197.	1.9	9
873	Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations. <i>Familial Cancer</i> , 2011, 10, 207-212.	1.9	4
874	BRCA1/2 genetic testing uptake and psychosocial outcomes in men. <i>Familial Cancer</i> , 2011, 10, 213-223.	1.9	27
875	Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. <i>Familial Cancer</i> , 2011, 10, 505-514.	1.9	6
876	Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families. <i>Familial Cancer</i> , 2011, 10, 521-528.	1.9	27
877	Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan. <i>Familial Cancer</i> , 2011, 10, 709-712.	1.9	7
878	The Development of a Methodology for Examining the Process of Family Communication of Genetic Test Results. <i>Journal of Genetic Counseling</i> , 2011, 20, 23-34.	1.6	12
879	Development and Evaluation of a Decision Aid for <i>BRCA</i> Carriers with Breast Cancer. <i>Journal of Genetic Counseling</i> , 2011, 20, 294-307.	1.6	33
880	Awareness and Preferences Regarding <i>BRCA1/2</i> Genetic Counseling and Testing Among Latinas and Non-Latina White Women at Increased Risk for Hereditary Breast and Ovarian Cancer. <i>Journal of Genetic Counseling</i> , 2011, 20, 625-638.	1.6	41
881	Clinical Management of Hereditary Breast Cancer Syndromes. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 17-25.	2.7	37
882	Phenotype-Genotype Correlation in Familial Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 27-40.	2.7	31
883	Inherited Mutations in Breast Cancer Genes™Risk and Response. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 3-15.	2.7	56

#	ARTICLE	IF	CITATIONS
884	No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 169-173.	2.5	26
885	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 855-860.	2.5	11
886	Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 79-84.	2.5	35
887	Body weight and risk of breast cancer in BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 193-202.	2.5	59
888	The CYP17A1 rs3424 polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 521-527.	2.5	3
889	Replication of genome-wide discovered breast cancer risk loci in the Cypriot population. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 267-272.	2.5	8
890	Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 119-130.	2.5	20
891	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 287-296.	2.5	73
892	Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 157-164.	2.5	8
893	Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 557-563.	2.5	20
894	Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 255-263.	2.5	10
895	Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 1001-1009.	2.5	13
896	Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO). <i>Breast Cancer Research and Treatment</i> , 2011, 130, 927-938.	2.5	46
897	Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 623-627.	1.7	31
898	Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women. <i>Cancer Epidemiology</i> , 2011, 35, 78-82.	1.9	2
899	De relatie tussen genetisch onderzoek, psychologisch welbevinden en medisch handelen Een vragenlijststudie bij vrouwelijke en mannelijke presymptomatische dragers en niet-dragers van een BRCA-genmutatie. <i>Psychologie and Gezondheid</i> , 2011, 39, 12-22.	0.0	1
900	The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. <i>BMC Medical Genetics</i> , 2011, 12, 9.	2.1	27
901	A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. <i>BMC Cancer</i> , 2011, 11, 265.	2.6	27

#	ARTICLE	IF	CITATIONS
902	Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial. <i>BMC Women's Health</i> , 2011, 11, 39.	2.0	14
903	Disease-specific prospective family study cohorts enriched for familial risk. <i>Epidemiologic Perspectives and Innovations</i> , 2011, 8, 2.	7.0	30
904	Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. <i>BMC Medical Genomics</i> , 2011, 4, 75.	1.5	40
905	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. <i>Hereditary Cancer in Clinical Practice</i> , 2011, 9, 10.	1.5	19
906	Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests. <i>Hereditary Cancer in Clinical Practice</i> , 2011, 9, 11.	1.5	2
907	The contribution of self-esteem and self-concept in psychological distress in women at risk of hereditary breast cancer. <i>Psycho-Oncology</i> , 2011, 20, 1170-1175.	2.3	21
908	Psychological distress in women at risk for hereditary breast cancer: the role of family communication and perceived social support. <i>Psycho-Oncology</i> , 2011, 20, 1317-1323.	2.3	30
909	New insights into the prevention and treatment of familial breast cancer. <i>Journal of Surgical Oncology</i> , 2011, 103, 294-298.	1.7	5
910	Diabetes and breast cancer among women with <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Cancer</i> , 2011, 117, 1812-1818.	4.1	62
911	Should patients be screened for hereditary cancer syndromes before starting anti-TNF- α therapy?. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E151-E152.	1.9	3
912	The Korean Hereditary Breast Cancer (KOHBRA) Study: Protocols and Interim Report. <i>Clinical Oncology</i> , 2011, 23, 434-441.	1.4	63
914	Hereditary breast cancer and the BRCA1-associated FANCD1/BACH1/BRIP1. <i>Future Oncology</i> , 2011, 7, 253-261.	2.4	94
915	Breast Cancer Risk – Genes, Environment and Clinics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2011, 71, 1056-1066.	1.8	55
916	Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?. <i>Current Medicinal Chemistry</i> , 2011, 18, 5519-5527.	2.4	56
917	Recruitment of Black Women for a Study of Inherited Breast Cancer Using a Cancer Registry-Based Approach. <i>Genetic Testing and Molecular Biomarkers</i> , 2011, 15, 69-77.	0.7	23
918	Chk2 DNA Damage Response Pathway and Inherited Breast Cancer Risk. <i>Journal of Clinical Oncology</i> , 2011, 29, 3813-3815.	1.6	16
919	Communicating BRCA1/2 genetic test results within the family: A qualitative analysis. <i>Psychology and Health</i> , 2011, 26, 1018-1035.	2.2	44
920	Breast Cancer Risk for Noncarriers of Family-Specific <i>BRCA1</i> and <i>BRCA2</i> Mutations: Findings From the Breast Cancer Family Registry. <i>Journal of Clinical Oncology</i> , 2011, 29, 4505-4509.	1.6	38

#	ARTICLE	IF	CITATIONS
921	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1032-1038.	2.5	16
922	Diagnostic Pathology of Ovarian Tumors. , 2011, , .		6
923	Genetic Variation in <i>IGF2</i> and <i>HTRA1</i> and Breast Cancer Risk among <i>BRCA1</i> and <i>BRCA2</i> Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1690-1702.	2.5	17
924	Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Annals of Oncology, 2011, 22, i11-i17.	1.2	75
925	Commentary: Children and Predictive Genomic Testing: Disease Prevention, Research Protection, and Our Future. Journal of Pediatric Psychology, 2011, 36, 1113-1121.	2.1	19
926	Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. Journal of Medical Genetics, 2011, 48, 266-272.	3.2	41
927	The Optimization of Breast Conservation. International Journal of Breast Cancer, 2011, 2011, 1-1.	1.2	0
928	Prophylactic and Therapeutic Breast Conservation in <i>BRCA1/2</i> Mutation Carriers. International Journal of Breast Cancer, 2011, 2011, 1-9.	1.2	7
929	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	2.9	32
930	BRCA in breast cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 2011, 22, vi31-vi34.	1.2	174
931	Hereditary breast cancer: clinical features and risk reduction strategies. Annals of Oncology, 2011, 22, i31-i36.	1.2	26
932	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	6.3	40
933	Molecular Biological Aspects on Canine and Human Mammary Tumors. Veterinary Pathology, 2011, 48, 132-146.	1.7	90
934	Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, 2011, 43, 879-882.	21.4	460
935	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British Journal of Cancer, 2011, 105, 22-27.	6.4	60
936	The genetics of breast and ovarian cancer V: application to income protection insurance. Scandinavian Actuarial Journal, 2011, 2011, 267-291.	1.7	1
937	Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Annals of Oncology, 2011, 22, 1346-1352.	1.2	170
938	The genetics of breast and ovarian cancer IV: a model of breast cancer progression. Scandinavian Actuarial Journal, 2011, 2011, 239-266.	1.7	1

#	ARTICLE	IF	CITATIONS
939	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	2.5	23
940	Genes and Cancer. , 2012, , 561-596.e6.		0
941	Choices for Young Women at Intermediate Risk of Breast Cancer. <i>Current Oncology</i> , 2012, 19, 112-114.	2.2	0
942	Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. <i>European Journal of Human Genetics</i> , 2012, 20, 4-10.	2.8	68
943	Genetics of breast cancer: Contribution of BRCA1/2 genes alterations to hereditary predisposition. <i>Vojnosanitetski Pregled</i> , 2012, 69, 700-706.	0.2	4
944	An integer linear programming approach for finding deregulated subgraphs in regulatory networks. <i>Nucleic Acids Research</i> , 2012, 40, e43-e43.	14.5	84
945	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. <i>Journal of Medical Genetics</i> , 2012, 49, 525-532.	3.2	97
946	HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells. <i>Cancer Biology and Therapy</i> , 2012, 13, 766-775.	3.4	39
947	Evaluating Breast Cancer Risk With Genome-Wide Association Studies: Is This Approach Patient Ready?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4288-4289.	1.6	0
948	Common Variation in Nemo-Like Kinase Is Associated with Risk of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 523-528.	2.5	8
949	Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study. <i>Genetics in Medicine</i> , 2012, 14, 60-68.	2.4	9
951	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment. <i>Cell Cycle</i> , 2012, 11, 4402-4413.	2.6	71
952	Differing clinical impact of <i>BRCA1</i> and <i>BRCA2</i> mutations in serous ovarian cancer. <i>Pharmacogenomics</i> , 2012, 13, 1523-1535.	1.3	63
954	Challenges in the treatment of younger women with breast cancer. <i>Breast Cancer Management</i> , 2012, 1, 127-134.	0.2	0
955	Using Radiation Risk Models in Cancer Screening Simulations: Important Assumptions and Effects on Outcome Projections. <i>Radiology</i> , 2012, 262, 977-984.	7.3	30
956	Epigenetic biomarkers in the diagnosis of ovarian cancer. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 421-438.	1.6	6
957	Efficient Identification and Referral of <i>Low-Income Women at High Risk for Hereditary Breast Cancer: A Practice-Based Approach. <i>Public Health Genomics</i> , 2012, 15, 172-180.	1.0	27
958	BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. <i>British Journal of Cancer</i> , 2012, 106, 1234-1238.	6.4	85

#	ARTICLE	IF	CITATIONS
959	Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. British Journal of Cancer, 2012, 107, 24-30.	6.4	167
960	Differences in Natural History between Breast Cancers in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468.	2.5	79
961	Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers. Endocrine-Related Cancer, 2012, 19, 69-81.	3.1	8
962	Hereditary ovarian cancer and two-compartment tumor metabolism. Cell Cycle, 2012, 11, 4152-4166.	2.6	53
963	Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer. Cancer Research, 2012, 72, 4141-4153.	0.9	115
964	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass), 2012, 18, 310-319.	2.0	22
965	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass), 2012, 18, 320-327.	2.0	48
966	Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Prevention Research, 2012, 5, 1291-1297.	1.5	24
967	Effectiveness of Risk-Reducing Salpingo-Oophorectomy in Preventing Ovarian Cancer in a High-Risk French Canadian Population. International Journal of Gynecological Cancer, 2012, 22, 974-978.	2.5	10
968	Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, The, 2012, 345, e5660-e5660.	6.0	186
969	Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts. Breast Care, 2012, 7, 364-369.	1.4	11
970	Journal Club. Breast Care, 2012, 7, 501-504.	1.4	0
971	Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a <i>BRCA1</i> / <i>BRCA2</i> French Canadian Founder Mutation. Cancer Prevention Research, 2012, 5, 765-777.	1.5	0
972	Clinicopathologic Characteristics and Survival in BRCA1- and BRCA2-Related Adnexal Cancer. International Journal of Gynecological Cancer, 2012, 22, 579-585.	2.5	9
973	Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers. Pathology, 2012, 44, 89-98.	0.6	7
974	Identification and Characterization of BRCA1 and BRCA2 Founder Mutations. Current Women's Health Reviews, 2012, 8, 17-22.	0.2	2
975	Modifiers of Risk in BRCA1/2 Mutation Carriers. Current Women's Health Reviews, 2012, 8, 23-29.	0.2	2
976	Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines. Current Women's Health Reviews, 2012, 8, 4-11.	0.2	0

#	ARTICLE	IF	CITATIONS
977	What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?. Current Women's Health Reviews, 2012, 8, 65-71.	0.2	1
978	Editorial from Guest Editor [Hot Topic: Familial and Hereditary Breast and Ovarian Tumors (Guest) Tj ETQq1 1 0.784314 rgBT /Overlook	0.2	0
979	Genetic Risk Assessments in Individuals at High Risk for Inherited Breast Cancer in the Breast Oncology Care Setting. Cancer Control, 2012, 19, 255-266.	1.8	37
980	Genetic markers for ovarian cancer risk: are we close to seeing a clinical impact?. Personalized Medicine, 2012, 9, 565-567.	1.5	3
981	Animal Studies of Charged Particle-induced Carcinogenesis. Health Physics, 2012, 103, 568-576.	0.5	48
982	Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy. International Journal of Gynecological Cancer, 2012, 22, 881-888.	2.5	7
983	Early Detection Biomarkers for Ovarian Cancer. Journal of Oncology, 2012, 2012, 1-15.	1.3	75
985	- Electrochemical Biosensor for Detection of Chronic Myelogenous Leukemia and Acute Promyelocytic Leukemia. , 2012, , 718-737.		0
986	A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1066-1077.	2.5	43
987	Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability. International Journal of Nanomedicine, 2012, 7, 3951.	6.7	57
988	Online Tool to Guide Decisions for<i>BRCA1/2</i>Mutation Carriers. Journal of Clinical Oncology, 2012, 30, 497-506.	1.6	81
989	Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. Translational Research, 2012, 160, 178-197.	5.0	32
990	Breast and Ovarian Cancer Risk and Risk Reduction in Jewish <i>BRCA1/2</i> Mutation Carriers. Journal of Clinical Oncology, 2012, 30, 1321-1328.	1.6	31
991	Variable Outcome of Mutations. Science, 2012, 335, 44-45.	12.6	3
992	Anthropometric Measures and Risk of Ovarian Cancer Among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Obesity, 2012, 20, 1288-1292.	3.0	10
993	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. Breast Cancer Research, 2012, 14, R63.	5.0	22
994	Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO). Breast Cancer Research, 2012, 14, R99.	5.0	32
995	The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Research, 2012, 14, R156.	5.0	112

#	ARTICLE	IF	CITATIONS
996	Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients. Breast Cancer Research and Treatment, 2012, 134, 1189-1197.	2.5	15
997	Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer. Breast Cancer Research and Treatment, 2012, 134, 1315-1326.	2.5	42
998	Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. Breast Cancer Research and Treatment, 2012, 135, 715-724.	2.5	81
999	Germline mutations in RAD51C in Jewish high cancer risk families. Breast Cancer Research and Treatment, 2012, 136, 869-874.	2.5	12
1000	Folate and breast cancer: what about high-risk women?. Cancer Causes and Control, 2012, 23, 1405-1420.	1.8	23
1001	A Patient With Metastatic Breast Cancer 15 Years After Bilateral Prophylactic Total Mastectomy and Oophorectomy. Clinical Breast Cancer, 2012, 12, 450-453.	2.4	0
1002	Fight against cancer around the Mediterranean area: "Many hands make light work". Critical Reviews in Oncology/Hematology, 2012, 84, e1-e5.	4.4	1
1003	Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome. Familial Cancer, 2012, 11, 473-482.	1.9	13
1004	Adequacy of family history taking in ovarian cancer patients: a population-based study. Familial Cancer, 2012, 11, 343-349.	1.9	12
1005	The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. Familial Cancer, 2012, 11, 403-410.	1.9	21
1006	Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Familial Cancer, 2012, 11, 429-439.	1.9	27
1007	Routine TP53 testing for breast cancer under age 30: ready for prime time?. Familial Cancer, 2012, 11, 607-613.	1.9	74
1008	Safety of hormone replacement therapy in gynaecological cancer survivors. Journal of Obstetrics and Gynaecology, 2012, 32, 321-325.	0.9	30
1009	Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Research and Treatment, 2012, 135, 355-366.	2.5	49
1010	Model of care for women at increased risk of breast and ovarian cancer. Maturitas, 2012, 71, 3-5.	2.4	16
1011	Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genetics, 2012, 205, 34-41.	0.4	42
1012	Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. Cancer Genetics, 2012, 205, 242-248.	0.4	33
1014	Three novel BRCA1/BRCA2 mutations in breast/ovarian cancer families in Croatia. Gene, 2012, 498, 169-176.	2.2	10

#	ARTICLE	IF	CITATIONS
1015	Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome. <i>Journal of Biological Chemistry</i> , 2012, 287, 7701-7716.	3.4	55
1016	DNA- and PKC-dependent NHEJ pathway supports the progression of topoisomerase II poison-induced chromosome aberrant cells. <i>Environmental and Molecular Mutagenesis</i> , 2012, 53, 608-618.	2.2	3
1017	The application of nonsense-mediated mRNA decay inhibition to the identification of breast cancer susceptibility genes. <i>BMC Cancer</i> , 2012, 12, 246.	2.6	4
1018	Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. <i>BMC Cancer</i> , 2012, 12, 454.	2.6	9
1019	Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer. <i>BMC Cancer</i> , 2012, 12, 531.	2.6	12
1020	DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct. <i>BMC Women's Health</i> , 2012, 12, 12.	2.0	9
1021	A Pilot study of the Sharing Risk Information Tool (ShaRIT) for Families with Hereditary Breast and Ovarian Cancer Syndrome. <i>Hereditary Cancer in Clinical Practice</i> , 2012, 10, 4.	1.5	28
1022	Cancer treatment according to BRCA1 and BRCA2 mutations. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 520-528.	27.6	69
1023	BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. <i>Clinical Genetics</i> , 2012, 82, 484-488.	2.0	26
1024	Two double heterozygotes in a South African Afrikaner family: implications for BRCA1 and BRCA2 predictive testing. <i>Clinical Genetics</i> , 2012, 82, 599-600.	2.0	4
1025	Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes. <i>Future Medicinal Chemistry</i> , 2012, 4, 51-72.	2.3	21
1026	Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. <i>Human Pathology</i> , 2012, 43, 1932-1939.	2.0	5
1027	PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells. <i>Biochemical Pharmacology</i> , 2012, 84, 1318-1331.	4.4	24
1028	Breast reconstruction in bilateral prophylactic mastectomy patients: Factors that influence decision making. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2012, 65, 1481-1489.	1.0	25
1029	Breast cancer genetic counseling after diagnosis but before treatment: A pilot study on treatment consequences and psychological impact. <i>Patient Education and Counseling</i> , 2012, 89, 89-95.	2.2	32
1030	Management of women with BRCA1/2 mutation-associated breast cancer. <i>Breast Cancer Management</i> , 2012, 1, 157-164.	0.2	0
1031	Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk. <i>Frontiers in Genetics</i> , 2012, 3, 258.	2.3	11
1032	Breast cancer genome-wide association studies: there is strength in numbers. <i>Oncogene</i> , 2012, 31, 2121-2128.	5.9	96

#	ARTICLE	IF	CITATIONS
1033	Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers. Current Breast Cancer Reports, 2012, 4, 199-206.	1.0	0
1034	Genetic Polymorphisms as Predictors of Breast Cancer Risk. Current Breast Cancer Reports, 2012, 4, 232-239.	1.0	1
1035	Hereditary Gynecologic Cancers. Obstetrics and Gynecology Clinics of North America, 2012, 39, 165-181.	1.9	9
1036	Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families. Familial Cancer, 2012, 11, 483-491.	1.9	29
1037	Cancer genetic risk assessment for individuals at risk of familial breast cancer. The Cochrane Library, 2012, , CD003721.	2.8	56
1038	High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Familial Cancer, 2012, 11, 623-628.	1.9	20
1039	Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clinical Chemistry and Laboratory Medicine, 2012, 50, 423-34.	2.3	31
1040	Rare Tumors In Children and Adolescents. Pediatric Oncology, 2012, , .	0.5	8
1041	A Genomewide Screen for Suppressors of Alu-Mediated Rearrangements Reveals a Role for PIF1. PLoS ONE, 2012, 7, e30748.	2.5	59
1042	The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS ONE, 2012, 7, e37891.	2.5	30
1044	By the Pricking of My Thumbs, Something Wicked This Way Comes: Sporadic Cancers Versus Eponymous Hereditary Cancer Predisposition Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 7-13.	4.9	0
1045	Understanding how decisions influence health. , 0, , 26-73.		0
1046	Hox Gene Expression in Ovarian Cancer. Annals of Oncology, 2012, 23, ix68.	1.2	0
1047	Prevention of Oncological Diseases: Primary and Secondary Prevention. International Journal of Biological Markers, 2012, 27, 337-343.	1.8	4
1048	Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil. Genetics and Molecular Biology, 2012, 35, 599-602.	1.3	26
1049	The impact of social and personal resources on psychological distress in women at risk for hereditary breast cancer. Psycho-Oncology, 2012, 21, 153-160.	2.3	20
1050	Translational advances regarding hereditary breast cancer syndromes. Journal of Surgical Oncology, 2012, 105, 444-451.	1.7	91
1051	Micronucleus assay in buccal smears of breast carcinoma patients. Diagnostic Cytopathology, 2012, 40, 664-666.	1.0	15

#	ARTICLE	IF	CITATIONS
1052	Evaluation of Association Methods for Analysing Modifiers of Disease Risk in Carriers of High-Risk Mutations. <i>Genetic Epidemiology</i> , 2012, 36, 274-291.	1.3	37
1053	Identification of fifteen novel germline variants in the <i>BRCA1</i> 3'UTR reveals a variant in a breast cancer case that introduces a functional <i>miR-103</i> target site. <i>Human Mutation</i> , 2012, 33, 1665-1675.	2.5	49
1054	The risk of breast cancer in women with a <i>BRCA1</i> mutation from North America and Poland. <i>International Journal of Cancer</i> , 2012, 131, 229-234.	5.1	38
1055	Annual screening strategies in <i>BRCA1</i> and <i>BRCA2</i> gene mutation carriers. <i>Cancer</i> , 2012, 118, 2021-2030.	4.1	104
1056	Clinical significance of large rearrangements in <i>BRCA1</i> and <i>BRCA2</i> . <i>Cancer</i> , 2012, 118, 5210-5216.	4.1	125
1057	Plasma micronutrients, trace elements, and breast cancer in <i>BRCA1</i> mutation carriers: an exploratory study. <i>Cancer Causes and Control</i> , 2012, 23, 1065-1074.	1.8	26
1058	French women's breast self-examination practices with time after undergoing <i>BRCA1/2</i> genetic testing. <i>Familial Cancer</i> , 2012, 11, 269-278.	1.9	8
1059	Direct-to-Consumer Genetic Testing: What Are We Talking About?. <i>Journal of Genetic Counseling</i> , 2012, 21, 361-366.	1.6	8
1060	Breast Alert: An On-line Tool for Predicting the Lifetime Risk of Women Breast Cancer. <i>Journal of Medical Systems</i> , 2012, 36, 1417-1424.	3.6	6
1061	Modern Trends into the Epidemiology and Screening of Ovarian Cancer. <i>Genetic Substrate of the Sporadic Form. Pathology and Oncology Research</i> , 2012, 18, 135-148.	1.9	9
1062	Accuracy of <i>BRCA1/2</i> Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. <i>World Journal of Surgery</i> , 2012, 36, 702-713.	1.6	19
1064	Prevalence and characterization of <i>BRCA1</i> and <i>BRCA2</i> germline mutations in Chinese women with familial breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 421-428.	2.5	63
1065	Phenocopy breast cancer rates in Israeli <i>BRCA1</i> <i>BRCA2</i> mutation carrier families: is the risk increased in non-carriers?. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 669-673.	2.5	7
1066	Molecular and clinical characterization of an in frame deletion of uncertain clinical significance in the <i>BRCA2</i> gene. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 725-734.	2.5	1
1067	Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 347-355.	2.5	21
1068	Rare germline large rearrangements in the <i>BRCA1/2</i> genes and eight candidate genes in 472 patients with breast cancer predisposition. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1179-1190.	2.5	20
1069	Germline Mutation in <i>ATR</i> in Autosomal-Dominant Oropharyngeal Cancer Syndrome. <i>American Journal of Human Genetics</i> , 2012, 90, 511-517.	6.2	68
1070	Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 527-536.	2.3	53

#	ARTICLE	IF	CITATIONS
1071	Screening for gynaecologic cancers in genetically predisposed women. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 267-282.	2.8	1
1072	Unravelling modifiers of breast and ovarian cancer risk for <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: update on genetic modifiers. <i>Journal of Internal Medicine</i> , 2012, 271, 331-343.	6.0	47
1073	Critique of "Evidence-Based Surgical Hypothesis: The case against BRCA1 and 2 testing". <i>Surgery</i> , 2012, 151, 634-637.	1.9	0
1074	BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. <i>Gynecologic Oncology</i> , 2012, 124, 236-243.	1.4	60
1075	Hereditary ovarian cancer: Beyond the usual suspects. <i>Gynecologic Oncology</i> , 2012, 124, 347-353.	1.4	135
1076	Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. <i>Gynecologic Oncology</i> , 2012, 126, 229-235.	1.4	6
1077	Familial Breast Cancer. <i>Clinical Genetics</i> , 2012, 82, 105-114.	2.0	147
1078	Who's to blame? Accounts of genetic responsibility and blame among Ashkenazi Jewish women at risk of BRCA breast cancer. <i>Sociology of Health and Illness</i> , 2012, 34, 776-790.	2.1	16
1079	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	5.0	78
1080	Managing the Breast in Patients Who Test Positive for Hereditary Breast Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1738-1744.	1.5	9
1081	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in Ashkenazi Jewish families with breast and pancreatic cancer. <i>Cancer</i> , 2012, 118, 493-499.	4.1	83
1082	Disparities in cancer screening in individuals with a family history of breast or colorectal cancer. <i>Cancer</i> , 2012, 118, 1656-1663.	4.1	28
1083	Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	2.5	34
1084	Genetic variants of fibroblast growth factor receptor 2 (FGFR2) are associated with breast cancer risk in Chinese women of the Han nationality. <i>Immunogenetics</i> , 2012, 64, 71-76.	2.4	15
1086	Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 981-985.	2.5	1
1087	BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. <i>Familial Cancer</i> , 2012, 11, 57-67.	1.9	19
1088	Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. <i>Familial Cancer</i> , 2012, 11, 77-84.	1.9	25
1089	Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer. <i>Familial Cancer</i> , 2012, 11, 33-40.	1.9	23

#	ARTICLE	IF	CITATIONS
1090	Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. <i>Molecular Biology Reports</i> , 2012, 39, 1037-1046.	2.3	76
1091	The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. <i>Psycho-Oncology</i> , 2013, 22, 212-219.	2.3	71
1092	Long-term psychological distress in women at risk for hereditary breast cancer adhering to regular surveillance: a risk profile. <i>Psycho-Oncology</i> , 2013, 22, 598-604.	2.3	27
1093	Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. <i>Breast Cancer Research</i> , 2013, 15, R17.	5.0	42
1094	Comparison of the Screening Practices of Unaffected Noncarriers under 40 and between 40 and 49 in BRCA1/2 Families. <i>Journal of Genetic Counseling</i> , 2013, 22, 469-481.	1.6	3
1095	Educational Needs and Preferred Methods of Learning Among Florida Practitioners Who Order Genetic Testing for Hereditary Breast and Ovarian Cancer. <i>Journal of Cancer Education</i> , 2013, 28, 690-697.	1.3	17
1096	The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. <i>Cell and Bioscience</i> , 2013, 3, 11.	4.8	38
1097	Perceived risk and adherence to breast cancer screening guidelines among women with a familial history of breast cancer: A review of the literature. <i>Breast</i> , 2013, 22, 395-404.	2.2	27
1098	Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. <i>Familial Cancer</i> , 2013, 12, 479-487.	1.9	97
1099	Familial Breast Cancer Risk. <i>Current Breast Cancer Reports</i> , 2013, 5, 170-182.	1.0	8
1100	Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. <i>BMC Cancer</i> , 2013, 13, 339.	2.6	47
1101	Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). <i>BMC Cancer</i> , 2013, 13, 243.	2.6	40
1102	First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report. <i>BMC Cancer</i> , 2013, 13, 46.	2.6	34
1103	Screening for genomic rearrangements at BRCA1 locus in Iranian women with breast cancer using multiplex ligation-dependent probe amplification. <i>Journal of Genetics</i> , 2013, 92, 131-134.	0.7	4
1104	The complex genetic landscape of familial breast cancer. <i>Human Genetics</i> , 2013, 132, 845-863.	3.8	125
1105	Parental origin of mutation and the risk of breast cancer in a prospective study of women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Clinical Genetics</i> , 2013, 84, 43-46.	2.0	16
1106	Providing access to risk prediction tools via the HL7 XML-formatted risk web service. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 187-193.	2.5	13
1107	Inherited Genetic Susceptibility to Breast Cancer. <i>American Journal of Pathology</i> , 2013, 183, 1038-1051.	3.8	82

#	ARTICLE	IF	CITATIONS
1108	Management of Gynecological Cancers in Older Women. , 2013, , .		2
1109	The risk of primary and contralateral breast cancer after ovarian cancer in <i>BRCA1</i>/<i>BRCA2</i> mutation carriers. Cancer, 2013, 119, 955-962.	4.1	31
1110	Costâ€effectiveness of alternating magnetic resonance imaging and digital mammography screening in <i>BRCA1</i> and <i>BRCA2</i> gene mutation carriers. Cancer, 2013, 119, 1266-1276.	4.1	73
1111	Management of sexual problems in cancer patients and survivors. Current Problems in Cancer, 2013, 37, 319-352.	2.0	34
1112	Proven non-carriers in BRCA families have an earlier age of onset of breast cancer. European Journal of Cancer, 2013, 49, 2101-2106.	2.8	15
1113	ParticularitÃ©s de lâ€™imagerie des cancers du sein chez les femmes jeunes et mutÃ©es. Imagerie De La Femme, 2013, 23, 76-86.	0.0	0
1114	A Clinically Validated Diagnostic Second-Generation Sequencing Assay for Detection of Hereditary BRCA1 and BRCA2 Mutations. Journal of Molecular Diagnostics, 2013, 15, 796-809.	2.8	29
1116	Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WE CARE Study Report. European Journal of Cancer, 2013, 49, 2979-2985.	2.8	72
1117	Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. Journal of the National Cancer Institute, 2013, 105, 812-822.	6.3	753
1118	Breast Cancer Risk Assessment, Prevention, and the Future. Obstetrics and Gynecology Clinics of North America, 2013, 40, 525-549.	1.9	9
1119	Local approaches to hereditary breast cancer. Annals of Oncology, 2013, 24, viii54-viii60.	1.2	7
1120	Ovarian Neoplasm Imaging. , 2013, , .		0
1121	EpidemiologÃ­a del cÃ¡ncer de mama. EMC - GinecologÃ­a-Obstetricia, 2013, 49, 1-19.	0.0	0
1122	Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. Breast, 2013, 22, 561-568.	2.2	27
1123	Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. Journal of Clinical Oncology, 2013, 31, 3091-3099.	1.6	148
1124	Tumour morphology predicts PALB2 germline mutation status. British Journal of Cancer, 2013, 109, 154-163.	6.4	19
1125	Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Annals of Oncology, 2013, 24, viii69-viii74.	1.2	95
1126	Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hereditary Cancer in Clinical Practice, 2013, 11, 12.	1.5	48

#	ARTICLE	IF	CITATIONS
1127	Comparison of whole genome amplification and nested-PCR methods for preimplantation genetic diagnosis for BRCA1 gene mutation on unfertilized oocytes—a pilot study. <i>Hereditary Cancer in Clinical Practice</i> , 2013, 11, 10.	1.5	7
1128	Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families. <i>BMC Medical Genetics</i> , 2013, 14, 82.	2.1	12
1129	Association of 8q24 rs13281615A>G polymorphism with breast cancer risk: evidence from 40,762 cases and 50,380 controls. <i>Molecular Biology Reports</i> , 2013, 40, 4065-4073.	2.3	5
1130	Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 283-296.	2.5	22
1131	Is the psychological impact of genetic testing moderated by support and sharing of test results to family and friends?. <i>Familial Cancer</i> , 2013, 12, 601-610.	1.9	9
1132	The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. <i>Familial Cancer</i> , 2013, 12, 587-595.	1.9	11
1133	Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. <i>Familial Cancer</i> , 2013, 12, 621-628.	1.9	18
1135	Review of risk factors for the development of contralateral breast cancer. <i>American Journal of Surgery</i> , 2013, 206, 704-708.	1.8	57
1136	BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 949-960.e4.	0.8	48
1137	The Different Impact of <i>BRCA</i> Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience. <i>Oncology</i> , 2013, 85, 122-127.	1.9	10
1138	Early Onset Breast Cancer in a Registry-based Sample of African-American Women:BRCA Mutation Prevalence, and Other Personal and System-level Clinical Characteristics. <i>Breast Journal</i> , 2013, 19, 189-192.	1.0	32
1139	Common breast cancer risk variants in the post-COGS era: a comprehensive review. <i>Breast Cancer Research</i> , 2013, 15, 212.	5.0	52
1140	A Critical Evaluation of the Evidence for Ovarian Conservation Versus Removal at the Time of Hysterectomy for Benign Disease. <i>Journal of Women's Health</i> , 2013, 22, 755-759.	3.3	12
1141	<i>BRCA1</i> Germ-Line Mutations and Tumor Characteristics in Eastern Chinese Women with Familial Breast Cancer. <i>Anatomical Record</i> , 2013, 296, 273-278.	1.4	15
1142	The appraisal and management of uncertainty: Implications for information-retrieval systems. <i>Information Processing and Management</i> , 2013, 49, 1241-1249.	8.6	49
1143	Keeping it simple: Genetics referrals for all invasive serous ovarian cancers. <i>Gynecologic Oncology</i> , 2013, 130, 329-333.	1.4	44
1144	Testing for the Recurrent <i>HOXB13</i> G84E Germline Mutation in Men with Clinical Indications for Prostate Biopsy. <i>Journal of Urology</i> , 2013, 189, 849-853.	0.4	12
1145	Paciente de 56 años con antecedente de mastectomía bilateral por cáncer de mama y lesión anexial izquierda. <i>Medicine</i> , 2013, 11, 1697.e1-1697.e3.	0.0	0

#	ARTICLE	IF	CITATIONS
1146	Hereditary Breast/Ovarian Cancer Syndrome. Obstetrics and Gynecology Clinics of North America, 2013, 40, 475-512.	1.9	11
1147	Hereditary gynaecological malignancies: advances in screening and treatment. Histopathology, 2013, 62, 2-30.	2.9	43
1148	Genotype in <i>BRCA</i> -associated Breast Cancers. Breast Journal, 2013, 19, 87-91.	1.0	6
1149	Ovarian Cancer: In Search of Better Marker Systems Based on DNA Repair Defects. International Journal of Molecular Sciences, 2013, 14, 640-673.	4.1	20
1150	BRCA1 and BRCA2 Mutations in the Ovarian Cancer Population across Race and Ethnicity: Special Reference to Asia. Oncology, 2013, 84, 226-232.	1.9	27
1151	Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Clinical Genetics, 2013, 83, 88-91.	2.0	14
1152	Genetic Predisposition Syndromes and Their Management. Surgical Clinics of North America, 2013, 93, 341-362.	1.5	26
1153	BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. British Journal of Cancer, 2013, 108, 1231-1237.	6.4	120
1154	Management of Genetic Syndromes Predisposing to Gynecologic Cancers. Current Treatment Options in Oncology, 2013, 14, 34-50.	3.0	9
1155	NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer. Journal of Genetic Counseling, 2013, 22, 155-163.	1.6	124
1156	10 rare tumors that warrant a genetics referral. Familial Cancer, 2013, 12, 1-18.	1.9	24
1157	Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Research and Treatment, 2013, 139, 571-579.	2.5	24
1158	Current approach to fertility preservation by embryo cryopreservation. Fertility and Sterility, 2013, 99, 1496-1502.	1.0	81
1159	Pharmacogenomics in Cancer Therapeutics. , 2013, , 89-116.		0
1160	Practical aspects of genetic counseling in breast cancer: Lights and shadows. Breast, 2013, 22, 375-382.	2.2	30
1161	Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Research and Treatment, 2013, 139, 155-161.	2.5	54
1162	Support of the "fallopian tube hypothesis"™ in a prospective series of risk-reducing salpingo-oophorectomy specimens. European Journal of Cancer, 2013, 49, 132-141.	2.8	95
1163	Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting <i>BRCA1/2</i> mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. Journal of Medical Genetics, 2013, 50, 360-367.	3.2	88

#	ARTICLE	IF	CITATIONS
1164	Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer. <i>Familial Cancer</i> , 2013, 12, 101-109.	1.9	10
1165	Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4188-4198.	1.6	221
1166	Baseline E2 levels are higher in BRCA2 mutation carriers: a potential target for prevention?. <i>Cancer Causes and Control</i> , 2013, 24, 421-426.	1.8	23
1167	Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. <i>Annals of Oncology</i> , 2013, 24, 2036-2042.	1.2	18
1168	Alternatives to risk-reducing surgery for ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, viii47-viii53.	1.2	15
1169	Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. <i>Familial Cancer</i> , 2013, 12, 65-73.	1.9	11
1170	Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 135-144.	2.5	35
1171	Unmet support needs and distress among women with a BRCA1/2 mutation. <i>Familial Cancer</i> , 2013, 12, 509-518.	1.9	21
1172	More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. <i>Familial Cancer</i> , 2014, 13, 143-51.	1.9	33
1173	Reproductive decision-making in young female carriers of a BRCA mutation. <i>Human Reproduction</i> , 2013, 28, 1006-1012.	0.9	62
1174	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours. <i>Geburtshilfe Und Frauenheilkunde</i> , 2013, 73, 874-889.	1.8	38
1176	Hereditary Breast Cancer: The Era of New Susceptibility Genes. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	230
1177	Identification, Evaluation, and Treatment of Patients with Hereditary Cancer Risk within the United States. <i>ISRN Oncology</i> , 2013, 2013, 1-8.	2.1	8
1178	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
1179	New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches. <i>BioMed Research International</i> , 2013, 2013, 1-13.	1.9	22
1180	Genetic Epidemiology of Breast Cancer. , 2013, , 1113-1125.		0
1181	Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1 α . <i>Anti-Cancer Drugs</i> , 2013, 24, 715-724.	1.4	25
1182	Understanding the Needs of Women Considering Risk-Reducing Salpingo-oophorectomy. <i>Cancer Nursing</i> , 2013, 36, E33-E38.	1.5	14

#	ARTICLE	IF	CITATIONS
1183	Epigenetics and the Social Work Imperative. <i>Social Work</i> , 2013, 58, 23-30.	1.1	28
1184	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. <i>Journal of Clinical Oncology</i> , 2013, 31, 49-57.	1.6	126
1185	Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases. <i>PLoS ONE</i> , 2013, 8, e58182.	2.5	27
1186	Age at Diagnosis May Trump Family History in Driving BRCA Testing in a Population of Breast Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1778-1785.	2.5	5
1187	Screening for Familial Ovarian Cancer: A Ray of Hope and a Light to Steer by. <i>Journal of Clinical Oncology</i> , 2013, 31, 8-10.	1.6	9
1189	Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 515-519.	1.3	16
1190	Biallelic Deleterious <i>BRCA1</i> Mutations in a Woman with Early-Onset Ovarian Cancer. <i>Cancer Discovery</i> , 2013, 3, 399-405.	9.4	124
1191	Prevalence and Type of <i>BRCA</i> Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. <i>Journal of Clinical Oncology</i> , 2013, 31, 210-216.	1.6	140
1192	Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 3474-3484.	7.0	76
1193	Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2013, 31, 1713-1718.	1.6	144
1194	Do <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3920-3925.	1.6	42
1195	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention. <i>Cancer Discovery</i> , 2013, 3, 812-825.	9.4	61
1196	Population-Based, Risk-Stratified Genetic Testing for Ovarian Cancer Risk: A Focus Group Study. <i>Public Health Genomics</i> , 2013, 16, 184-191.	1.0	29
1197	Preventive Care and Evaluation of the Adolescent with a Breast Mass. <i>Seminars in Plastic Surgery</i> , 2013, 27, 013-018.	2.1	9
1198	Genomic approaches in breast cancer research. <i>Briefings in Functional Genomics</i> , 2013, 12, 391-396.	2.7	23
1199	A Statewide Survey of Practitioners to Assess Knowledge and Clinical Practices Regarding Hereditary Breast and Ovarian Cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 367-375.	0.7	57
1200	Public health implications from COGS and potential for risk stratification and screening. <i>Nature Genetics</i> , 2013, 45, 349-351.	21.4	108
1201	Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families. <i>Journal of Human Genetics</i> , 2013, 58, 59-66.	2.3	6

#	ARTICLE	IF	CITATIONS
1202	Young adult daughters of <i>BRCA1/2</i> positive mothers: What do they know about hereditary cancer and how much do they worry?. <i>Psycho-Oncology</i> , 2013, 22, 2024-2031.	2.3	46
1203	Risk of metachronous breast cancer after <i>BRCA</i> mutation-associated ovarian cancer. <i>Cancer</i> , 2013, 119, 1344-1348.	4.1	58
1204	Breast cancer chemoprevention: a challenge for doctors and patients. <i>The Prescriber</i> , 2013, 24, 7-8.	0.3	0
1205	Optimal age to start preventive measures in women with <i>BRCA1/2</i> mutations or high familial breast cancer risk. <i>International Journal of Cancer</i> , 2013, 133, 156-163.	5.1	20
1206	Challenging and Complex Decisions in the Management of the BRCA Mutation Carrier. <i>Journal of Women's Health</i> , 2013, 22, 825-834.	3.3	46
1207	Suitable trial designs and cohorts for preventive breast cancer agents. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 677-687.	27.6	5
1208	An insight into the public acceptance of nutrigenomic-based personalised nutrition. <i>Nutrition Research Reviews</i> , 2013, 26, 39-48.	4.1	51
1209	Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. <i>Cell Cycle</i> , 2013, 12, 2723-2732.	2.6	104
1210	Breast cancer in<i>BRCA</i>mutation carriers: breast-conserving therapy or bilateral mastectomy?. <i>Clinical Practice (London, England)</i> , 2013, 10, 751-764.	0.1	2
1211	A Young Woman With Bilateral Breast Cancer: Identifying a Genetic Cause and Implications for Management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 512-517.	4.9	3
1212	Common low-penetrance risk variants associated with breast cancer in Polish women. <i>BMC Cancer</i> , 2013, 13, 510.	2.6	19
1213	Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. <i>Obstetrics and Gynecology</i> , 2013, 121, 14-24.	2.4	134
1214	Buried Flap Reconstruction after Nipple-Sparing Mastectomy. <i>Plastic and Reconstructive Surgery</i> , 2013, 132, 489e-497e.	1.4	28
1215	Mutation Screening of the BRCA1 Gene in Early Onset and Familial Breast/Ovarian Cancer in Moroccan Population. <i>International Journal of Medical Sciences</i> , 2013, 10, 60-67.	2.5	56
1216	Establishing a Program for Individuals at High Risk for Breast Cancer. <i>Journal of Cancer</i> , 2013, 4, 433-446.	2.5	14
1217	Salpingectomy to Prevent Ovarian Cancer. <i>Current Oncology</i> , 2013, 20, 145-147.	2.2	20
1218	Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. <i>OncoTargets and Therapy</i> , 2013, 6, 1197.	2.0	12
1219	Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. <i>Medical Journal of Australia</i> , 2013, 199, 680-683.	1.7	39

#	ARTICLE	IF	CITATIONS
1221	Identity-by-Descent Mapping to Detect Rare Variants Conferring Susceptibility to Multiple Sclerosis. PLoS ONE, 2013, 8, e56379.	2.5	18
1222	Comparative In Vitro and In Silico Analyses of Variants in Splicing Regions of BRCA1 and BRCA2 Genes and Characterization of Novel Pathogenic Mutations. PLoS ONE, 2013, 8, e57173.	2.5	64
1223	PALB2 and breast cancer: ready for clinical translation!. The Application of Clinical Genetics, 2013, 6, 43.	3.0	40
1224	Genetic etiology of sporadic ovarian cancer. , 0, , 141-150.		0
1225	Risk factors for psychological distress in women at risk for hereditary/familial breast cancer: a systematic review. Breast Cancer Management, 2013, 2, 149-162.	0.2	2
1226	Pathogenesis, prevention, diagnosis and treatment of breast cancer. World Journal of Clinical Oncology, 2014, 5, 283.	2.3	184
1227	The BRCA1 Variant p.Ser36Tyr Abrogates BRCA1 Protein Function and Potentially Confers a Moderate Risk of Breast Cancer. PLoS ONE, 2014, 9, e93400.	2.5	3
1228	The Validation and Clinical Implementation of BRCaPlus: A Comprehensive High-Risk Breast Cancer Diagnostic Assay. PLoS ONE, 2014, 9, e97408.	2.5	67
1229	BRCA-Associated Ovarian Cancer: From Molecular Genetics to Risk Management. BioMed Research International, 2014, 2014, 1-11.	1.9	59
1230	Clinical features and management of em BRCA1 em and em BRCA2- em associated prostate cancer. Frontiers in Bioscience - Elite, 2014, E6, 15-30.	1.8	21
1231	The Affordable Care Act and Genetic Testing for Inheritable Cancer Syndromes: Impact on High-Risk Underserved Minorities. Journal of Health Care for the Poor and Underserved, 2014, 25, 46-62.	0.8	15
1232	Specific BRCA1 gene variations amongst young Moroccan breast cancer patients. Genetics and Molecular Research, 2014, 13, 791-798.	0.2	12
1233	Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World Journal of Clinical Oncology, 2014, 5, 495.	2.3	37
1235	Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. Journal of Medical Genetics, 2014, 51, 108-113.	3.2	58
1236	The frequency and outcome of breast cancer risk-reducing surgery in finnish BRCA1 and BRCA2 mutation carriers. Scandinavian Journal of Surgery, 2014, 103, 34-40.	2.6	5
1237	Genome-wide association studies and the clinic: a focus on breast cancer. Biomarkers in Medicine, 2014, 8, 287-296.	1.4	13
1238	Functional characterization of BRCA1 gene variants by mini-gene splicing assay. European Journal of Human Genetics, 2014, 22, 1362-1368.	2.8	58
1239	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Annals of Oncology, 2014, 25, 32-40.	1.2	290

#	ARTICLE	IF	CITATIONS
1240	Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer. International Journal of Molecular Sciences, 2014, 15, 23024-23041.	4.1	54
1241	A Randomized, Controlled Trial to Increase Discussion of Breast Cancer in Primary Care. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1245-1253.	2.5	33
1242	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . New England Journal of Medicine, 2014, 371, 1650-1652.	27.0	68
1243	Eurocan Platform meeting: European recommendations for biomarker-based chemoprevention trials. Ecanccrmedalscience, 2014, 8, 488.	1.1	0
1244	A Prior Diagnosis of Breast Cancer is a Risk Factor for Breast Cancer in Brca1 and Brca2 Carriers. Current Oncology, 2014, 21, 64-68.	2.2	11
1245	<i>In Vitro</i> Antioxidant, Antibacterial, and Cytotoxic Activity and <i>In Vivo</i> Effect of <i>Syngonium podophyllum</i> and <i>Eichhornia crassipes</i> Leaf Extracts on Isoniazid Induced Oxidative Stress and Hepatic Markers. BioMed Research International, 2014, 2014, 1-11.	1.9	44
1246	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
1247	Genetic Testing in Hereditary Breast and Ovarian Cancer Using Massive Parallel Sequencing. BioMed Research International, 2014, 2014, 1-8.	1.9	17
1248	A Paternally Inherited <i>BRCA1</i> Mutation Associated with an Unusual Aggressive Clinical Phenotype. Case Reports in Genetics, 2014, 2014, 1-3.	0.2	3
1249	BRCA and Early Events in the Development of Serous Ovarian Cancer. Frontiers in Oncology, 2014, 4, 5.	2.8	59
1250	Oncogenes and Tumor Suppressor Genes as a Biomarker in Breast Cancer. , 2014, , 41-51.		0
1253	Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?. Future Oncology, 2014, 10, 499-502.	2.4	15
1256	Preimplantation genetic diagnosis using combined strategies on a breast cancer patient with a novel genomic deletion in BRCA2. Journal of Assisted Reproduction and Genetics, 2014, 31, 1719-1726.	2.5	8
1257	Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14. Breast Cancer Research and Treatment, 2014, 148, 629-635.	2.5	12
1258	The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. British Medical Bulletin, 2014, 112, 57-69.	6.9	19
1259	Risk-reducing surgery for women at high risk of epithelial ovarian cancer. The Obstetrician and Gynaecologist, 2014, 16, 185-191.	0.4	7
1260	Hereditary breast and ovarian cancer syndrome: Considering the complexities. Current Problems in Cancer, 2014, 38, 226-234.	2.0	0
1261	Risk of having <i>BRCA1</i> mutation in high-risk women with triple-negative breast cancer: a meta-analysis. Clinical Genetics, 2014, 85, 43-48.	2.0	45

#	ARTICLE	IF	CITATIONS
1262	Pharmacogenomics in Developing Countries. , 2014, , 327-351.		0
1263	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
1264	Serous adenocarcinoma of the ovary diagnosed during ultrasound evaluation for fertility preservation. Future Oncology, 2014, 10, 1907-1912.	2.4	0
1265	Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause, 2014, 21, 763-768.	2.0	34
1266	Prophylactic Nipple-sparing Mastectomy Leaves More Terminal Duct Lobular Units In Situ as Compared With Skin-sparing Mastectomy. American Journal of Surgical Pathology, 2014, 38, 706-712.	3.7	21
1267	Risk Factors for Ovarian Cancers With and Without Microsatellite Instability. International Journal of Gynecological Cancer, 2014, 24, 664-669.	2.5	10
1268	Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy. Cancer Biology and Therapy, 2014, 15, 371-379.	3.4	6
1269	Genetics and Gene-Environment Interactions. , 2014, , 21-31.		0
1270	Breast Cancer Following Ovarian Cancer in <i>BRCA</i> Mutation Carriers. JAMA Surgery, 2014, 149, 1306.	4.3	41
1271	Omics Approaches in Breast Cancer. , 2014, , .		10
1272	Breast Cancer Genomics. , 2014, , 53-103.		0
1273	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ, The, 2014, 348, g226-g226.	6.0	238
1274	â€˜The <i>BRCA</i> Clock is Ticking!â€™: Negotiating medical concerns and reproductive goals in preimplantation genetic diagnosis. Human Fertility, 2014, 17, 159-164.	1.7	24
1275	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. Journal of Medical Genetics, 2014, 51, 98-107.	3.2	74
1276	One Case of a <i>BRCA1</i> Germ Line Mutation Ovarian Carcinoma Patient Based on Abnormal Immunohistochemistry Finding. Korean Journal of Pathology, 2014, 48, 379-381.	1.3	0
1277	Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female <i>BRCA</i> Mutation Carriers in the Netherlands. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2482-2491.	2.5	11
1278	Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory. Patient Education and Counseling, 2014, 96, 106-112.	2.2	20
1279	Hereditary gynecologic cancers. International Journal of Gynecology and Obstetrics, 2014, 124, 189-192.	2.3	14

#	ARTICLE	IF	CITATIONS
1280	Health care provider recommendations for reducing cancer risks among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Clinical Genetics</i> , 2014, 85, 21-30.	2.0	19
1281	Changes in Specialistsâ€™ Perspectives on Cancer Genetic Testing, Prophylactic Surgery and Insurance Discrimination: Then and Now. <i>Journal of Genetic Counseling</i> , 2014, 23, 164-171.	1.6	10
1282	Identification of genes and candidate agents associated with pancreatic cancer. <i>Tumor Biology</i> , 2014, 35, 81-88.	1.8	8
1283	Clinical implications of genetic testing for <scp>BRCA1</scp> and <scp>BRCA2</scp> mutations in Austria. <i>Clinical Genetics</i> , 2014, 85, 72-75.	2.0	7
1284	Familial breast cancer genetic testing in the West of Ireland. <i>Irish Journal of Medical Science</i> , 2014, 183, 199-206.	1.5	3
1285	Association between polymorphisms within the susceptibility region 8q24 and breast cancer in a Chinese population. <i>Tumor Biology</i> , 2014, 35, 2649-2654.	1.8	9
1286	Baseline and post prophylactic tubalâ€“ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers. <i>Familial Cancer</i> , 2014, 13, 197-203.	1.9	3
1287	The Impact of Bilateral Salpingo-Oophorectomy on Breast MRI Background Parenchymal Enhancement and Fibroglandular Tissue. <i>European Radiology</i> , 2014, 24, 162-168.	4.5	34
1288	Epidemiology of Ovarian Cancer: An Update. , 2014, , 1-21.		3
1289	The impact of germline mutations on targeted therapy. <i>Journal of Pathology</i> , 2014, 232, 230-243.	4.5	7
1290	Determinants of genetic counseling uptake and its impact on breast cancer outcome: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 379-389.	2.5	18
1291	Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 635-642.	2.5	11
1292	An Investigation of Genetic Counselorsâ€™ Testing Recommendations: Pedigree Analysis and the Use of Multiplex Breast Cancer Panel Testing. <i>Journal of Genetic Counseling</i> , 2014, 23, 618-632.	1.6	10
1294	Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 133-142.	2.5	23
1295	MRI Volumetric Analysis of Breast Fibroglandular Tissue to Assess Risk of the Spared Nipple in BRCA1 and BRCA2 Mutation Carriers. <i>Annals of Surgical Oncology</i> , 2014, 21, 1583-1588.	1.5	19
1296	Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 663-670.	1.7	22
1297	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 579-586.	2.5	68
1298	African American Women's Limited Knowledge and Experiences with Genetic Counseling for Hereditary Breast Cancer. <i>Journal of Genetic Counseling</i> , 2014, 23, 311-322.	1.6	55

#	ARTICLE	IF	CITATIONS
1299	Cancer Risk Assessment Using Genetic Panel Testing: Considerations for Clinical Application. Journal of Genetic Counseling, 2014, 23, 604-617.	1.6	40
1300	Family History and BRCA1/BRCA2 Status Among Japanese Ovarian Cancer Patients and Occult Cancer in a BRCA1 Mutant Case. Japanese Journal of Clinical Oncology, 2014, 44, 49-56.	1.3	12
1301	The expanding role of yeast in cancer research and diagnosis: insights into the function of the oncosuppressors p53 and BRCA1/2. FEMS Yeast Research, 2014, 14, 2-16.	2.3	51
1302	BRCA sequencing and large rearrangement testing in young Black women with breast cancer. Journal of Community Genetics, 2014, 5, 157-165.	1.2	16
1303	Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study. International Journal of Cancer, 2014, 135, 2940-2949.	5.1	13
1304	Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Research and Treatment, 2014, 145, 707-714.	2.5	144
1305	BRCA1 and BRCA2 – Update and implications on the genetics of breast cancer: a clinical perspective. Clinical Genetics, 2014, 85, 1-4.	2.0	17
1306	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. British Journal of Cancer, 2014, 110, 530-534.	6.4	120
1307	Reproductive factors and breast cancer risk among BRCA1 or BRCA2 mutation carriers: Results from ten studies. Cancer Epidemiology, 2014, 38, 1-8.	1.9	40
1308	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. British Journal of Cancer, 2014, 110, 535-545.	6.4	191
1309	Large numbers of individuals are required to classify and define risk for rare variants in known cancer risk genes. Genetics in Medicine, 2014, 16, 529-534.	2.4	21
1311	Realizing the promise of cancer predisposition genes. Nature, 2014, 505, 302-308.	27.8	483
1312	Tracking progesterone receptor-mediated actions in breast cancer. , 2014, 142, 114-125.		63
1313	BRCA1 mRNA levels following a 6-week intervention with oral 3,3'-diindolylmethane. British Journal of Cancer, 2014, 111, 1269-1274.	6.4	20
1314	Physician Knowledge of Ethnicity Specific Differences in BRCA Genetic Testing. Breast Journal, 2014, 20, 669-670.	1.0	1
1315	Systemic Treatment Considerations for Women with BRCA1/2-Associated Breast Cancer. Current Breast Cancer Reports, 2014, 6, 139-145.	1.0	2
1316	Applying Synthetic Lethality for the Selective Targeting of Cancer. New England Journal of Medicine, 2014, 371, 1725-1735.	27.0	197
1317	Adapting the coping in deliberation (CODE) framework: A multi-method approach in the context of familial ovarian cancer risk management. Patient Education and Counseling, 2014, 97, 200-210.	2.2	5

#	ARTICLE	IF	CITATIONS
1318	The impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy on survival in patients with a history of breast cancer—A population-based data linkage study. <i>International Journal of Cancer</i> , 2014, 134, 2211-2222.	5.1	19
1320	Recent BRCAPRO Upgrades Significantly Improve Calibration. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1689-1695.	2.5	20
1321	Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. <i>British Journal of Cancer</i> , 2014, 111, 1542-1551.	6.4	42
1322	A Major Step Forward for BRCA1/2-Related Cancer Risk Management. <i>Journal of Clinical Oncology</i> , 2014, 32, 1531-1533.	1.6	8
1323	The Angelina effect: immediate reach, grasp, and impact of going public. <i>Genetics in Medicine</i> , 2014, 16, 516-521.	2.4	128
1324	Cultural Aspects of Healthy BRCA Carriers From Two Ethnocultural Groups. <i>Qualitative Health Research</i> , 2014, 24, 665-681.	2.1	19
1325	High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families. <i>Familial Cancer</i> , 2014, 13, 603-609.	1.9	9
1326	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. <i>British Journal of Cancer</i> , 2014, 110, 1088-1100.	6.4	21
1327	Prediabetes, Diabetes, and Risk of Breast Cancer: A Case-Control Study. <i>Archives of Medical Research</i> , 2014, 45, 432-438.	3.3	23
1328	Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1375-1382.	2.4	10
1329	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 113-118.	2.5	24
1330	Breast-Cancer Risk in Families with Mutations in <i>PALB2</i> . <i>New England Journal of Medicine</i> , 2014, 371, 497-506.	27.0	745
1331	An Efficient Pipeline for the Generation and Functional Analysis of Human <i>BRCA2</i> Variants of Uncertain Significance. <i>Human Mutation</i> , 2014, 35, n/a-n/a.	2.5	12
1332	Management of women at high risk of breast cancer. <i>BMJ, The</i> , 2014, 348, g2756-g2756.	6.0	29
1333	The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 15-23.	2.5	7
1334	Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 451-460.	2.5	8
1335	Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. <i>Familial Cancer</i> , 2014, 13, 291-299.	1.9	56
1336	Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer. <i>Familial Cancer</i> , 2014, 13, 153-162.	1.9	5

#	ARTICLE	IF	CITATIONS
1337	Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history. <i>Familial Cancer</i> , 2014, 13, 423-430.	1.9	3
1338	Novel BRCA1 deleterious mutation (c.1918C>T) in familial breast and ovarian cancer syndrome who share a common ancestry. <i>Familial Cancer</i> , 2014, 13, 431-435.	1.9	4
1339	Cost Sharing and Hereditary Cancer Risk: Predictors of Willingness to Pay for Genetic Testing. <i>Journal of Genetic Counseling</i> , 2014, 23, 1002-1011.	1.6	19
1340	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Medellín, Colombia. <i>Hereditary Cancer in Clinical Practice</i> , 2014, 12, 11.	1.5	42
1341	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. <i>European Journal of Human Genetics</i> , 2014, 22, 1305-1313.	2.8	217
1342	Use of Exogenous Hormones and Risks of Breast and Ovarian Cancers in BRCA1/2 Mutation Carriers; Methodological and Clinical Considerations. <i>Current Breast Cancer Reports</i> , 2014, 6, 121-131.	1.0	1
1343	Prospective study of high-risk, BRCA1/2-mutation negative women: the "negative study"™. <i>BMC Cancer</i> , 2014, 14, 221.	2.6	10
1344	Development of Synthetic Lethality Anticancer Therapeutics. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7859-7873.	6.4	56
1345	Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program. <i>Journal of Clinical Oncology</i> , 2014, 32, 2224-2230.	1.6	106
1346	Population-based screening for breast and ovarian cancer risk due to <i>BRCA1</i> and <i>BRCA2</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 14205-14210.	7.1	286
1347	Genomics in Primary Care Practice. <i>Primary Care - Clinics in Office Practice</i> , 2014, 41, 421-435.	1.6	9
1348	Diffusion-weighted imaging of the high-risk breast: Apparent diffusion coefficient values and their relationship to breast density. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 805-811.	3.4	10
1349	BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 159-171.	4.4	31
1350	Arsenic exposure alters expression of cell cycle and lipid metabolism genes in the liver of adult zebrafish (<i>Danio rerio</i>). <i>Aquatic Toxicology</i> , 2014, 153, 66-72.	4.0	34
1351	Reduced penetrance in human inherited disease. <i>Egyptian Journal of Medical Human Genetics</i> , 2014, 15, 103-111.	1.0	32
1352	Central European BRCA2 mutation carriers: Birth cohort status correlates with onset of breast cancer. <i>Maturitas</i> , 2014, 77, 68-72.	2.4	14
1353	Genetic testing and familial implications in breast-ovarian cancer families. <i>Maturitas</i> , 2014, 78, 252-257.	2.4	24
1354	Risk-reducing mastectomy in BRCA1/2 mutation carriers: Factors influencing uptake and timing. <i>Maturitas</i> , 2014, 77, 180-184.	2.4	18

#	ARTICLE	IF	CITATIONS
1355	Estimation du risque individuel de cancer du sein: introduction et limites des modèles de calcul de risque. <i>Imagerie De La Femme</i> , 2014, 24, 97-104.	0.0	1
1356	Opportunities and challenges of next-generation DNA sequencing for breast units. <i>British Journal of Surgery</i> , 2014, 101, 889-898.	0.3	7
1357	Ovarian cancer. <i>Lancet, The</i> , 2014, 384, 1376-1388.	13.7	1,491
1358	Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal. <i>Clinical Genetics</i> , 2014, 85, 31-35.	2.0	12
1359	Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. <i>Clinical Genetics</i> , 2014, 85, 68-71.	2.0	16
1360	DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review). <i>Molecular Medicine Reports</i> , 2014, 10, 3-9.	2.4	66
1361	BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer. <i>Oncology Reports</i> , 2014, 31, 365-369.	2.6	8
1362	Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics. <i>Breast Cancer: Basic and Clinical Research</i> , 2014, 8, BCBCR.S18715.	1.1	71
1363	Impact of epithelial ovarian cancer screening on patient-relevant outcomes in average-risk postmenopausal women. <i>The Cochrane Library</i> , 0, , .	2.8	1
1364	Characterizing biased cancer-related cognitive processing: Relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.. <i>Health Psychology</i> , 2014, 33, 1003-1011.	1.6	5
1365	Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. <i>Annals of Internal Medicine</i> , 2014, 160, 255-266.	3.9	218
1366	Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. <i>Annals of Internal Medicine</i> , 2014, 160, 271-281.	3.9	321
1367	Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique. <i>SpringerPlus</i> , 2014, 3, 264.	1.2	3
1368	Primary osteoporosis in postmenopausal women. <i>Maturitas</i> , 2015, 82, 315.	2.4	3
1369	The impact of mutation position on the gene and family history on ovarian cancer risk in BRCA1/2 mutation carriers. <i>Maturitas</i> , 2015, 82, 315.	2.4	0
1370	Rehabilitating the sick role: the experiences of high-risk women who undergo risk reducing breast surgery. <i>Health Sociology Review</i> , 2015, 24, 186-198.	2.8	4
1371	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy. <i>Maturitas</i> , 2015, 82, 315-316.	2.4	4
1372	Convergence and divergence of genetic and modular networks between diabetes and breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1094-1102.	3.6	3

#	ARTICLE	IF	CITATIONS
1373	Guidelines for complex genetic analysis of hereditary breast ovarian cancer syndrome in slovak population. Acta Facultatis Pharmaceuticae Universitatis Comenianae, 2015, 62, 2-7.	0.2	0
1375	External validation of a publicly available computer assisted diagnostic tool for mammographic mass lesions with two high prevalence research datasets. Medical Physics, 2015, 42, 4987-4996.	3.0	6
1376	In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose. Journal of Visualized Experiments, 2015, , e52721.	0.3	8
1377	Committee Opinion No. 634. Obstetrics and Gynecology, 2015, 125, 1538-1543.	2.4	38
1378	A Quest for Better Mouse Models of Breast and Ovarian Cancers. EBioMedicine, 2015, 2, 1268-1269.	6.1	4
1379	Endometriosis as a risk factor for ovarian or endometrial cancer – results of a hospital-based case–control study. BMC Cancer, 2015, 15, 751.	2.6	25
1380	Idiopathic Granulomatous Mastitis with Broad Ligament Fibroid: Masqueraders of Cancer in Synergy. Indian Journal of Gynecologic Oncology, 2015, 13, 1.	0.3	0
1381	Socioeconomic disparities in breast cancer incidence and survival among parous women: findings from a population-based cohort, 1964–2008. BMC Cancer, 2015, 15, 921.	2.6	25
1382	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
1383	Targeting tumor suppressor genes for cancer therapy. BioEssays, 2015, 37, 1277-1286.	2.5	65
1385	Clinically Important Parameters that Influence Sensor Utility: Considerations on How Not to Make a Sensor with No (or Limited) Clinical Application. Electroanalysis, 2015, 27, 616-620.	2.9	1
1386	Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks. Human Mutation, 2015, 36, 1205-1214.	2.5	27
1387	Analysis of Multivariate Failure Times in the Presence of Selection Bias with Application to Breast Cancer. Journal of the Royal Statistical Society Series C: Applied Statistics, 2015, 64, 525-541.	1.0	1
1388	Breast Self-examination Education for BRCA Mutation Carriers by Clinical Nurse Specialists. Clinical Nurse Specialist, 2015, 29, E1-E7.	0.5	11
1389	Genetic counselors' practices and confidence regarding variant of uncertain significance results and reclassification from <i><sc>BRCA</sc></i> testing. Clinical Genetics, 2015, 88, 523-529.	2.0	27
1390	Should women at high risk for cancer use oral contraceptive pills?. Personalized Medicine, 2015, 12, 533-535.	1.5	0
1391	Fanconi anemia and solid malignancies in childhood: A national retrospective study. Pediatric Blood and Cancer, 2015, 62, 463-470.	1.5	36
1392	The molecular and genetic basis of inherited cancer risk inÂgynaecology. The Obstetrician and Gynaecologist, 2015, 17, 233-241.	0.4	8

#	ARTICLE	IF	CITATIONS
1393	Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?. <i>Future Oncology</i> , 2015, 11, 3053-3055.	2.4	2
1394	ATL. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 584-592.	2.5	1
1395	Surgical management of breast cancer. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2015, 28, 47-55.	0.3	2
1396	Management of cancer of the ovary. , 0, , 345-359.		0
1397	Utilization of Magnetic Resonance Imaging in Breast Cancer Screening. <i>Current Oncology</i> , 2015, 22, 332-335.	2.2	7
1398	Assessing the interactions between the associations of common genetic variants on 2q35 and 16q12 with breast cancer risk. <i>Neoplasia</i> , 2015, 62, 315-325.	1.6	1
1399	Apoptotic Molecular Advances in Breast Cancer Management. , 2015, , .		3
1400	Endometrial cancer occurrence five years after breast cancer in BRCA2 mutation patient. <i>Obstetrics and Gynecology Science</i> , 2015, 58, 175.	1.6	3
1401	The BRCA1 and BRCA2 Breast and Ovarian Cancer Susceptibility Genes " Implications for DNA Damage Response, DNA Repair and Cancer Therapy. , 2015, , .		4
1402	The Activities and Impact of State Programs to Address Hereditary Breast and Ovarian Cancer, 2011"2014. <i>Healthcare (Switzerland)</i> , 2015, 3, 948-963.	2.0	14
1403	Repeated Nipple Fluid Aspiration: Compliance and Feasibility Results from a Prospective Multicenter Study. <i>PLoS ONE</i> , 2015, 10, e0127895.	2.5	11
1404	Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. <i>PLoS ONE</i> , 2015, 10, e0136192.	2.5	11
1405	Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory. <i>PLoS ONE</i> , 2015, 10, e0136419.	2.5	41
1406	Breast cancer risk factors. <i>Przegląd Menopauzalny</i> , 2015, 3, 196-202.	1.3	185
1407	BRCA1 Gene's EXON 11 and Breast Carcinoma: A Mutational Hot Spot for Familial Patients and Prone to Metastases in Northern India. , 2015, 05, .		2
1408	Early Detection of Cancer: Past, Present, and Future. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 57-65.	3.8	161
1409	Common BRCA1 and BRCA2 Mutations among Latin American Breast Cancer Subjects: A Meta-Analysis. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2015, 06, .	0.3	5
1410	Risk-reducing surgery in BRCA 1/2 mutation carriers: a point of view. <i>Oncotarget</i> , 2015, 6, 39391-39392.	1.8	1

#	ARTICLE	IF	CITATIONS
1411	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Current Opinion in Obstetrics and Gynecology, 2015, 27, 23-33.	2.0	33
1412	Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2015, 151, 435-441.	2.5	12
1413	An update on PARP inhibitors for the treatment of cancer. OncoTargets and Therapy, 2015, 8, 519.	2.0	72
1414	HBOC multi-gene panel testing: comparison of two sequencing centers. Breast Cancer Research and Treatment, 2015, 152, 129-136.	2.5	38
1416	Reproductive Issues in BRCA Mutation Carriers. , 2015, , 83-102.		1
1417	Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer, 2015, 22, 327-334.	2.9	24
1418	Multiple-Gene Panels and the Future of Genetic Testing. Current Breast Cancer Reports, 2015, 7, 98-104.	1.0	1
1419	Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecologic Oncology, 2015, 138, 109-114.	1.4	98
1420	Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257.	27.0	764
1421	New perspectives on targeted therapy in ovarian cancer. International Journal of Women's Health, 2015, 7, 189.	2.6	93
1422	DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncogenes C-MET and HER3. Journal of Translational Medicine, 2015, 13, 335.	4.4	16
1423	Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation. Journal of Nutrigenetics and Nutrigenomics, 2015, 8, 174-184.	1.3	21
1425	Give Prevention A Chance: Reducing Environmental Exposures to Improve Breast Health. Breast Diseases, 2015, 26, 197-202.	0.0	1
1426	Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature. Cancer Treatment Reviews, 2015, 41, 187-196.	7.7	47
1427	Next-Generation Sequencing of the BRCA1 and BRCA2 Genes for the Genetic Diagnostics of Hereditary Breast and/or Ovarian Cancer. Journal of Molecular Diagnostics, 2015, 17, 162-170.	2.8	44
1428	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology, 2015, 136, 3-7.	1.4	246
1429	Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: A review. Breast, 2015, 24, 100-106.	2.2	32
1430	Magnetic Resonance Imaging Improves Breast Screening Sensitivity in <i>BRCA</i> Mutation Carriers Age ≥ 50 Years: Evidence From an Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 349-356.	1.6	72

#	ARTICLE	IF	CITATIONS
1431	Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in <i>BRCA1/2</i> Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 698-707.	2.5	21
1432	The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. <i>Cancer Causes and Control</i> , 2015, 26, 333-344.	1.8	40
1433	Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. <i>European Journal of Cancer</i> , 2015, 51, 400-408.	2.8	32
1434	The effect of oral 3,3'-diindolylmethane supplementation on the 2:16 \pm -OHE ratio in BRCA1 mutation carriers. <i>Familial Cancer</i> , 2015, 14, 281-286.	1.9	6
1435	Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model. <i>Molecular Pharmaceutics</i> , 2015, 12, 542-553.	4.6	27
1436	The Japanese Breast Cancer Society clinical practice guideline for epidemiology and prevention of breast cancer. <i>Breast Cancer</i> , 2015, 22, 16-27.	2.9	10
1437	Tumor-associated inflammation as a potential prognostic tool in BRCA1/2-associated breast cancer. <i>Human Pathology</i> , 2015, 46, 182-190.	2.0	23
1438	Differences in BRCA counseling and testing practices based on ordering provider type. <i>Genetics in Medicine</i> , 2015, 17, 51-57.	2.4	47
1439	Skin cancer risk in <i>BRCA1/2</i> mutation carriers. <i>British Journal of Dermatology</i> , 2015, 172, 1498-1506.	1.5	45
1440	Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2015, 107, 379.	6.3	146
1441	Breast Cancer Screening. <i>Medical Clinics of North America</i> , 2015, 99, 451-468.	2.5	55
1442	Beliefs about weight and breast cancer: an interview study with high risk women following a 12-month weight loss intervention. <i>Hereditary Cancer in Clinical Practice</i> , 2015, 13, 1.	1.5	25
1443	Nipple-Sparing Mastectomy in BRCA1/2 Mutation Carriers: An Interim Analysis and Review of the Literature. <i>Annals of Surgical Oncology</i> , 2015, 22, 370-376.	1.5	120
1444	Population-based genetic risk prediction and stratification for ovarian cancer: views from women at high risk. <i>Familial Cancer</i> , 2015, 14, 135-144.	1.9	11
1445	DNA repair gene polymorphisms and clinical outcome of patients with primary small cell carcinoma of the esophagus. <i>Tumor Biology</i> , 2015, 36, 1539-1548.	1.8	9
1446	Randomized controlled trial of Inquiry-Based Stress Reduction (IBSR) technique for <i>BRCA1/2</i> mutation carriers. <i>Psycho-Oncology</i> , 2015, 24, 726-731.	2.3	9
1447	Surgical Menopause. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 531-542.	3.2	49
1448	How medical choices influence quality of life of women carrying a BRCA mutation. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 555-568.	4.4	22

#	ARTICLE	IF	CITATIONS
1449	Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk. <i>Maturitas</i> , 2015, 82, 197-202.	2.4	4
1450	Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. <i>European Journal of Human Genetics</i> , 2015, 23, 588-595.	2.8	13
1451	Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines. <i>Familial Cancer</i> , 2015, 14, 641-649.	1.9	10
1452	Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of <i>BRCA1/2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2015, 33, 2553-2562.	1.6	22
1453	Claudin-4 SPECT Imaging Allows Detection of Aplastic Lesions in a Mouse Model of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 745-751.	5.0	26
1454	DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 271-282.	2.5	26
1455	Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. <i>British Journal of Cancer</i> , 2015, 113, 453-459.	6.4	17
1456	Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. <i>Gynecologic Oncology</i> , 2015, 138, 757-761.	1.4	32
1457	Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. <i>Psycho-Oncology</i> , 2015, 24, 33-39.	2.3	28
1458	BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review. <i>Clinical Oncology</i> , 2015, 27, 527-535.	1.4	13
1459	Fertility preservation and breast cancer: a review. <i>Ecancermedicalscience</i> , 2015, 9, 503.	1.1	34
1460	Effect of Oophorectomy on Survival After Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA Oncology</i> , 2015, 1, 306.	7.1	107
1461	Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. <i>Fertility and Sterility</i> , 2015, 103, 1305-1312.	1.0	51
1462	Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 289-298.	2.5	49
1463	Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 169-176.	2.5	78
1464	Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. <i>Familial Cancer</i> , 2015, 14, 287-295.	1.9	22
1465	The importance of proper bioinformatics analysis and clinical interpretation of tumor genomic profiling: a case study of undifferentiated sarcoma and a constitutional pathogenic BRCA2 mutation and an MLH1 variant of uncertain significance. <i>Familial Cancer</i> , 2015, 14, 481-485.	1.9	8
1466	To Reflex or Not: Additional BRCA1/2 Testing in Ashkenazi Jewish Individuals Without Founder Mutations. <i>Journal of Genetic Counseling</i> , 2015, 24, 285-293.	1.6	7

#	ARTICLE	IF	CITATIONS
1467	Breast Cancer Risk Gene Discovery: Opportunities and Challenges. <i>Current Genetic Medicine Reports</i> , 2015, 3, 82-91.	1.9	0
1468	Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. <i>Gynecologic Oncology</i> , 2015, 137, 86-92.	1.4	97
1469	Validation of an NGS Approach for Diagnostic BRCA1/BRCA2 Mutation Testing. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 119-130.	3.8	23
1470	Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2005-2012.	2.5	23
1471	Intensified Surveillance for Early Detection of Breast Cancer in High-Risk Patients. <i>Breast Care</i> , 2015, 10, 13-20.	1.4	30
1472	Ovarian carcinoma in a 14-year-old with classical salt-wasting congenital adrenal hyperplasia and bilateral adrenalectomy. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2015, 28, 663-7.	0.9	3
1473	Breast MRI Fibroglandular Volume and Parenchymal Enhancement in BRCA1 and BRCA2 Mutation Carriers Before and Immediately After Risk-Reducing Salpingo-Oophorectomy. <i>American Journal of Roentgenology</i> , 2015, 204, 669-673.	2.2	34
1474	Elucidating the genomic landscape of breast cancer: how will this affect treatment?. <i>Pharmacogenomics</i> , 2015, 16, 569-572.	1.3	2
1475	Psychological distress related to BRCA testing in ovarian cancer patients. <i>Familial Cancer</i> , 2015, 14, 495-504.	1.9	20
1476	Epigenetic changes in BRCA1-mutated familial breast cancer. <i>Cancer Genetics</i> , 2015, 208, 237-240.	0.4	15
1477	Whole-exome DNA sequence analysis of <i>Brca2</i> and <i>Trp53</i> deficient mouse mammary gland tumours. <i>Journal of Pathology</i> , 2015, 236, 186-200.	4.5	14
1478	Genetic Tests to Identify Risk for Breast Cancer. <i>Seminars in Oncology Nursing</i> , 2015, 31, 100-107.	1.5	30
1479	Breast Cancer Risks and Risk Prediction Models. <i>Breast Care</i> , 2015, 10, 7-12.	1.4	47
1480	Breast Cancer Prevention Across the Cancer Care Continuum. <i>Seminars in Oncology Nursing</i> , 2015, 31, 89-99.	1.5	8
1482	Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins. <i>Cold Spring Harbor Perspectives in Biology</i> , 2015, 7, a016600.	5.5	636
1483	Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. <i>Cancer</i> , 2015, 121, 2108-2120.	4.1	202
1484	Protein stability versus function: effects of destabilizing missense mutations on <i>BRCA1</i> DNA repair activity. <i>Biochemical Journal</i> , 2015, 466, 613-624.	3.7	12
1485	Breast MRI as an Adjunct to Mammography for Breast Cancer Screening in High-Risk Patients: Retrospective Review. <i>American Journal of Roentgenology</i> , 2015, 204, 889-897.	2.2	49

#	ARTICLE	IF	CITATIONS
1486	Prospective multicenter cohort study of estrogen and insulin-like growth factor system in BRCA mutation carriers. <i>Cancer Causes and Control</i> , 2015, 26, 1087-1092.	1.8	5
1487	Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. <i>Gynecologic Oncology</i> , 2015, 139, 104-111.	1.4	47
1488	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v8-v30.	1.2	1,168
1489	Parlez-vous VUS?. <i>Genome Research</i> , 2015, 25, 1423-1426.	5.5	36
1490	A risk prediction algorithm for ovarian cancer incorporating <i>BRCA1</i> , <i>BRCA2</i> , common alleles and other familial effects. <i>Journal of Medical Genetics</i> , 2015, 52, 465-475.	3.2	52
1491	LIFESTYLE und erblicher Brustkrebs. <i>Medizinische Genetik</i> , 2015, 27, 237-243.	0.2	0
1492	Spectrum and frequencies of <i>BRCA1/2</i> mutations in Bulgarian high risk breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 523.	2.6	15
1493	Epidemiology of Patients with Ovarian Cancer with and Without a <i>BRCA1/2</i> Mutation. <i>Molecular Diagnosis and Therapy</i> , 2015, 19, 351-364.	3.8	23
1495	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers?. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 163-169.	2.5	6
1497	Lifestyle and Breast Cancer Incidence and Survival. <i>American Journal of Lifestyle Medicine</i> , 2015, 9, 241-246.	1.9	0
1498	The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. <i>Familial Cancer</i> , 2015, 14, 539-544.	1.9	11
1499	Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. <i>Familial Cancer</i> , 2015, 14, 521-530.	1.9	14
1500	Utilization and Outcomes of <i>BRCA</i> Genetic Testing and Counseling in a National Commercially Insured Population. <i>JAMA Oncology</i> , 2015, 1, 1251.	7.1	108
1501	Dysregulation of ubiquitin ligases in cancer. <i>Drug Resistance Updates</i> , 2015, 23, 1-11.	14.4	42
1502	Rescreening for genetic mutations using multi-gene panel testing in patients who previously underwent non-informative genetic screening. <i>Gynecologic Oncology</i> , 2015, 139, 211-215.	1.4	45
1503	Breast cancer risk for Korean women with germline mutations in <i>BRCA1</i> and <i>BRCA2</i> . <i>Breast Cancer Research and Treatment</i> , 2015, 152, 659-665.	2.5	18
1504	Weight Gain After Oophorectomy Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>Women's Health</i> , 2015, 11, 453-459.	1.5	2
1505	The Genetics of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 705-732.	1.5	5

#	ARTICLE	IF	CITATIONS
1506	Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 412-421.	1.5	11
1507	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	311
1508	Common Hereditary Cancer Syndromes. , 2015, , 645-673.		0
1509	The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 441-453.	2.5	63
1510	Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. <i>Breast</i> , 2015, 24, 237-241.	2.2	48
1511	Odds per Adjusted Standard Deviation: Comparing Strengths of Associations for Risk Factors Measured on Different Scales and Across Diseases and Populations: Table 1.. <i>American Journal of Epidemiology</i> , 2015, 182, 863-867.	3.4	80
1512	Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 139, 253-260.	1.4	17
1513	Early salpingectomy (Tubectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. <i>BMC Cancer</i> , 2015, 15, 593.	2.6	88
1514	Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations. <i>Genetics in Medicine</i> , 2015, 17, 726-732.	2.4	17
1516	Hereditary Cancer-Associated Mutations in Women Diagnosed with Two Primary Cancers: An Opportunity to Identify Hereditary Cancer Syndromes after the First Cancer Diagnosis. <i>Oncology</i> , 2015, 88, 226-233.	1.9	11
1517	Factors influencing ovulation and the risk of ovarian cancer in <scp><i>BRCA1</i></scp> and <scp><i>BRCA2</i></scp> mutation carriers. <i>International Journal of Cancer</i> , 2015, 137, 1136-1146.	5.1	56
1518	Testing for Hereditary Breast Cancer: Panel or Targeted Testing? Experience from a Clinical Cancer Genetics Practice. <i>Journal of Genetic Counseling</i> , 2015, 24, 683-687.	1.6	19
1519	The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. <i>International Journal of Cancer</i> , 2015, 137, 2785-2794.	5.1	72
1520	Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2015, 148, 556-564.	1.3	256
1521	Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability. <i>Familial Cancer</i> , 2015, 14, 117-128.	1.9	12
1522	Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 1-19.	2.8	23
1523	Hereditary breast cancer syndromes and genetic testing. <i>Journal of Surgical Oncology</i> , 2015, 111, 66-80.	1.7	30
1524	Cancer Risk Management Decision Making for BRCA+ Women. <i>Western Journal of Nursing Research</i> , 2015, 37, 66-84.	1.4	18

#	ARTICLE	IF	CITATIONS
1525	Pretest genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida. <i>Clinical Genetics</i> , 2015, 87, 473-477.	2.0	59
1526	Psychiatric implications of cancer genetic testing. <i>Cancer</i> , 2015, 121, 341-360.	4.1	44
1527	Different Patterns in the Prognostic Value of Age for Breast Cancer-Specific Mortality Depending on Hormone Receptor Status: A SEER Population-Based Analysis. <i>Annals of Surgical Oncology</i> , 2015, 22, 1102-1110.	1.5	27
1528	Recurrent <i>BRCA1</i> and <i>BRCA2</i> Mutations in Mexican Women with Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 498-505.	2.5	29
1529	Topoisomerase III α in chromosome instability and personalized cancer therapy. <i>Oncogene</i> , 2015, 34, 4019-4031.	5.9	166
1530	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> mutations in unselected breast cancer patients from Peru. <i>Clinical Genetics</i> , 2015, 88, 371-375.	2.0	50
1531	Cancers associated with <i>BRCA1</i> and <i>BRCA2</i> mutations other than breast and ovarian. <i>Cancer</i> , 2015, 121, 269-275.	4.1	407
1532	<i>BRCA1</i> and <i>BRCA2</i> mutations and the risk for colorectal cancer. <i>Clinical Genetics</i> , 2015, 87, 411-418.	2.0	73
1533	Implementation of a risk assessment program in a breast-imaging community practice. <i>Breast Cancer</i> , 2016, 23, 273-278.	2.9	3
1534	How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e72-e78.	3.8	28
1535	Hereditary Cancer: Example of a Public Health Approach to Ensure Population Health Benefits of Genetic Medicine. <i>Healthcare (Switzerland)</i> , 2016, 4, 6.	2.0	10
1536	TRANSCRIPTOME ANALYSIS OF MRNA EXPRESSION PROFILING TO PREDICT POTENTIAL BIOMARKERS INDUCED IN BREAST CANCER-BRCA1. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2016, 9, 270.	0.3	1
1537	Disrupted cooperation between transcription factors across diverse cancer types. <i>BMC Genomics</i> , 2016, 17, 560.	2.8	4
1538	Pancreatic Cancer Genetics. <i>International Journal of Biological Sciences</i> , 2016, 12, 314-325.	6.4	90
1539	Simultaneous detection of <i>BRCA</i> mutations and large genomic rearrangements in germline DNA and FFPE tumor samples. <i>Oncotarget</i> , 2016, 7, 61845-61859.	1.8	24
1540	Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support. <i>Healthcare (Switzerland)</i> , 2016, 4, 35.	2.0	13
1541	Women's Health Issues for BRCA Mutation Carriers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 14-17.	3.8	1
1542	How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e72-e78.	3.8	40

#	ARTICLE	IF	CITATIONS
1543	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 44-56.	3.8	19
1544	ReCAP: Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for <i>BRCA1/2</i> Mutations in Geographically Underserved Areas. Journal of Oncology Practice, 2016, 12, 59-59.	2.5	18
1545	Association between Basal-Like Phenotype and <i>BRCA1/2</i> Germline Mutations in Korean Breast Cancer Patients. Current Oncology, 2016, 23, 298-303.	2.2	7
1546	Improved Efficiency and Reliability of NGS Amplicon Sequencing Data Analysis for Genetic Diagnostic Procedures Using AGSA Software. BioMed Research International, 2016, 2016, 1-11.	1.9	4
1547	Contribution of <i>BRCA1</i> and <i>BRCA2</i> Germline Mutations to Early Algerian Breast Cancer. Disease Markers, 2016, 2016, 1-7.	1.3	16
1548	Evaluation of expression profiles of microRNAs and two target genes, <i>FOXO3a</i> and <i>RUNX2</i> , effectively supports diagnostics and therapy predictions in breast cancer. Neoplasma, 2016, 63, 941-951.	1.6	11
1549	<i>BRCA2</i> gene mutations and coagulation-associated biomarkers. Thrombosis and Haemostasis, 2016, 115, 415-423.	3.4	8
1550	Ovarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for Prevention. Frontiers in Oncology, 2016, 6, 108.	2.8	57
1551	Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the “Angelina Jolie Effect”. BMC Cancer, 2016, 16, 436.	2.6	49
1552	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
1553	The Tumor-Associated Variant <i>RAD51</i> G151D Induces a Hyper-Recombination Phenotype. PLoS Genetics, 2016, 12, e1006208.	3.5	26
1554	Developmental Exposure to Endocrine Disrupting Chemicals Alters the Epigenome: Identification of Reprogrammed Targets. Gynecology and Obstetrics Research: Open Journal, 2016, 3, 1-6.	1.6	34
1555	Fighting cancer through an informed society. Journal of Social Health and Diabetes, 2016, 04, 057-066.	0.3	0
1556	Role of <i>BRCA1</i> in Breast Cancer Metastasis. , 0, , .		0
1557	Identification of a founder <i>BRCA1</i> mutation in the Moroccan population. Clinical Genetics, 2016, 90, 361-365.	2.0	13
1558	Addressing inherited predisposition for breast cancer in transplant recipients. Journal of Surgical Oncology, 2016, 113, 605-608.	1.7	1
1559	Prioritizing Variants in Complete Hereditary Breast and Ovarian Cancer Genes in Patients Lacking Known <i>BRCA</i> Mutations. Human Mutation, 2016, 37, 640-652.	2.5	39
1560	A Review of Whole-Exome Sequencing Efforts Toward Hereditary Breast Cancer Susceptibility Gene Discovery. Human Mutation, 2016, 37, 835-846.	2.5	43

#	ARTICLE	IF	CITATIONS
1561	Decision making, psychological wellbeing and psychosocial outcomes for high risk women who choose to undergo bilateral prophylactic mastectomy – A review of the literature. <i>Breast</i> , 2016, 28, 130-135.	2.2	30
1562	<i>BRAT1</i> mutations present with a spectrum of clinical severity. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 2265-2273.	1.2	34
1563	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
1564	Breast Cancer Survivorship. , 2016, , .		3
1565	Recurrent <i>HOXB13</i> mutations in the Dutch population do not associate with increased breast cancer risk. <i>Scientific Reports</i> , 2016, 6, 30026.	3.3	3
1566	Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. <i>Scientific Reports</i> , 2016, 6, 29506.	3.3	165
1567	Curcumin and extracellular matrix proteins synergistically act to inhibit the proliferation of breast cancer cells. <i>Breast Cancer Management</i> , 2016, 5, 93-106.	0.2	3
1568	Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. <i>Obstetrics and Gynecology</i> , 2016, 128, e210-e226.	2.4	199
1569	Breast Cancer Screening and Prevention. <i>Annals of Internal Medicine</i> , 2016, 164, ITC81.	3.9	30
1570	Invited Speakers™ Abstracts. <i>Breast</i> , 2016, 29, S1-S10.	2.2	0
1571	Tumor characteristics and prognosis in familial breast cancer. <i>BMC Cancer</i> , 2016, 16, 924.	2.6	24
1573	Effectiveness of Prophylactic Surgeries in <i>BRCA1</i> or <i>BRCA2</i> Mutation Carriers: A Meta-analysis and Systematic Review. <i>Clinical Cancer Research</i> , 2016, 22, 3971-3981.	7.0	160
1574	Breast cancer risk in Chinese women with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 441-445.	2.5	30
1575	Salpingectomy and prevention of ovarian carcinoma. <i>Gynecology and Minimally Invasive Therapy</i> , 2016, 5, 102-105.	0.9	0
1577	Male breast cancer: Medical and psychological management in comparison to female breast cancer. A review. <i>Cancer Treatment Communications</i> , 2016, 7, 23-34.	0.4	19
1578	Clinical follow-up and breast and ovarian cancer screening of true <i>BRCA1/2</i> noncarriers: a qualitative investigation. <i>Genetics in Medicine</i> , 2016, 18, 627-634.	2.4	6
1579	The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada. <i>Journal of Genetic Counseling</i> , 2016, 25, 1309-1316.	1.6	24
1580	Genetic testing. <i>Journal of the American Dental Association</i> , 2016, 147, 157-159.	1.5	0

#	ARTICLE	IF	CITATIONS
1581	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	27.6	1,938
1582	Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 597-611.	4.1	44
1583	Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 557-566.	2.5	19
1584	Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. <i>BMC Urology</i> , 2016, 16, 15.	1.4	52
1585	Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. <i>Nature Reviews Endocrinology</i> , 2016, 12, 394-406.	9.6	112
1586	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515.	2.5	27
1587	Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1082-1086.	2.4	13
1588	The Dose-Response Effects of Aerobic Exercise on Body Composition and Breast Tissue among Women at High Risk for Breast Cancer: A Randomized Trial. <i>Cancer Prevention Research</i> , 2016, 9, 581-588.	1.5	24
1589	Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 362-369.	2.8	4
1590	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. <i>Human Reproduction</i> , 2016, 31, 1126-1132.	0.9	84
1591	Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling. <i>European Journal of Human Genetics</i> , 2016, 24, 1104-1111.	2.8	13
1592	PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives. <i>Geburtshilfe Und Frauenheilkunde</i> , 2016, 76, 164-169.	1.8	5
1593	Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 580-594.	2.8	38
1594	Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific. <i>Breast Cancer Research</i> , 2016, 18, 87.	5.0	9
1595	Genetics of triple-negative breast cancer: Implications for patient care. <i>Current Problems in Cancer</i> , 2016, 40, 130-140.	2.0	24
1596	Prevalencia mutacional de los genes BRCA1 y BRCA2 en pacientes con cáncer de mama y ovario atendidos en el Área de Salud de La Ribera (Comunidad Valenciana, España). <i>Revista Espanola De Patologia</i> , 2016, 49, 214-218.	0.2	2
1597	PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. <i>British Journal of Cancer</i> , 2016, 115, 1157-1173.	6.4	163
1598	BRCA to the future: towards best testing practice in the era of personalised healthcare. <i>European Journal of Human Genetics</i> , 2016, 24, S1-S2.	2.8	12

#	ARTICLE	IF	CITATIONS
1599	Synthetic lethality in lung cancer and translation to clinical therapies. <i>Molecular Cancer</i> , 2016, 15, 61.	19.2	31
1600	Cancro della mammella: ruolo del medico generico nella gestione. <i>EMC - AKOS - Trattato Di Medicina</i> , 2016, 18, 1-5.	0.0	0
1601	Cancer and Genomic Instability. , 2016, , 463-486.		1
1602	The genetics of breast cancer risk in the post-genome era: thoughts on study design to move past BRCA and towards clinical relevance. <i>Breast Cancer Research</i> , 2016, 18, 99.	5.0	72
1603	A Nano-Biosensor for the Detection of 185delAG Mutation in <i>BRCA1</i> Gene, Leading to Breast Cancer. <i>Cancer Investigation</i> , 2016, 34, 431-439.	1.3	6
1604	Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer. <i>Current Breast Cancer Reports</i> , 2016, 8, 165-174.	1.0	0
1605	Breast cancer in young women: Pathologic features and molecular phenotype. <i>Breast</i> , 2016, 29, 109-116.	2.2	30
1606	Hereditary breast and ovarian cancer: new genes in confined pathways. <i>Nature Reviews Cancer</i> , 2016, 16, 599-612.	28.4	305
1607	Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 671-677.	4.7	23
1608	<i>BRCA1</i> and <i>BRCA2</i> mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. <i>Cancer</i> , 2016, 122, 84-90.	4.1	50
1609	Effect of lifestyle and reproductive factors on the onset of breast cancer in female <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 172-177.	1.2	21
1610	Diagnostic Performance of MR-guided Vacuum-Assisted Breast Biopsy: 8 Years of Experience. <i>Breast Journal</i> , 2016, 22, 83-89.	1.0	23
1611	Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature. <i>Breast Journal</i> , 2016, 22, 35-44.	1.0	34
1612	Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. <i>Endocrine-Related Cancer</i> , 2016, 23, T69-T84.	3.1	63
1613	The biological effects and clinical implications of BRCA mutations: where do we go from here?. <i>European Journal of Human Genetics</i> , 2016, 24, S3-S9.	2.8	77
1614	A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 131-138.	2.5	20
1615	Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2016, 143, 231-235.	1.4	71
1616	Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic. <i>Annals of Surgical Oncology</i> , 2016, 23, 634-641.	1.5	10

#	ARTICLE	IF	CITATIONS
1617	Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees. <i>Breast</i> , 2016, 30, 66-72.	2.2	22
1618	BRCA Share: A Collection of Clinical BRCA Gene Variants. <i>Human Mutation</i> , 2016, 37, 1318-1328.	2.5	57
1619	Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2016, 143, 109-112.	1.4	20
1620	Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. <i>Gynecologic Oncology</i> , 2016, 143, 113-119.	1.4	23
1621	Synthetic lethality: the road to novel therapies for breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T39-T55.	3.1	17
1622	DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. <i>Oncologist</i> , 2016, 21, 940-945.	3.7	29
1623	Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. <i>Modern Pathology</i> , 2016, 29, 1381-1389.	5.5	90
1624	Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation. <i>Climacteric</i> , 2016, 19, 419-422.	2.4	14
1625	Saving the spandrels? Adaptive genomic variation in conservation and fisheries management. <i>Journal of Fish Biology</i> , 2016, 89, 2697-2716.	1.6	48
1626	Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. <i>Seminars in Oncology</i> , 2016, 43, 528-535.	2.2	54
1628	Genetics and cancer screening. , 0, , 39-48.		0
1629	Effect of BRCA germline mutations on breast cancer prognosis. <i>Medicine (United States)</i> , 2016, 95, e4975.	1.0	168
1631	Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 12.	1.5	2
1632	Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 809-812.	4.9	3
1633	Use of systemic hormone therapy in BRCA mutation carriers. <i>Menopause</i> , 2016, 23, 1026-1027.	2.0	24
1634	Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingo-oophorectomy. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1415-1420.	2.5	19
1635	Genomic Disparities in Breast Cancer among Latinas. <i>Cancer Control</i> , 2016, 23, 359-372.	1.8	46
1636	Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. <i>Cancer</i> , 2016, 122, 1913-1920.	4.1	11

#	ARTICLE	IF	CITATIONS
1637	Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies. <i>Nutrition Reviews</i> , 2016, 74, 432-443.	5.8	83
1638	Breast Cancer Prevention and Treatment. , 2016, , .		6
1639	Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients. <i>BMC Research Notes</i> , 2016, 9, 248.	1.4	9
1640	Molecular characterization, homology modeling and docking studies of the R2787H missense variation in BRCA2 gene: Association with breast cancer. <i>Journal of Theoretical Biology</i> , 2016, 403, 188-196.	1.7	5
1641	RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. <i>Nature Medicine</i> , 2016, 22, 933-939.	30.7	224
1642	Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 2403-2404.	27.0	16
1643	Factors forming the BRCA1-A complex orchestrate BRCA1 recruitment to the sites of DNA damage. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 658-664.	2.0	28
1644	Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. <i>Annals of Oncology</i> , 2016, 27, 1532-1538.	1.2	103
1645	Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 511-516.	2.5	30
1646	Inquiry-based stress reduction (IBSR) meditation technique for BRCA1 / 2 mutation carriersâ€”A qualitative study. <i>European Journal of Integrative Medicine</i> , 2016, 8, 958-964.	1.7	6
1647	BRCA2-positive spinal intramedullary ovarian metastatic disease: case report. <i>Spine Journal</i> , 2016, 16, e201-e207.	1.3	1
1649	PALB2: research reaching to clinical outcomes for women with breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 9.	1.5	27
1650	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 581-588.	27.6	258
1651	Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1251-1258.	2.5	9
1652	Cardiovascular risk of BRCA1/2 mutation carriers: A review. <i>Maturitas</i> , 2016, 91, 135-139.	2.4	28
1653	Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study. <i>Irish Journal of Medical Science</i> , 2016, 185, 189-194.	1.5	3
1654	Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1 / 2 mutation carriers and decreasing risk in the general population. <i>Gynecologic Oncology</i> , 2016, 140, 289-294.	1.4	1
1655	Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review. <i>Advances in Therapy</i> , 2016, 33, 129-150.	2.9	46

#	ARTICLE	IF	CITATIONS
1656	The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. <i>Familial Cancer</i> , 2016, 15, 155-162.	1.9	47
1657	Uninterrupted Sedentary Behavior Downregulates <i>BRCA1</i> Gene Expression. <i>Cancer Prevention Research</i> , 2016, 9, 83-88.	1.5	13
1658	Molecular biology of gynecological cancer. <i>Oncology Letters</i> , 2016, 11, 16-22.	1.8	16
1659	Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 215-222.	2.5	25
1660	Quality of life among patients after bilateral prophylactic mastectomy: a systematic review of patient-reported outcomes. <i>Quality of Life Research</i> , 2016, 25, 1409-1421.	3.1	82
1661	Milk Production and Fertility in Cattle. <i>Annual Review of Animal Biosciences</i> , 2016, 4, 269-290.	7.4	98
1662	Multilocus Inherited Neoplasia Alleles Syndrome. <i>JAMA Oncology</i> , 2016, 2, 373.	7.1	43
1663	The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. <i>British Journal of Cancer</i> , 2016, 114, 1160-1164.	6.4	24
1664	A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap. <i>Annales De Chirurgie Plastique Et Esthetique</i> , 2016, 61, 177-182.	0.6	12
1665	The genetic prediction of risk for gynecologic cancers. <i>Gynecologic Oncology</i> , 2016, 141, 10-16.	1.4	41
1666	The guardians of inherited oncogenic vulnerabilities. <i>Evolution; International Journal of Organic Evolution</i> , 2016, 70, 1-6.	2.3	10
1667	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	2.9	106
1668	A two-stage approach to genetic risk assessment in primary care. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 375-383.	2.5	13
1669	Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. <i>Gynecologic Oncology</i> , 2016, 140, 565-574.	1.4	43
1670	Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. <i>Familial Cancer</i> , 2016, 15, 497-506.	1.9	10
1671	BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population. <i>Familial Cancer</i> , 2016, 15, 507-512.	1.9	9
1672	Modeling the dyadic effects of parenting, stress, and coping on parent-child communication in families tested for hereditary breast-ovarian cancer risk. <i>Familial Cancer</i> , 2016, 15, 513-522.	1.9	5
1673	The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 454-468.	27.0	227

#	ARTICLE	IF	CITATIONS
1674	Living With Genetic Vulnerability: a Life Course Perspective. Journal of Genetic Counseling, 2016, 25, 49-61.	1.6	15
1675	Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis. Academic Radiology, 2016, 23, 358-367.	2.5	8
1676	Breast Cancer Genetics for the Surgeon: An Update on Causes and Testing Options. Journal of the American College of Surgeons, 2016, 222, 906-914.	0.5	7
1677	Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. British Journal of Cancer, 2016, 114, 631-637.	6.4	99
1679	Understanding inherited genetic risk of adult glioma – a review. Neuro-Oncology Practice, 2016, 3, 10-16.	1.6	62
1680	Epidemiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 3-18.	1.8	15
1681	No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families. Familial Cancer, 2016, 15, 523-528.	1.9	3
1682	High Satisfaction and Low Distress in Breast Cancer Patients One Year after <i>BRCA</i> Mutation Testing without Prior Face-to-Face Genetic Counseling. Journal of Genetic Counseling, 2016, 25, 504-514.	1.6	30
1683	A cost analysis of a cancer genetic service model in the UK. Journal of Community Genetics, 2016, 7, 185-194.	1.2	29
1684	Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. Critical Reviews in Oncology/Hematology, 2016, 101, 50-59.	4.4	40
1685	Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery. Familial Cancer, 2016, 15, 371-384.	1.9	4
1686	The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition. Breast Cancer, 2016, 23, 343-356.	2.9	17
1687	Hereditary cancer syndromes as model systems for chemopreventive agent development. Seminars in Oncology, 2016, 43, 134-145.	2.2	15
1688	Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report. Japanese Journal of Clinical Oncology, 2016, 46, 254-259.	1.3	18
1689	Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecologic Oncology, 2016, 140, 101-106.	1.4	39
1690	Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Research and Treatment, 2016, 155, 165-173.	2.5	16
1691	Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients. Gynecologic Oncology, 2016, 141, 318-322.	1.4	17
1692	Association between parental history and genetic risk scores for coronary heart disease prediction: The population-based CoLaus study. Atherosclerosis, 2016, 244, 59-65.	0.8	30

#	ARTICLE	IF	CITATIONS
1693	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
1695	Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer. Clinical Biochemistry, 2016, 49, 253-259.	1.9	5
1696	Exploration of Male Attitudes on Partnerships and Sexuality with Female <i>BRCA1/2</i> Mutation Carriers. Journal of Genetic Counseling, 2016, 25, 290-297.	1.6	9
1697	Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. Journal of Medical Genetics, 2016, 53, 34-42.	3.2	63
1698	Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population. Breast Cancer, 2016, 23, 807-812.	2.9	6
1699	Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer. International Journal of Clinical Oncology, 2016, 21, 270-275.	2.2	13
1700	The more you look, the more you will find. Cancer, 2016, 122, 14-16.	4.1	0
1701	Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Journal of Cancer Research and Clinical Oncology, 2016, 142, 333-340.	2.5	27
1702	Willingness of Japanese patients with breast cancer to have genetic testing of BRCA without burden of expenses. Breast Cancer, 2016, 23, 649-653.	2.9	11
1703	Comprehensive spectrum of<i>BRCA1</i>and<i>BRCA2</i>deleterious mutations in breast cancer in Asian countries. Journal of Medical Genetics, 2016, 53, 15-23.	3.2	82
1704	Genetic testing and interpretive complexity: a BRCA1 gene mutation example. Irish Journal of Medical Science, 2016, 185, 955-957.	1.5	0
1705	Georgia Primary Care Providersâ€™ Knowledge of Hereditary Breast and Ovarian Cancer Syndrome. Journal of Cancer Education, 2017, 32, 119-124.	1.3	16
1706	Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families. Breast Cancer, 2017, 24, 238-244.	2.9	17
1707	Hereditary Ovarian Cancer and Risk Reduction. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 31-48.	2.8	40
1708	Genetics of gynaecological cancers. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 42, 114-124.	2.8	13
1709	A study of over 35,000 women with breast cancer tested with a 25â€ gene panel of hereditary cancer genes. Cancer, 2017, 123, 1721-1730.	4.1	303
1710	Ovarian cancer: density equalizing mapping of the global research architecture. International Journal of Health Geographics, 2017, 16, 3.	2.5	28
1711	Out-RANKing BRCA1 in Mutation Carriers. Cancer Research, 2017, 77, 595-600.	0.9	33

#	ARTICLE	IF	CITATIONS
1712	Moving towards population-based genetic risk prediction for ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 855-858.	2.3	5
1713	Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. Breast, 2017, 32, 186-191.	2.2	24
1714	Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients. Breast Cancer Research and Treatment, 2017, 163, 139-150.	2.5	13
1715	Candidate Gene Analysis of Breast Cancer in the Jordanian Population of Arab Descent: A Case-Control Study. Cancer Investigation, 2017, 35, 256-270.	1.3	19
1716	Can MTHFR C677T and A1298C Polymorphisms Alter the Risk and Severity of Sporadic Breast Cancer in Brazilian Women?. Clinical Breast Cancer, 2017, 17, e199-e208.	2.4	11
1717	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
1719	Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral. Breast Cancer Research and Treatment, 2017, 162, 275-282.	2.5	3
1720	Breast Density Legislation and Clinical Evidence. Radiologic Clinics of North America, 2017, 55, 513-526.	1.8	23
1721	Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress. Scientific Reports, 2017, 7, 43435.	3.3	7
1722	Racial disparities in <i>BRCA</i> testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer, 2017, 123, 2497-2505.	4.1	192
1724	Current and future role of genetic screening in gynecologic malignancies. American Journal of Obstetrics and Gynecology, 2017, 217, 512-521.	1.3	34
1725	Therapeutic targeting and patient selection for cancers with homologous recombination defects. Expert Opinion on Drug Discovery, 2017, 12, 565-581.	5.0	32
1726	Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series. Cancer Genetics, 2017, 214-215, 1-8.	0.4	5
1727	Breast Cancer Risk Assessment Models and High-Risk Screening. Radiologic Clinics of North America, 2017, 55, 457-474.	1.8	25
1729	Evolution of Premalignant Disease. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026542.	6.2	23
1730	Next Generation Sequencing Based Clinical Molecular Diagnosis of Human Genetic Disorders. , 2017, , .		2
1731	Effect of genomics-related literacy on non-communicable diseases. Journal of Human Genetics, 2017, 62, 839-846.	2.3	12
1732	Practice Patterns of Hereditary Ovarian Cancer Management in Korea. International Journal of Gynecological Cancer, 2017, 27, 895-899.	2.5	10

#	ARTICLE	IF	CITATIONS
1733	Emerging therapies for breast cancer. Journal of Hematology and Oncology, 2017, 10, 98.	17.0	60
1734	Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical and pathological features in BRCA carriers and non-carriers. Familial Cancer, 2017, 16, 477-489.	1.9	14
1735	Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertility and Sterility, 2017, 107, 1256-1265.e6.	1.0	55
1736	Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians. Carcinogenesis, 2017, 38, 511-518.	2.8	38
1737	The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Current Treatment Options in Oncology, 2017, 18, 27.	3.0	25
1738	Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecologic Oncology, 2017, 146, 205-214.	1.4	16
1739	Impact of Bilateral Prophylactic Mastectomy and Immediate Reconstruction on Health-Related Quality of Life in Women at High Risk for Breast Carcinoma: Results of the Mastectomy Reconstruction Outcomes Consortium Study. Annals of Surgical Oncology, 2017, 24, 2502-2508.	1.5	43
1740	Identification and Characterization of a New BRCA2 Rearrangement in an Italian Family with Hereditary Breast and Ovarian Cancer Syndrome. Molecular Diagnosis and Therapy, 2017, 21, 539-545.	3.8	12
1741	Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric, 2017, 20, 212-221.	2.4	38
1742	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	7.4	1,898
1743	Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries. Maturitas, 2017, 105, 113-118.	2.4	5
1744	BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. Breast Cancer Research, 2017, 19, 64.	5.0	32
1745	Recent omics technologies and their emerging applications for personalised medicine. IET Systems Biology, 2017, 11, 87-98.	1.5	13
1746	BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management. Radiographics, 2017, 37, 1005-1023.	3.3	56
1747	Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper. Gynecologic Oncology, 2017, 146, 217-224.	1.4	89
1749	BERing the burden of damage: Pathway crosstalk and posttranslational modification of base excision repair proteins regulate DNA damage management. DNA Repair, 2017, 56, 51-64.	2.8	44
1750	Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 797-803.	4.9	11
1751	Familial breast cancer. InnovAiT, 2017, 10, 82-88.	0.0	0

#	ARTICLE	IF	CITATIONS
1752	MAMMARY GLAND ADENOCARCINOMA IN A MALE BORNEAN ORANGUTAN (<i>PONGO PYGMAEUS</i>). Journal of Zoo and Wildlife Medicine, 2017, 48, 224-227.	0.6	3
1753	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. Journal of the National Cancer Institute, 2017, 109, djw290.	6.3	171
1754	A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value in Health, 2017, 20, 567-576.	0.3	54
1755	A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. Value in Health, 2017, 20, 547-555.	0.3	40
1756	Risk-Reducing Strategies for Ovarian Cancer in <i>BRCA</i> Mutation Carriers: A Balancing Act. Oncologist, 2017, 22, 450-459.	3.7	36
1757	Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?. Cancer, 2017, 123, 1699-1702.	4.1	2
1758	Inherited mutations in DNA repair genes and cancer risk. Current Problems in Cancer, 2017, 41, 251-264.	2.0	28
1759	Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients. Journal of Genetic Counseling, 2017, 26, 1116-1129.	1.6	90
1760	Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer. Familial Cancer, 2017, 16, 461-469.	1.9	3
1761	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. Gynecologic Oncology, 2017, 145, 346-351.	1.4	33
1762	David Skae and his nineteenth century etiologic psychiatric diagnostic system: looking forward by looking back. Molecular Psychiatry, 2017, 22, 802-807.	7.9	6
1763	Screening for Epithelial Ovarian Cancer: An Updated Review. Indian Journal of Gynecologic Oncology, 2017, 15, 1.	0.3	1
1764	Breast and ovarian cancer referrals to the <scp>ACT</scp> Genetic Service: are we meeting guidelines?. Internal Medicine Journal, 2017, 47, 311-317.	0.8	4
1765	Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 116-125.	2.5	6
1766	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. Journal of Human Genetics, 2017, 62, 379-387.	2.3	2
1767	Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Annals of Surgical Oncology, 2017, 24, 375-397.	1.5	61
1768	Lifestyle Risk Factors for Breast Cancer in BRCA1/2 Mutation Carriers Around Childbearing Age. Journal of Genetic Counseling, 2017, 26, 785-791.	1.6	6
1769	MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells. Nature Communications, 2017, 8, 860.	12.8	311

#	ARTICLE	IF	CITATIONS
1770	Imaging and Screening of Hereditary Cancer Syndromes. Radiologic Clinics of North America, 2017, 55, 1293-1309.	1.8	2
1771	Ovarian Cancer Prevention in High-risk Women. Clinical Obstetrics and Gynecology, 2017, 60, 738-757.	1.1	25
1772	Risk-reducing Surgery in Women at Low Lifetime Risk of Developing Ovarian Carcinoma: Opportunistic Salpingectomy. Clinical Obstetrics and Gynecology, 2017, 60, 758-770.	1.1	7
1774	Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis. Archives of Gynecology and Obstetrics, 2017, 296, 1135-1144.	1.7	22
1775	Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals. Breast, 2017, 36, 74-78.	2.2	9
1776	Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know. Cancer Treatment Reviews, 2017, 61, 1-5.	7.7	19
1777	The Role of Hereditary Factors in Ovarian Carcinoma. Clinical Obstetrics and Gynecology, 2017, 60, 728-737.	1.1	1
1778	Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. Biological Research, 2017, 50, 35.	3.4	37
1779	Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecologic Oncology, 2017, 147, 705-713.	1.4	69
1780	Taking the Tube: From Normal Fallopian Tube Epithelium to Ovarian High-grade Serous Carcinoma. Clinical Obstetrics and Gynecology, 2017, 60, 697-710.	1.1	11
1781	Mathematical modelling of radiation-induced cancer risk from breast screening by mammography. European Journal of Radiology, 2017, 96, 98-103.	2.6	12
1782	CdSe Quantum Dots Based Nano-Biosensor for Detection of 185delAG Mutation in BRCA1 Gene, Responsible for Breast Cancer. Journal of Inorganic and Organometallic Polymers and Materials, 2017, 27, 1911-1917.	3.7	6
1783	Oncogenética de los cánceres pÂ©lvicos. EMC - GinecologÃa-Obstetricia, 2017, 53, 1-12.	0.0	0
1784	Breast cancer genetics in young women: What do we know?. Mutation Research - Reviews in Mutation Research, 2017, 774, 33-45.	5.5	23
1785	A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nature Genetics, 2017, 49, 1476-1486.	21.4	427
1786	Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstetrics and Gynecology, 2017, 130, e110-e126.	2.4	149
1787	Breast Cancer Genetics for Plastic Surgeons. Plastic and Reconstructive Surgery, 2017, 140, 455-460.	1.4	3
1788	BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination. Nature Communications, 2017, 8, 525.	12.8	119

#	ARTICLE	IF	CITATIONS
1789	Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?. Archives of Gynecology and Obstetrics, 2017, 296, 1055-1062.	1.7	49
1790	A Breast Cancer Review: Through the Eyes of the Doctor, Nurse, and Patient. Journal of Radiology Nursing, 2017, 36, 158-165.	0.4	12
1791	ASPECTOS REPRODUCTIVOS EN MUJERES PORTADORAS DE MUTACIONES GENÉTICAS BRCA. Revista Médica Clínica Las Condes, 2017, 28, 632-643.	0.2	0
1792	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications, 2017, 8, 319.	12.8	212
1793	Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. Ca-A Cancer Journal for Clinicians, 2017, 67, 493-506.	329.8	58
1794	BRCA1 expression serves a role in vincristine resistance in colon cancer cells. Oncology Letters, 2017, 14, 345-348.	1.8	9
1795	Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations. Annals of Surgical Oncology, 2017, 24, 3107-3109.	1.5	4
1796	A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy. Breast Cancer Research and Treatment, 2017, 166, 109-116.	2.5	12
1797	Was Angelina Jolie Right? Optimizing Cancer Prevention Strategies Among BRCA Mutation Carriers. Decision Analysis, 2017, 14, 139-169.	2.1	10
1798	Correction of a pathogenic gene mutation in human embryos. Nature, 2017, 548, 413-419.	27.8	781
1799	Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome. Journal of Cellular and Molecular Medicine, 2017, 21, 510-518.	3.6	13
1800	Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors. Cancer Science, 2017, 108, 1834-1842.	3.9	23
1801	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. Gynecologic Oncology, 2017, 147, 110-114.	1.4	46
1802	BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Therapeutic Advances in Medical Oncology, 2017, 9, 519-531.	3.2	96
1803	Ovarian Aging in Women With BRCA Germline Mutations. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3839-3847.	3.6	80
1804	Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1 / BRCA2. Journal of Molecular Diagnostics, 2017, 19, 809-816.	2.8	24
1805	Screening for familial cancer risk: Focus on breast cancer. Maturitas, 2017, 105, 69-77.	2.4	24
1806	Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer. Genetic Testing and Molecular Biomarkers, 2017, 21, 547-554.	0.7	10

#	ARTICLE	IF	CITATIONS
1808	Identification and management of familial breast cancer in Austria. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2017, 32, .	0.7	2
1809	A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. <i>Npj Breast Cancer</i> , 2017, 3, 49.	5.2	47
1810	Personalised Medicine: A New Approach to Improving Health in Indigenous Australian Populations. <i>Public Health Genomics</i> , 2017, 20, 58-62.	1.0	6
1811	Estimating the prevalence of functional exonic splice regulatory information. <i>Human Genetics</i> , 2017, 136, 1059-1078.	3.8	26
1812	Managing BRCA Mutation Carriers. , 2017, , .		0
1813	Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. <i>BMC Cancer</i> , 2017, 17, 438.	2.6	48
1814	Family Communication, Risk Perception and Cancer Knowledge of Young Adults from <i>BRCA1/2</i> Families: a Systematic Review. <i>Journal of Genetic Counseling</i> , 2017, 26, 1179-1196.	1.6	33
1815	Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients. <i>Scientific Reports</i> , 2017, 7, 4713.	3.3	31
1816	Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2011-2024.	2.5	30
1818	The management of sexuality, intimacy, and menopause symptoms (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in "previvors". <i>Maturitas</i> , 2017, 105, 46-51.	2.4	6
1819	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
1820	Reproductive Decision-Making in Women with BRCA1/2 Mutations. <i>Journal of Genetic Counseling</i> , 2017, 26, 594-603.	1.6	61
1821	Pathology and Molecular Pathology of Uterine and Ovarian Cancers. , 2017, , 247-278.		0
1823	Breast Cancer Before 40. <i>Pediatric Oncology</i> , 2017, , 177-202.	0.5	1
1824	Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 11-16.	2.5	27
1825	Whole-exome sequencing of Finnish hereditary breast cancer families. <i>European Journal of Human Genetics</i> , 2017, 25, 85-93.	2.8	20
1826	Why Are There So Many Mastectomies in the United States?. <i>Annual Review of Medicine</i> , 2017, 68, 229-241.	12.2	37
1828	Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery. <i>Annals of Surgical Oncology</i> , 2017, 24, 77-83.	1.5	19

#	ARTICLE	IF	CITATIONS
1829	Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant. <i>Modern Pathology</i> , 2017, 30, 15-25.	5.5	2
1830	Alpha-fetoprotein and Fanconi Anemia: Relevance to DNA Repair and Breast Cancer Susceptibility. <i>Fetal and Pediatric Pathology</i> , 2017, 36, 49-61.	0.7	7
1831	Commercially available lifestyle modification program: randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer survivors after risk-reducing salpingo-oophorectomy. <i>Journal of Cancer Survivorship</i> , 2017, 11, 246-255.	2.9	17
1832	Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients. <i>Oncology Letters</i> , 2017, 14, 4384-4390.	1.8	2
1833	Awareness and current knowledge of breast cancer. <i>Biological Research</i> , 2017, 50, 33.	3.4	724
1834	Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 287-313.	1.6	7
1835	Germline Testing for Predisposition to Ovarian/Breast Cancer Should be Routinely Recommended in all Patients with Invasive Epithelial Ovarian Cancer. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 27-30.	0.3	0
1836	Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK. <i>BMJ Open</i> , 2017, 7, e017675.	1.9	16
1837	Homologous Recombination and Replication Fork Protection: BRCA2 and More!. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2017, 82, 329-338.	1.1	54
1838	Characterization of mutations in BRCA1/2 and the relationship with clinicopathological features of breast cancer in a hereditarily high-risk sample of chinese population. <i>Oncology Letters</i> , 2017, 15, 3068-3074.	1.8	4
1839	Radiation induced breast cancer risk in BRCA mutation carriers from low-dose radiological exposures: a systematic review. <i>Radioprotection</i> , 2017, 52, 231-240.	1.0	20
1840	Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. <i>F1000Research</i> , 2017, 6, 84.	1.6	16
1841	Unexpected <i>CDH1</i> Mutations Identified on Multigene Panels Pose Clinical Management Challenges. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	3.0	29
1842	GWAS in Breast Cancer. , 2017, , .		1
1843	The Scope of Big Data in One Medicine: Unprecedented Opportunities and Challenges. <i>Frontiers in Veterinary Science</i> , 2017, 4, 194.	2.2	55
1844	Metabolic Activity of Normal Glandular Tissue on ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Correlation with Menstrual Cycles and Parenchymal Enhancements. <i>Journal of Breast Cancer</i> , 2017, 20, 386.	1.9	12
1845	Ten Important Considerations for Ovarian Cancer Screening. <i>Diagnostics</i> , 2017, 7, 22.	2.6	5
1846	A Resident's Perspective of Ovarian Cancer. <i>Diagnostics</i> , 2017, 7, 24.	2.6	11

#	ARTICLE	IF	CITATIONS
1847	Vitamin D, Its Receptor Gene Polymorphism and Breast Cancer. , 2017, , .		0
1848	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	2.5	105
1849	Monoallelic characteristic-bearing heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer. BMC Medical Genetics, 2017, 18, 85.	2.1	7
1850	CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. BMC Cancer, 2017, 17, 620.	2.6	29
1851	Racial health disparities in ovarian cancer: not just black and white. Journal of Ovarian Research, 2017, 10, 58.	3.0	30
1852	Computational Analysis of BRCA1 Mutations in Pediatric Patients with Malignancies and Their Mothers. , 2017, , .		1
1853	Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Scientific Reports, 2017, 7, 15742.	3.3	9
1854	<i>BRCA1</i>-mutated ovarian cancer with skin metastasis: a case report. Obstetrics and Gynecology Science, 2017, 60, 477.	1.6	1
1855	Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget, 2017, 8, 50252-50272.	1.8	50
1856	Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Oncotarget, 2017, 8, 47064-47075.	1.8	68
1857	Simultaneous detection of genetic and copy number alterations in BRCA1/2 genes. Oncotarget, 2017, 8, 114463-114473.	1.8	11
1858	Breast Cancer: Exploring the Facts and Holistic Needs during and beyond Treatment. Healthcare (Switzerland), 2017, 5, 26.	2.0	21
1859	Bioinformatic analysis of computational identified differentially expressed genes in tumor stoma of pregnancy-associated breast cancer. Molecular Medicine Reports, 2017, 16, 3345-3350.	2.4	5
1860	Epidemiology of ovarian cancer: a review. Cancer Biology and Medicine, 2017, 14, 9-32.	3.0	981
1861	How Can Contingent Valuation Inform theÂBioethics Debate? Evidence from aÂSurvey on Hereditary Cancers in France. Revue Economique, 2017, Vol. 68, 379-404.	0.3	2
1862	No Evidence of Excessive Cancer Screening in Female Noncarriers from BRCA1/2 Mutationâ€Positive Families. Current Oncology, 2017, 24, 352-359.	2.2	3
1863	Current state and controversies in fertility preservation in women with breast cancer. World Journal of Clinical Oncology, 2017, 8, 241.	2.3	43
1864	Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists. Drug Design, Development and Therapy, 2017, Volume 11, 3471-3479.	4.3	12

#	ARTICLE	IF	CITATIONS
1866	Homologous Recombination Deficiency in Breast Cancer: A Clinical Review. JCO Precision Oncology, 2017, 1, 1-13.	3.0	50
1867	Interventions to improve psychosocial well-being in female <i>BRCA</i>-mutation carriers following risk-reducing surgery. The Cochrane Library, 0, , .	2.8	2
1868	Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer. Journal of Clinical Oncology, 2017, 35, 2232-2239.	1.6	212
1869	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology, 2017, 35, 1411-1420.	1.6	148
1871	Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precision Oncology, 2017, 1, 1-12.	3.0	96
1872	Tumor-derived exosomes in ovarian cancer - liquid biopsies for early detection and real-time monitoring of cancer progression. Oncotarget, 2017, 8, 104687-104703.	1.8	54
1873	Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer. PLoS ONE, 2017, 12, e0169673.	2.5	8
1874	Translational Challenges and Therapeutic Opportunities in BRCA1-Related Breast Cancer. , 2017, , .		0
1875	Characterization of BRCA1/2 mutations in patients with family history of breast cancer in Armenia. F1000Research, 2017, 6, 29.	1.6	6
1876	Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Research and Treatment, 2018, 170, 189-196.	2.5	60
1877	The Abductive Art of Discovery. International Journal of Qualitative Methods, The, 2018, 17, 160940691775097.	2.8	0
1878	Intraoperative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes. Histopathology, 2018, 73, 109-123.	2.9	9
1879	Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes. Journal of Clinical Laboratory Analysis, 2018, 32, e22418.	2.1	5
1880	PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 647-658.	2.3	58
1881	Impact of preoperative<i>BRCA1/2</i>-testing on surgical decision making in patients with newly diagnosed breast cancer. Breast Journal, 2018, 24, 541-548.	1.0	12
1882	Risk management decisions in women with BRCA1 and BRCA2 mutations. American Journal of Surgery, 2018, 215, 899-903.	1.8	7
1883	Is there a "right time" for bad news? Kairos in familial communication on hereditary breast and ovarian cancer risk. Social Science and Medicine, 2018, 202, 13-19.	3.8	9
1884	Difference in Risk of Breast and Ovarian Cancer According to Putative Functional Domain Regions in Korean BRCA1/2 Mutation Carriers. Clinical Breast Cancer, 2018, 18, 362-373.e1.	2.4	4

#	ARTICLE	IF	CITATIONS
1885	Integrating mammographic breast density in glandular dose calculation. British Journal of Radiology, 2018, 91, 20180032.	2.2	6
1886	Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review. Clinical Oncology, 2018, 30, 463-471.	1.4	18
1888	A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors. Medical Oncology, 2018, 35, 18.	2.5	10
1889	“Second-Class Status?” Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome. Journal of Genetic Counseling, 2018, 27, 885-893.	1.6	16
1890	Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women. Journal of Genetic Counseling, 2018, 27, 863-873.	1.6	5
1891	Fanconi anaemia and cancer: an intricate relationship. Nature Reviews Cancer, 2018, 18, 168-185.	28.4	275
1892	Pre-Menopause, Menopause and Beyond. ISGE Series, 2018, , .	0.2	7
1893	BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia. Breast Cancer Research and Treatment, 2018, 168, 745-753.	2.5	8
1894	Quality-of-life implications of risk-reducing cancer surgery. British Journal of Surgery, 2018, 105, e121-e130.	0.3	15
1895	Optimizing Breast Cancer Management. Cancer Treatment and Research, 2018, , .	0.5	2
1896	Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program. Molecular Genetics & Genomic Medicine, 2018, 6, 213-223.	1.2	9
1897	Hereditary Cancers in Gynecology. Obstetrics and Gynecology Clinics of North America, 2018, 45, 155-173.	1.9	4
1898	Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Internal Medicine, 2018, 178, 494.	5.1	36
1899	Multi-gene Panel Testing in Breast Cancer Management. Cancer Treatment and Research, 2018, 173, 121-140.	0.5	17
1900	No Evidence for the Pathogenicity of the <i>BRCA2</i> c.6937A>G Deep Intronic Variant: A Case-Control Analysis. Genetic Testing and Molecular Biomarkers, 2018, 22, 85-89.	0.7	3
1901	Clinical study of hereditary ovarian cancer syndrome in Shandong province, East China. International Journal of Gynecology and Obstetrics, 2018, 141, 234-239.	2.3	1
1902	Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic. Clinical Breast Cancer, 2018, 18, e695-e698.	2.4	2
1903	Breast Cancer Genetics. , 2018, , 237-249.e5.		2

#	ARTICLE	IF	CITATIONS
1904	Molecular Oncology of Breast Cancer. , 2018, , 282-307.e5.		16
1905	Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK. Breast Journal, 2018, 24, 580-585.	1.0	11
1906	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Seminars in Cancer Biology, 2018, 52, 26-38.	9.6	49
1907	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. Journal of Genetic Counseling, 2018, 27, 854-862.	1.6	5
1908	Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Scientific Reports, 2018, 8, 92.	3.3	4
1909	BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far. Current Problems in Cancer, 2018, 42, 189-207.	2.0	19
1910	The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer. Hormones and Cancer, 2018, 9, 95-107.	4.9	6
1911	XPAT: a toolkit to conduct cross-platform association studies with heterogeneous sequencing datasets. Nucleic Acids Research, 2018, 46, e32-e32.	14.5	6
1912	Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families. Cancer Medicine, 2018, 7, 46-55.	2.8	28
1913	High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Breast Cancer Research and Treatment, 2018, 168, 695-702.	2.5	35
1914	Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. Genetics in Medicine, 2018, 20, 985-994.	2.4	76
1915	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. BMC Cancer, 2018, 18, 454.	2.6	14
1916	BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway. Hereditary Cancer in Clinical Practice, 2018, 16, 3.	1.5	23
1917	Influences on Satisfaction with Reconstructed Breasts and Intimacy in Younger Women Following Bilateral Prophylactic Mastectomy: a Qualitative Analysis. International Journal of Behavioral Medicine, 2018, 25, 390-398.	1.7	11
1918	Disparities in genetics assessment for women with ovarian cancer: Can we do better?. Gynecologic Oncology, 2018, 149, 84-88.	1.4	50
1919	The importance of hCG in human endometrial adenocarcinoma and breast cancer. International Journal of Biological Markers, 2018, 33, 33-39.	1.8	34
1920	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. Genetics in Medicine, 2018, 20, 1575-1582.	2.4	15
1921	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	1.9	11

#	ARTICLE	IF	CITATIONS
1922	Biosocial Research in Social Work Journals. Research on Social Work Practice, 2018, 28, 107-115.	1.9	6
1923	The <i>BRCA1</i> c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	3.2	50
1924	Is there a genetic anticipation in breast and/or ovarian cancer families with the germline c.3481_3491del11 mutation?. Familial Cancer, 2018, 17, 5-14.	1.9	3
1925	High demoralization in a minority of oophorectomized <i>BRCA1/2</i> mutation carriers influences quality of life. Journal of Psychosomatic Obstetrics and Gynaecology, 2018, 39, 96-104.	2.1	7
1926	Heightened perception of breast cancer risk in young women at risk of familial breast cancer. Familial Cancer, 2018, 17, 15-22.	1.9	17
1927	The Application of CRISPR/Cas Technology to Efficiently Model Complex Cancer Genomes in Stem Cells. Journal of Cellular Biochemistry, 2018, 119, 134-140.	2.6	13
1928	Performance of <i>BRCA1</i> 2 mutation prediction models in male breast cancer patients. Clinical Genetics, 2018, 93, 52-59.	2.0	5
1929	Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study. Journal of Cancer Education, 2018, 33, 1213-1221.	1.3	5
1930	Genes and Cancer. , 2018, , 493-527.e6.		0
1931	Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2018, 24, 326-333.	7.0	40
1932	Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations. Familial Cancer, 2018, 17, 333-344.	1.9	5
1933	Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine. Familial Cancer, 2018, 17, 345-349.	1.9	7
1934	Changing Paradigms in the Management of Breast Cancer. , 2018, , .		1
1935	Mechanisms of DNA damage repair in adult stem cells and implications for cancer formation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 89-101.	3.8	40
1936	<i>BRCA</i> mutations in women with inflammatory breast cancer. Cancer, 2018, 124, 466-474.	4.1	14
1937	Influences on decision-making for young women undergoing bilateral prophylactic mastectomy. Patient Education and Counseling, 2018, 101, 318-323.	2.2	13
1938	Breast Cancer Treatment in Young Women. , 2018, , 209-215.		0
1939	Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review. Breast Cancer, 2018, 25, 243-249.	2.9	2

#	ARTICLE	IF	CITATIONS
1940	Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer. <i>Acta Oncologica</i> , 2018, 57, 595-603.	1.8	19
1941	Precision Medicine from a Public Health Perspective. <i>Annual Review of Public Health</i> , 2018, 39, 153-168.	17.4	95
1942	Risk-Reducing Breast and Ovarian Surgery for Women at High Familial Risk. , 2018, , 69-78.		0
1943	Bisphenol A (BPA) and cell signaling pathways. <i>Biotechnology Advances</i> , 2018, 36, 311-327.	11.7	234
1944	Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 308-315.	2.5	7
1945	GENE THERAPY TREATMENTS FOR CANCER. <i>Frontiers in Nanobiomedical Research</i> , 2018, , 25-87.	0.1	0
1946	<i>BRCA</i> Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 69-76.	2.5	16
1947	Characterization of a novel germline BRCA1 splice variant, c.5332+4delA. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 543-550.	2.5	5
1948	Cancer Risk-Reducing Opportunities in Gynecologic Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2018, 25, 1179-1193.	0.6	5
1949	BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 803-814.	2.5	36
1950	The molecular basis of cytotoxicity of Î±-spinasterol from <i>Ganoderma resinaceum</i> : Induction of apoptosis and overexpression of p53 in breast and ovarian cancer cell lines. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3892-3902.	2.6	17
1951	Identification of Pleiotropic Cancer Susceptibility Variants from Genome-Wide Association Studies Reveals Functional Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 75-85.	2.5	25
1952	Information and support needs of young women regarding breast cancer risk and genetic testing: adapting effective interventions for a novel population. <i>Familial Cancer</i> , 2018, 17, 351-360.	1.9	13
1953	Identifying DNA mismatches at single-nucleotide resolution by probing individual surface potentials of DNA-capped nanoparticles. <i>Nanoscale</i> , 2018, 10, 538-547.	5.6	11
1954	Frequency of BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) mutations in Egyptian women with breast cancer compared to healthy controls. <i>Meta Gene</i> , 2018, 15, 35-41.	0.6	6
1955	FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices. <i>Journal of Genetic Counseling</i> , 2018, 27, 131-139.	1.6	21
1956	Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	215
1957	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> Mutations Among High-Risk Saudi Patients With Breast Cancer. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	8

#	ARTICLE	IF	CITATIONS
1958	Prevalence of germline BRCA mutations among women with carcinoma of the peritoneum or fallopian tube. Journal of Gynecologic Oncology, 2018, 29, e43.	2.2	14
1959	No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 1497-1510.	0.7	21
1960	Expression of β -Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia. International Journal of Gynecological Cancer, 2018, 28, 363-370.	2.5	2
1961	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	2.9	21
1962	CLDN10 single nucleotide polymorphism rs1325774 alters the risk of breast cancer in south chinese women. Medicine (United States), 2018, 97, e13187.	1.0	5
1963	Attitudes towards a programme of risk assessment and stratified management for ovarian cancer: a focus group study of UK South Asians™ perspectives. BMJ Open, 2018, 8, e021782.	1.9	4
1964	Introductory Chapter: Genes Expression in the Control of Cell Cycle and Their Potential Value in Cancer Prognosis. , 0, , .		0
1965	Le cancer, les espoirs et les dangers d'un mouvement rapide vers un modèle le poids de la génétique constitutionnelle va en augmentant. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1605-1614.	0.0	0
1966	Breast and ovarian cancer penetrance of <i>BRCA1/2</i> mutations among Hong Kong women. Oncotarget, 2018, 9, 25025-25033.	1.8	8
1967	A MOLECULAR-BASED APPROACH TO INVESTIGATE BREAST CANCER 1 AND BREAST CANCER 2 STATUS IN OVARIAN CANCER AMONG IRAQI WOMEN. Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 199.	0.3	0
1968	Novel Revolution in Diagnosis and Therapy of Breast and prostate Cancer. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	0
1969	Ovarian Cancer Genetics: Subtypes and Risk Factors. , 0, , .		17
1971	No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 1511-1527.	0.7	0
1972	Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. Cancers, 2018, 10, 453.	3.7	14
1973	Possible role of p53/MiRNA-regulated mitochondrial quality control as a tumor suppressor in human breast cancer. Cancer Science, 2018, 109, 3910-3920.	3.9	19
1974	The 10th Oxbridge varsity medical ethics debate-should we fear the rise of direct-to-consumer genetic testing?. Philosophy, Ethics, and Humanities in Medicine, 2018, 13, 14.	1.5	3
1975	Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment. BMJ Open, 2018, 8, e023115.	1.9	3
1976	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genetics, 2018, 14, e1007752.	3.5	148

#	ARTICLE	IF	CITATIONS
1977	Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature. <i>Oncology Letters</i> , 2018, 15, 4093-4096.	1.8	10
1978	Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions. <i>Clinical Cancer Drugs</i> , 2018, 5, 3-12.	0.3	0
1979	BRCA Mutations and Breast Cancer Prevention. <i>Cancers</i> , 2018, 10, 524.	3.7	71
1980	BRCA1-Dependent Transcriptional Regulation: Implication in Tissue-Specific Tumor Suppression. <i>Cancers</i> , 2018, 10, 513.	3.7	13
1982	Recommendations on screening for breast cancer in women aged 40â€“74 years who are not at increased risk for breast cancer. <i>Cmaj</i> , 2018, 190, E1441-E1451.	2.0	142
1983	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	3.7	40
1984	Hereditary breast cancer; Genetic penetrance and current status with BRCA. <i>Journal of Cellular Physiology</i> , 2019, 234, 5741-5750.	4.1	76
1985	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. <i>Cancers</i> , 2018, 10, 487.	3.7	154
1986	PARP Inhibitors in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 392-410.	1.6	102
1987	Germline <i>BRCA1</i> and <i>BRCA2</i> deleterious mutations and variants of unknown clinical significance associated with breast/ovarian cancer: a report from North India. <i>Cancer Management and Research</i> , 2018, Volume 10, 6505-6516.	1.9	24
1988	Co-differential Gene Selection and Clustering Based on Graph Regularized Multi-View NMF in Cancer Genomic Data. <i>Genes</i> , 2018, 9, 586.	2.4	25
1989	Comprehensive Proteomic Profilingâ€‘derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1262-1272.	3.7	3
1990	Microfluidic platforms for rapid screening of cancer affinity reagents by using tissue samples. <i>Biomicrofluidics</i> , 2018, 12, 054108.	2.4	14
1991	Defective DNA repair in hereditary ovarian cancers: Implications for therapy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1697-1707.	1.0	4
1992	Biomarkers in Breast Cancer. , 0, , .		2
1993	Nipple-sparing mastectomy in women at high risk of developing breast cancer. <i>Gland Surgery</i> , 2018, 7, 325-336.	1.1	5
1995	Penetrance and Expressivity in Inherited Cancer Predisposing Syndromes. <i>Trends in Cancer</i> , 2018, 4, 718-728.	7.4	36
1996	Rare loss of function variants in candidate genes and risk of colorectal cancer. <i>Human Genetics</i> , 2018, 137, 795-806.	3.8	10

#	ARTICLE	IF	CITATIONS
1997	Risk Factors for Ovarian Carcinoma. Hematology/Oncology Clinics of North America, 2018, 32, 891-902.	2.2	23
1998	Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial. Contemporary Clinical Trials, 2018, 73, 123-135.	1.8	10
1999	Role of the general practitioner in the care of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: General practitioner and patient perspectives. Molecular Genetics & Genomic Medicine, 2018, 6, 957-965.	1.2	6
2000	BRCA-analyzer: Automatic workflow for processing NGS reads of BRCA1 and BRCA2 genes. Computational Biology and Chemistry, 2018, 77, 297-306.	2.3	10
2001	<i>BRCA1</i> and <i>BRCA2</i> Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 1178-1189.	6.3	92
2002	Population Testing for High Penetrance Genes: Are We There Yet?. Journal of the National Cancer Institute, 2018, 110, 687-689.	6.3	6
2003	A Dietary Intervention to Lower Serum Levels of IGF-I in BRCA Mutation Carriers. Cancers, 2018, 10, 309.	3.7	18
2004	Tissue and plasma proteomics for early stage cancer detection. Molecular Omics, 2018, 14, 405-423.	2.8	28
2005	Assessing Multi-Modality Breast Cancer Screening Strategies for BRCA 1/2 Gene Mutation Carriers and Other High-Risk Populations. SSRN Electronic Journal, 0, , .	0.4	2
2006	Molecular Diagnostics in Clinical Oncology. Frontiers in Molecular Biosciences, 2018, 5, 76.	3.5	93
2007	Predictive Genetic Testing in Multifactorial Disorders. , 2018, , 229-261.		1
2008	Cancer genetics, precision prevention and a call to action. Nature Genetics, 2018, 50, 1212-1218.	21.4	94
2009	Breast cancer in adolescents and young adults. Pediatric Blood and Cancer, 2018, 65, e27397.	1.5	117
2010	Breast Cancer Screening and Optimizing Recommendations. Seminars in Roentgenology, 2018, 53, 280-293.	0.6	2
2011	<i>Genetic Testing for Hereditary Breast Cancer: The Decision to Decline</i>. American Surgeon, 2018, 84, 154-160.	0.8	10
2012	Nextâ€generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drugâ€resistant recurrent ovarian cancer. Molecular Genetics & Genomic Medicine, 2018, 6, 638-647.	1.2	29
2013	Assessing Pelvic Epithelial Cancer Risk and Intercepting Early Malignancy. , 2018, , 844-864.		0
2014	Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52â€ssDNA association. RSC Advances, 2018, 8, 18859-18869.	3.6	9

#	ARTICLE	IF	CITATIONS
2015	BRCA Mutations in the Young, High-Risk Female Population. Plastic and Reconstructive Surgery, 2018, 141, 1341-1350.	1.4	10
2016	The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics, 2018, 19, 581-590.	16.3	1,102
2017	Pervasive genetic testing. Lancet, The, 2018, 391, 2089-2091.	13.7	3
2018	Uptake of Preimplantation Genetic Diagnosis in Female BRCA1 and BRCA2 Mutation Carriers. Journal of Genetic Counseling, 2018, 27, 1386-1394.	1.6	23
2019	A Trans-Feminine Youth with a <i>BRCA1</i> Mutation: Case Study. LGBT Health, 2018, 5, 270-272.	3.4	2
2020	Clinical Genetics for the Gynecologist. , 2018, , 297-308.		1
2021	A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?. Critical Reviews in Oncology/Hematology, 2018, 127, 29-41.	4.4	24
2022	Breast cancer and ovarian tissue cryopreservation: Review of the literature. Journal of Gynecology Obstetrics and Human Reproduction, 2018, 47, 351-357.	1.3	11
2023	Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-10.	4.0	99
2024	Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. Gynecologic Oncology, 2018, 150, 219-226.	1.4	17
2025	Complex Medical Decision-Making for a Trans-Feminine Youth with a <i>BRCA1</i> Mutation. LGBT Health, 2018, 5, 221-225.	3.4	8
2026	Ataxia-“Telangiectasia Gene (ATM) Mutation Heterozygosity in Breast Cancer: A Narrative Review. Current Oncology, 2018, 25, 176-180.	2.2	67
2027	Surgical prevention strategies in ovarian cancer. Gynecologic Oncology, 2018, 151, 166-175.	1.4	38
2028	Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?. PLoS ONE, 2018, 13, e0195497.	2.5	4
2029	Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection. Journal of Molecular Diagnostics, 2018, 20, 754-764.	2.8	9
2030	BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecologic Oncology, 2018, 151, 145-152.	1.4	35
2031	Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. Frontiers in Oncology, 2018, 8, 16.	2.8	105
2032	Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers, 2018, 10, 57.	3.7	24

#	ARTICLE	IF	CITATIONS
2033	Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer. <i>Annals of Diagnostic Pathology</i> , 2018, 36, 28-30.	1.3	1
2034	Variation of exon 11 of the BRCA1 gene in patients with familial breast cancer at Mohammed VI center for treatment of cancers. <i>Gene Reports</i> , 2018, 12, 243-247.	0.8	0
2035	Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma.. <i>Cancer Treatment and Research Communications</i> , 2018, 16, 9-12.	1.7	5
2036	Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France. <i>BMC Health Services Research</i> , 2018, 18, 3.	2.2	12
2037	Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds. <i>Hereditary Cancer in Clinical Practice</i> , 2018, 16, 4.	1.5	7
2038	Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 173-180.	2.5	4
2039	Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature. <i>Clinical Oncology</i> , 2018, 30, 472-483.	1.4	14
2040	Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. <i>Gynecologic Oncology</i> , 2018, 150, 79-84.	1.4	44
2041	Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 833-839.	3.1	16
2042	Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 947-958.	2.4	5
2043	The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment. <i>Cancers</i> , 2018, 10, 277.	3.7	50
2044	Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers. <i>Clinical Breast Cancer</i> , 2018, 18, e1361-e1366.	2.4	25
2046	Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val). <i>Breast Cancer Research and Treatment</i> , 2018, 172, 497-503.	2.5	7
2047	Patterns and mechanisms of structural variations in human cancer. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-11.	7.7	73
2048	Constructions of Decision Making for Risk-Reducing Mastectomy. <i>Qualitative Health Research</i> , 2018, 28, 1595-1609.	2.1	1
2049	Taking stock: A systematic review of archaeological evidence of cancers in human and early hominin remains. <i>International Journal of Paleopathology</i> , 2018, 21, 12-26.	1.4	21
2050	Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. <i>Cancer Treatment Reviews</i> , 2018, 69, 66-71.	7.7	12
2051	Breast Cancer in Men. <i>New England Journal of Medicine</i> , 2018, 378, 2311-2320.	27.0	208

#	ARTICLE	IF	CITATIONS
2052	The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Scientific Reports, 2018, 8, 9188.	3.3	61
2053	Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations. , 2015, 19, 48-79.		232
2054	High-risk women's risk perception after receiving personalized polygenic breast cancer risk information. Journal of Community Genetics, 2019, 10, 197-206.	1.2	16
2055	The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance. Current Medical Research and Opinion, 2019, 35, 2103-2110.	1.9	4
2056	Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. JAMA - Journal of the American Medical Association, 2019, 322, 652.	7.4	297
2057	Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women. JAMA - Journal of the American Medical Association, 2019, 322, 666.	7.4	100
2058	Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib. AAPS PharmSciTech, 2019, 20, 276.	3.3	22
2059	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. BMC Cancer, 2019, 19, 787.	2.6	10
2060	The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. Clinical Cancer Research, 2019, 25, 6206-6216.	7.0	34
2061	Update on Genetic Testing in Gynecologic Cancer. Journal of Clinical Oncology, 2019, 37, 2501-2509.	1.6	26
2062	Effects of long-term intermittent versus chronic calorie restriction on oxidative stress in a mouse cancer model. IUBMB Life, 2019, 71, 1973-1985.	3.4	9
2063	Detection of BRCA1/2 large genomic rearrangements in breast and ovarian cancer patients: an overview of the current methods. Expert Review of Molecular Diagnostics, 2019, 19, 795-802.	3.1	10
2064	Contemporary management of adnexa at the time of benign hysterectomy: a review of the literature. Journal of Obstetrics and Gynaecology, 2019, 39, 896-902.	0.9	5
2065	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 177, 723-733.	2.5	111
2066	Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan. Scientific Reports, 2019, 9, 10229.	3.3	13
2067	Somatic variants of potential clinical significance in the tumors of BRCA phenocopies. Hereditary Cancer in Clinical Practice, 2019, 17, 21.	1.5	1
2068	Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. Breast Cancer Research and Treatment, 2019, 178, 151-159.	2.5	17
2069	Breast Cancer Susceptibility Towards Individualised Risk Prediction. Current Genetic Medicine Reports, 2019, 7, 124-135.	1.9	4

#	ARTICLE	IF	CITATIONS
2070	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. <i>BMC Cancer</i> , 2019, 19, 695.	2.6	4
2072	Psychosocial Effects of Multigene Panel Testing in the Context of Cancer Genomics. <i>Hastings Center Report</i> , 2019, 49, S44-S52.	1.0	15
2073	ABCB1 variants (C1236T, rs1128503 and G2677T/A, rs2032582) do not show an association with recurrence and survival in patients with breast cancer undergoing anthracycline-based chemotherapy. <i>Meta Gene</i> , 2019, 21, 100596.	0.6	1
2074	Choosing high-risk screening vs. surgery and the effect of treatment modality on anxiety and breast-specific sensuality in BRCA mutation carriers. <i>Gland Surgery</i> , 2019, 8, 249-257.	1.1	6
2075	Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2019, 26, 3025-3031.	1.5	184
2076	Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer. <i>Journal of Surgical Oncology</i> , 2019, 120, 864-872.	1.7	11
2077	Inflammatory signaling in genomically instable cancers. <i>Cell Cycle</i> , 2019, 18, 1830-1848.	2.6	21
2078	Riskâ€reducing surgery in <i>BRCA1</i>/<i>BRCA2</i> mutation carriers: Are there factors associated with the choice?. <i>Psycho-Oncology</i> , 2019, 28, 1871-1878.	2.3	9
2079	A genome-wide association study of periodontitis. <i>Journal of Japanese Society of Periodontology</i> , 2019, 61, 127-135.	0.1	1
2080	Human Papillomavirus Epitope Mimicry and Autoimmunity: The Molecular Truth of Peptide Sharing. <i>Pathobiology</i> , 2019, 86, 285-295.	3.8	24
2081	From decision to incision: Ideologies of gender in surgical cancer care. <i>Social Science and Medicine</i> , 2019, 239, 112550.	3.8	8
2082	Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. <i>Gynecologic Oncology</i> , 2019, 155, 508-514.	1.4	10
2083	Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. <i>Fertility and Sterility</i> , 2019, 112, 1034-1042.	1.0	4
2084	A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population. <i>Cancers</i> , 2019, 11, 1246.	3.7	9
2085	Surgically Induced Menopauseâ€”A Practical Review of Literature. <i>Medicina (Lithuania)</i> , 2019, 55, 482.	2.0	27
2086	Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights From the BabySeq Project. <i>Pediatrics</i> , 2019, 143, S37-S43.	2.1	45
2087	Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy. <i>European Journal of Medical Research</i> , 2019, 24, 32.	2.2	6
2088	Evaluation of National Comprehensive Cancer Network guidelineâ€based Tool for Risk Assessment for breast and ovarian Cancer (Nâ€TRAC): A patientâ€reported survey for genetic highâ€risk assessment for breast and ovarian cancers in women. <i>Journal of Genetic Counseling</i> , 2019, 28, 507-515.	1.6	4

#	ARTICLE	IF	CITATIONS
2089	Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. <i>Gynecologic Oncology</i> , 2019, 153, 192-200.	1.4	80
2090	Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 66-75.	4.4	24
2091	Cancer Screening and Prevention Highlights in Gynecologic Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 19-36.	1.9	11
2092	A mini review of bisphenol A (BPA) effects on cancer-related cellular signaling pathways. <i>Environmental Science and Pollution Research</i> , 2019, 26, 8459-8467.	5.3	56
2093	Hereditary Breast and Hereditary Ovarian Cancer: Implications for the Oncology Nurse. <i>Seminars in Oncology Nursing</i> , 2019, 35, 47-57.	1.5	4
2094	NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program. <i>Cancers</i> , 2019, 11, 707.	3.7	14
2095	Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies. <i>Surgical Oncology</i> , 2019, 29, 126-133.	1.6	20
2096	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019, 40, 1557-1578.	2.5	102
2097	<i>BRCA</i> Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance. <i>Journal of Cancer</i> , 2019, 10, 2109-2127.	2.5	125
2098	DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. <i>DNA Repair</i> , 2019, 80, 59-84.	2.8	30
2099	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	6.4	19
2100	The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. <i>Cancers</i> , 2019, 11, 838.	3.7	160
2101	BRCA mutation characteristics in a series of index cases of breast cancer selected independent of family history. <i>Breast Journal</i> , 2019, 25, 1029-1033.	1.0	6
2102	Cancer Genetics: Risks and Mechanisms of Cancer in Women with Hereditary Predisposition to Epithelial Ovarian Cancer. , 2019, , 29-43.		0
2103	Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?. <i>British Journal of Cancer</i> , 2019, 121, 1-2.	6.4	2
2104	Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations. <i>Gynecologic Oncology</i> , 2019, 154, 374-378.	1.4	3
2105	Achieving World Class. <i>Journal - American Water Works Association</i> , 2019, 111, 58-61.	0.3	0
2106	Association Rule-Based Breast Cancer Prevention and Control System. <i>IEEE Transactions on Computational Social Systems</i> , 2019, 6, 1106-1114.	4.4	9

#	ARTICLE	IF	CITATIONS
2107	Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. BMC Medical Genomics, 2019, 12, 84.	1.5	20
2108	Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genetics and Molecular Biology, 2019, 42, 215-231.	1.3	14
2109	Prevention of Ovarian Cancer. , 2019, , 257-272.		0
2110	Novel BRCA2 pathogenic variant c.5219 T > G; p.(Leu1740Ter) in a consanguineous Senegalese family with hereditary breast cancer. BMC Medical Genetics, 2019, 20, 73.	2.1	7
2111	Understanding <i>BRCA</i> Mutation Carriersâ€™ Preferences for Communication of Genetic Modifiers of Breast Cancer Risk. Journal of Health Communication, 2019, 24, 377-384.	2.4	7
2112	Cyanobacterial bioactive compound EMTAHDCA recovers splenomegaly, affects protein profile of E. coli and spleen of lymphoma bearing mice. Molecular Biology Reports, 2019, 46, 2617-2629.	2.3	3
2113	Assessment of High Risk of Hereditary Breast and Ovarian Cancer (HBOC) and Acceptance for Genetic Testing Among Cases of Ovarian and Breast Cancer in Indian Set-up. Indian Journal of Gynecologic Oncology, 2019, 17, 1.	0.3	1
2114	BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. Breast Cancer Research, 2019, 21, 51.	5.0	16
2115	Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. European Journal of Cancer Prevention, 2019, 28, 500-506.	1.3	6
2116	An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nature Medicine, 2019, 25, 838-849.	30.7	486
2117	Association of BRCA Mutations and Anti-mâ€™llerian Hormone Level in Young Breast Cancer Patients. Frontiers in Endocrinology, 2019, 10, 235.	3.5	29
2118	BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer, 2019, 19, 387.	2.6	17
2119	<i>BRCA</i> Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations. Radiology, 2019, 291, 554-569.	7.3	39
2120	The association of <i>BRCA1</i> and <i>BRCA2</i> mutations with prostate cancer risk, frequency, and mortality: A metaâ€™analysis. Prostate, 2019, 79, 880-895.	2.3	100
2122	Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China. Breast Cancer Research and Treatment, 2019, 175, 749-754.	2.5	21
2123	Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model. Gynecologic Oncology, 2019, 153, 87-91.	1.4	11
2124	Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control. Genes, 2019, 10, 186.	2.4	6
2125	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers, 2019, 11, 416.	3.7	49

#	ARTICLE	IF	CITATIONS
2126	Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result. <i>Journal of Community Genetics</i> , 2019, 10, 501-514.	1.2	3
2127	Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms. <i>Breast</i> , 2019, 46, 48-51.	2.2	8
2128	Increased risk of brain metastases in ovarian cancer patients with BRCA mutations. <i>Gynecologic Oncology</i> , 2019, 153, 568-573.	1.4	38
2129	Effectiveness of chemoradiotherapy for radiation-induced bilateral external auditory canal cancer: A case report and literature review. <i>Head and Neck</i> , 2019, 41, E113-E119.	2.0	3
2130	BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 459-464.	1.4	15
2132	Variant classification changes over time in BRCA1 and BRCA2. <i>Genetics in Medicine</i> , 2019, 21, 2248-2254.	2.4	37
2133	Functional analysis of BARD1 missense variants in homology-directed repair and damage sensitivity. <i>PLoS Genetics</i> , 2019, 15, e1008049.	3.5	23
2134	Identifying a BRCA2 c.5722_5723del mutation in a Han-Chinese family with breast cancer. <i>Bioscience Reports</i> , 2019, 39, .	2.4	5
2136	Prevalence and clinical outcomes of germline mutations in <i>BRCA1/2</i> and <i>PALB2</i> genes in 2769 unselected breast cancer patients in China. <i>International Journal of Cancer</i> , 2019, 145, 1517-1528.	5.1	37
2137	Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015. <i>Journal of the National Cancer Institute</i> , 2019, 111, 795-802.	6.3	28
2138	Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. <i>Cancers</i> , 2019, 11, 193.	3.7	12
2139	Association between family history, mutation locations, and prevalence of <i>BRCA1</i> or <i>BRCA2</i> mutations in ovarian cancer patients. <i>Cancer Medicine</i> , 2019, 8, 1875-1881.	2.8	17
2140	Diagnostic utility of epigenetics in breast cancer - A review. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100125.	1.7	19
2141	Genetic Epidemiology of Breast Cancer in Latin America. <i>Genes</i> , 2019, 10, 153.	2.4	34
2142	The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway. <i>MDM Policy and Practice</i> , 2019, 4, 238146831882110.	0.9	30
2143	Design choices for observational studies of the effect of exposure on disease incidence. <i>BMJ Open</i> , 2019, 9, e031031.	1.9	25
2145	Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery. <i>The Cochrane Library</i> , 2019, 10, CD012894.	2.8	14
2146	Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. <i>Melanoma Research</i> , 2019, 29, 483-490.	1.2	13

#	ARTICLE	IF	CITATIONS
2147	Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. <i>Nature Communications</i> , 2019, 10, 5296.	12.8	45
2148	Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain). <i>BMC Cancer</i> , 2019, 19, 1145.	2.6	18
2149	Personalizing Decision-Making for Patients Choosing Contralateral Prophylactic Mastectomy: A Utility Analysis of Genetic Factors and the Relative Risk of Breast Cancer. <i>Plastic Surgery</i> , 2019, 27, 319-324.	1.0	0
2150	Diagnosis and Treatment of Breast Cancer in Young Women. <i>Current Treatment Options in Oncology</i> , 2019, 20, 86.	3.0	70
2151	Culturally Targeted Video Improves Psychosocial Outcomes in Latina Women at Risk of Hereditary Breast and Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4793.	2.6	17
2152	Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy. <i>Menopause</i> , 2019, 26, 132-139.	2.0	20
2153	Management of ovarian cancer risk in women with <i>BRCA1/2</i> pathogenic variants. <i>Cmaj</i> , 2019, 191, E886-E893.	2.0	10
2154	The Translational Status of Cancer Liquid Biopsies. <i>Regenerative Engineering and Translational Medicine</i> , 2021, 7, 312-352.	2.9	39
2155	Hereditary Cancer Syndromes and Risk Assessment. <i>Obstetrics and Gynecology</i> , 2019, 134, e143-e149.	2.4	43
2156	The Effect of Prophylactic Adnexectomy on the Quality of Life and Psychosocial Functioning of Women with the BRCA1/BRCA2 Mutations. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4995.	2.6	6
2157	Contraception options for patients with known hereditary risk for ovarian cancer. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2019, 32, 37-41.	0.3	0
2158	Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (<i>scs</i> PURSUE study): a randomised controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 402-411.	2.3	20
2159	Ovarian metastasis from breast cancer: a comprehensive review. <i>Clinical and Translational Oncology</i> , 2019, 21, 819-827.	2.4	13
2160	Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers. <i>European Journal of Cancer</i> , 2019, 107, 68-78.	2.8	10
2161	Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 719-726.	2.5	5
2162	Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 1205-1227.	10.5	21
2163	Impact of p38 ^β mitogen-activated protein kinase (MAPK) on MDA-MB-231 breast cancer cells using metabolomic approach. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 107, 6-13.	2.8	6
2164	Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 741-748.	2.5	17

#	ARTICLE	IF	CITATIONS
2165	Identifying breast cancer susceptibility genes – a review of the genetic background in familial breast cancer. <i>Acta Oncologica</i> , 2019, 58, 135-146.	1.8	86
2166	Global Disparities in Breast Cancer Genetics Testing, Counselling and Management. <i>World Journal of Surgery</i> , 2019, 43, 1264-1270.	1.6	18
2167	Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 47-64.	2.5	27
2168	The Tumor Suppressor PALB2: Inside Out. <i>Trends in Biochemical Sciences</i> , 2019, 44, 226-240.	7.5	83
2169	Genetic epidemiology of ovarian cancer in the 22 Arab countries: A systematic review. <i>Gene</i> , 2019, 684, 154-164.	2.2	25
2170	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 58-73.	4.4	30
2171	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	6.3	30
2172	PARP inhibitors in ovarian cancer. <i>Cancer Treatment Reviews</i> , 2019, 73, 1-9.	7.7	158
2173	Breast cancer risk in neurofibromatosis type 1 is a function of the type of <i>NF1</i> gene mutation: a new genotype-phenotype correlation. <i>Journal of Medical Genetics</i> , 2019, 56, 209-219.	3.2	26
2174	Opening the 'black box' of informed consent appointments for genome sequencing: a multisite observational study. <i>Genetics in Medicine</i> , 2019, 21, 1083-1091.	2.4	15
2175	Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2019, 26, 253-265.	0.6	11
2176	Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review. <i>Clinical Breast Cancer</i> , 2019, 19, e48-e65.	2.4	34
2177	Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 330-339.	2.3	40
2178	Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 63-70.	6.3	14
2179	Breast cancer risk in <i>BRCA1/2</i> mutation carriers and noncarriers under prospective intensified surveillance. <i>International Journal of Cancer</i> , 2020, 146, 999-1009.	5.1	32
2180	Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program. <i>Journal of the National Cancer Institute</i> , 2020, 112, 136-144.	6.3	55
2181	Effects of malignancies on fertility preservation outcomes and relevant cryobiological advances. <i>Science China Life Sciences</i> , 2020, 63, 217-227.	4.9	5
2182	Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020, 46, 139-147.	1.0	9

#	ARTICLE	IF	CITATIONS
2183	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectrum, 2020, 4, pkz075.	2.9	11
2184	Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor \pm antagonism. Cancer Letters, 2020, 469, 78-88.	7.2	8
2185	<i>BRCA</i> testing in unaffected young women in the United States, 2006–2017. Cancer, 2020, 126, 337-343.	4.1	15
2186	Genetic Factors. , 2020, , 180-208.e11.		4
2188	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
2189	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. European Urology, 2020, 77, 24-35.	1.9	124
2190	PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells. Molecular Cell, 2020, 77, 461-474.e9.	9.7	148
2191	<i>BRCA1</i> promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. International Journal of Cancer, 2020, 146, 1293-1298.	5.1	33
2192	<i>BRCA1/BRCA2</i> Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies. Annals of Laboratory Medicine, 2020, 40, 114-121.	2.5	67
2193	Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients. Cancer Genetics, 2020, 240, 23-32.	0.4	11
2194	Mechanisms of tissue and cell-type specificity in heritable traits and diseases. Nature Reviews Genetics, 2020, 21, 137-150.	16.3	105
2195	Prophylactic Mastectomy: Postoperative Skin Flap Thickness Evaluated by MRT, Ultrasound and Clinical Examination. Annals of Surgical Oncology, 2020, 27, 2221-2228.	1.5	7
2196	Spectrum of BRCA1/BRCA2 variants in 1419 Turkish breast and ovarian cancer patients: a single center study. Turkish Journal of Biochemistry, 2020, 45, 83-90.	0.5	12
2197	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
2198	Knowledge and opinions regarding <i>BRCA1</i> and <i>BRCA2</i> genetic testing among primary care physicians. Journal of Genetic Counseling, 2020, 29, 122-130.	1.6	16
2199	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology, 2020, 156, 377-386.	1.4	14
2200	Tissue engineering and regenerative medicine strategies for the female breast. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 369-387.	2.7	21
2201	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecologic Oncology, 2020, 156, 131-139.	1.4	8

#	ARTICLE	IF	CITATIONS
2202	Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank. <i>Journal of the National Cancer Institute</i> , 2020, 112, 893-901.	6.3	100
2203	Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 615-626.	2.5	3
2204	BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan. <i>Scientific Reports</i> , 2020, 10, 17573.	3.3	15
2205	Discrepancies in Genetic Testing Procedures of BRCA1/2 Mutations: A National Survey Across China. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 715-721.	3.8	0
2206	Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C. <i>Cell Death and Disease</i> , 2020, 11, 812.	6.3	6
2207	Analysis of mutational signatures in <i>C. elegans</i> : Implications for cancer genome analysis. <i>DNA Repair</i> , 2020, 95, 102957.	2.8	8
2208	DNA helicases and their roles in cancer. <i>DNA Repair</i> , 2020, 96, 102994.	2.8	20
2209	Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study). <i>Scientific Reports</i> , 2020, 10, 16511.	3.3	15
2210	Roles of OB-Fold Proteins in Replication Stress. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 574466.	3.7	18
2211	Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA. <i>Oncogene</i> , 2020, 39, 7051-7062.	5.9	18
2212	Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. <i>Breast Journal</i> , 2020, 26, 1520-1527.	1.0	17
2213	Gynaecological cancer in Caribbean women: data from the French population-based cancer registries of Martinique, Guadeloupe and French Guiana (2007–2014). <i>BMC Cancer</i> , 2020, 20, 643.	2.6	6
2214	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
2215	Germline genomic patterns are associated with cancer risk, oncogenic pathways, and clinical outcomes. <i>Science Advances</i> , 2020, 6, .	10.3	12
2216	Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program. <i>Cancers</i> , 2020, 12, 3479.	3.7	13
2217	Methodological and clinical challenges associated with biomarkers for psychiatric disease: A scoping review. <i>Journal of Psychiatric Research</i> , 2021, 143, 572-579.	3.1	11
2218	Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. <i>Frontiers in Genetics</i> , 2020, 11, 552971.	2.3	9
2219	Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 169.	3.5	11

#	ARTICLE	IF	CITATIONS
2220	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 265-275.	2.5	22
2221	Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112635.	5.5	18
2222	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. <i>Nature Communications</i> , 2020, 11, 3833.	12.8	88
2223	The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study. <i>European Journal of Cancer Prevention</i> , 2020, 29, 350-356.	1.3	3
2224	BRCA sequencing of tumors: understanding its implications in the oncology community. <i>Chinese Clinical Oncology</i> , 2020, 9, 66-66.	1.2	6
2225	Pathology of Hereditary Breast and Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 531790.	2.8	30
2226	BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women. <i>Genes</i> , 2020, 11, 1251.	2.4	11
2227	Returning Results of Stored Biological Samples and Biobanks: Perspectives of Saudi Arabian Biomedical Researchers. <i>Biopreservation and Biobanking</i> , 2020, 18, 395-402.	1.0	4
2228	Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. <i>Breast Cancer</i> , 2021, 28, 1167-1180.	2.9	118
2229	XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way. <i>Cancer Cell International</i> , 2020, 20, 436.	4.1	15
2230	Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies. <i>Breast Cancer</i> , 2021, 28, 1195-1211.	2.9	4
2231	RASAL1 and ROS1 Gene Variants in Hereditary Breast Cancer. <i>Cancers</i> , 2020, 12, 2539.	3.7	2
2232	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564601.	3.7	315
2233	Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer – Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 932-940.	1.8	7
2234	Multifactorial disorders and polygenic risk scores: predicting common diseases and the possibility of adverse selection in life and protection insurance. <i>Annals of Actuarial Science</i> , 2020, , 1-16.	1.5	8
2235	Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. <i>Nature Communications</i> , 2020, 11, 3635.	12.8	277
2236	Space-time analysis of ovarian cancer mortality rates by age groups in spanish provinces (1989–2015). <i>BMC Public Health</i> , 2020, 20, 1244.	2.9	3
2237	<p>Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 227-238.	0.7	8

#	ARTICLE	IF	CITATIONS
2238	A Mediterranean Dietary Intervention in Female Carriers of BRCA Mutations: Results from an Italian Prospective Randomized Controlled Trial. <i>Cancers</i> , 2020, 12, 3732.	3.7	14
2239	Prediction of Breast Cancer Using Electronic Health Record. , 2020, , .		1
2240	Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. <i>American Surgeon</i> , 2020, 86, 1243-1247.	0.8	3
2241	Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort. <i>Clinical Breast Cancer</i> , 2021, 21, e168-e176.	2.4	13
2242	Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?. <i>Cancers</i> , 2020, 12, 3645.	3.7	1
2243	EpidemiologÃa del cÃncer de mama. <i>EMC - GinecologÃa-Obstetricia</i> , 2020, 56, 1-21.	0.0	0
2244	Genomic Diversity in Sporadic Breast Cancer in a Latin American Population. <i>Genes</i> , 2020, 11, 1272.	2.4	4
2245	Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses. <i>Neoplasia</i> , 2020, 22, 663-678.	5.3	37
2246	Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients. <i>Diagnostics</i> , 2020, 10, 269.	2.6	14
2247	Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 104-112.	0.5	13
2248	Emerging functions of Fanconi anemia genes in replication fork protection pathways. <i>Human Molecular Genetics</i> , 2020, 29, R158-R164.	2.9	17
2249	Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer. <i>Radiographics</i> , 2020, 40, 913-936.	3.3	13
2250	Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome. <i>Npj Breast Cancer</i> , 2020, 6, 25.	5.2	21
2251	Risk of second primary breast cancer among cancer survivors: Implications for prevention and screening practice. <i>PLoS ONE</i> , 2020, 15, e0232800.	2.5	8
2252	Functional genomics based on germline genome-wide association studies of endocrine therapy for breast cancer. <i>Pharmacogenomics</i> , 2020, 21, 615-625.	1.3	1
2253	Changing practice: moving to a specialist nurse-led service for BRCA gene testing. <i>British Journal of Nursing</i> , 2020, 29, S6-S13.	0.7	18
2254	3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial. <i>Carcinogenesis</i> , 2020, 41, 1395-1401.	2.8	10
2255	Difficulties in establishing a causal link between chemical exposures and cancer cannot be overcome by court assessments. <i>Human and Experimental Toxicology</i> , 2020, 39, 1095-1107.	2.2	3

#	ARTICLE	IF	CITATIONS
2256	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Global Oncology, 2020, 6, 439-452.	1.8	25
2257	Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 46-65.	2.8	24
2258	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers, 2020, 12, 710.	3.7	3
2259	Tumor Microenvironment. Cancer Treatment and Research, 2020, , .	0.5	12
2260	Electronic health records and polygenic risk scores for predicting disease risk. Nature Reviews Genetics, 2020, 21, 493-502.	16.3	78
2261	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel <i>BRCA1/2</i> Genetic Risk Modifier Test. Public Health Genomics, 2020, 23, 6-19.	1.0	7
2262	Transvaginal laparoscopic salpingo-oophorectomy: an oncological risk-reducing procedure. Future Science OA, 2020, 6, FSO429.	1.9	0
2263	Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management. Frontiers in Oncology, 2020, 10, 301.	2.8	40
2264	Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer, 2020, 20, 185.	2.6	15
2265	3. HereditÄres Mammakarzinom. , 2020, , 121-126.		0
2266	Implementation of interventions targeting the uptake of genetic testing services for breast cancer risk: protocol for a systematic review. BMJ Open, 2020, 10, e031727.	1.9	0
2267	Epidemiology and Genetic Susceptibility of Breast and Ovarian Cancer in Sardinian Population. , 0, , .		0
2268	Impact of Adjuvant Radiation Therapy in Patients With Male Breast Cancer: A Multicenter International Analysis. Advances in Radiation Oncology, 2020, 5, 345-349.	1.2	7
2269	Characterization and in silico analyses of the BRCA1/2 variants identified in individuals with personal and/or family history of BRCA-related cancers. International Journal of Biological Macromolecules, 2020, 162, 1166-1177.	7.5	5
2270	Updates in hereditary breast cancer genetic testing and practical high risk breast management in gene carriers. Seminars in Oncology, 2020, 47, 182-186.	2.2	5
2271	Quality of Life after Bilateral and Contralateral Prophylactic Mastectomy with Implant Reconstruction. Breast Care, 2020, 15, 519-526.	1.4	8
2272	Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors. Journal of Human Genetics, 2020, 65, 577-587.	2.3	14
2274	<i>BRCA</i> and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes. Radiographics, 2020, 40, 306-325.	3.3	13

#	ARTICLE	IF	CITATIONS
2275	Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing. <i>BioMed Research International</i> , 2020, 2020, 1-10.	1.9	7
2276	Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention. <i>Familial Cancer</i> , 2020, 19, 143-151.	1.9	4
2277	Oncologist-led BRCA “mainstreaming”™ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. <i>Scientific Reports</i> , 2020, 10, 3390.	3.3	34
2278	Management of Male Breast Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1849-1863.	1.6	122
2279	Fertility preservation in BRCA mutation carriers’ efficacy and safety issues: a review. <i>Reproductive Biology and Endocrinology</i> , 2020, 18, 11.	3.3	17
2280	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 3335-3342.	5.1	10
2281	Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1128.	4.1	61
2282	Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal. <i>Npj Genomic Medicine</i> , 2020, 5, 8.	3.8	12
2283	Underlying Breast Cancer Risk and Menopausal Hormone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2299-e2307.	3.6	20
2284	Family storytelling about hereditary cancer: Framing shared understandings of risk. <i>Journal of Genetic Counseling</i> , 2020, 29, 936-948.	1.6	7
2285	Interval breast cancers “ insights into a complex phenotype. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 138-139.	27.6	2
2286	Plastic and Cosmetic Surgery of the Male Breast. , 2020, , .		1
2287	Diagnostic yield of a custom-designed multi-gene cancer panel in Irish patients with breast cancer. <i>Irish Journal of Medical Science</i> , 2020, 189, 849-864.	1.5	1
2288	Genomics Education in the Era of Personal Genomics: Academic, Professional, and Public Considerations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 768.	4.1	38
2289	BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. <i>International Journal of Cancer</i> , 2020, 147, 1334-1342.	5.1	7
2290	Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. <i>Familial Cancer</i> , 2020, 19, 133-142.	1.9	16
2291	The Role of Circulating Adiponectin and SNP276G>T at <i>ADIPOQ</i> Gene in <i>BRCA</i> -mutant Women. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 301-307.	2.0	7
2292	Mutational signatures are jointly shaped by DNA damage and repair. <i>Nature Communications</i> , 2020, 11, 2169.	12.8	137

#	ARTICLE	IF	CITATIONS
2293	Case report: Analysis of BRCA1 and BRCA2 gene mutations in a hereditary ovarian cancer family. Journal of Assisted Reproduction and Genetics, 2020, 37, 1489-1495.	2.5	5
2294	Clinical Effects of Early or Surgical Menopause. Obstetrics and Gynecology, 2020, 135, 853-868.	2.4	63
2295	The Landscape of Targeted Therapies in TNBC. Cancers, 2020, 12, 916.	3.7	232
2296	Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models. Stem Cell Reports, 2020, 14, 717-729.	4.8	105
2297	Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report. Familial Cancer, 2020, 19, 291-295.	1.9	2
2298	A Novel Method of Implant Coverage for Post-Mastectomy Reconstruction after Previous Augmentation: A Case Report. Breast Care, 2020, 15, 534-537.	1.4	1
2299	Risk of colorectal cancer associated with <i>BRCA1</i> and/or <i>BRCA2</i> mutation carriers: systematic review and meta-analysis. British Journal of Surgery, 2020, 107, 951-959.	0.3	34
2300	Racial/ethnic disparities in ovarian cancer research. Advances in Cancer Research, 2020, 146, 1-21.	5.0	24
2301	Effects of Breast Cancer Genes 1 and 2 on Cardiovascular Diseases. Current Problems in Cardiology, 2021, 46, 100421.	2.4	10
2302	Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients. Breast Cancer Research and Treatment, 2021, 185, 851-861.	2.5	7
2303	Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. International Journal of Cancer, 2021, 148, 941-949.	5.1	11
2304	The Role of Imaging in Health Screening: Screening for Specific Conditions. Academic Radiology, 2021, 28, 548-563.	2.5	5
2305	<i>BRCA1/2</i> mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study. Journal of Genetic Counseling, 2021, 30, 383-393.	1.6	1
2306	The role of genomics in global cancer prevention. Nature Reviews Clinical Oncology, 2021, 18, 116-128.	27.6	22
2307	The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database. Journal of Human Genetics, 2021, 66, 307-314.	2.3	32
2308	Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy. Genes Chromosomes and Cancer, 2021, 60, 358-372.	2.8	18
2309	Droplet digital PCR for large genomic rearrangements detection: A promising strategy in tissue BRCA1 testing. Clinica Chimica Acta, 2021, 513, 17-24.	1.1	18
2310	Process evaluation of a culturally targeted video for Latinas at risk of hereditary breast and ovarian cancer. Journal of Genetic Counseling, 2021, 30, 730-741.	1.6	5

#	ARTICLE	IF	CITATIONS
2311	Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?. Journal of Minimally Invasive Gynecology, 2021, 28, 403-408.	0.6	9
2312	Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?. Maturitas, 2021, 143, 59-64.	2.4	3
2313	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188459.	7.4	5
2314	Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 185, 391-399.	2.5	7
2315	Clinical phenotypes combined with saturation genome editing identifying the pathogenicity of BRCA1 variants of uncertain significance in breast cancer. Familial Cancer, 2021, 20, 85-95.	1.9	4
2316	Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling. Breast Cancer Research and Treatment, 2021, 185, 195-204.	2.5	10
2317	Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 714-726.	2.3	13
2318	Breast Cancer Genetics. , 2021, , 19-31.		2
2319	Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening. Frontiers in Oncology, 2020, 10, 568786.	2.8	6
2321	Hereditary Gynecological Malignancy and Molecular Features. Current Human Cell Research and Applications, 2021, , 145-165.	0.1	0
2322	A New Treatment Strategy for BRCA1-Related Breast Cancer. , 2021, , 107-115.		0
2323	PredTAD: A machine learning framework that models 3D chromatin organization alterations leading to oncogene dysregulation in breast cancer cell lines. Computational and Structural Biotechnology Journal, 2021, 19, 2870-2880.	4.1	2
2324	BRCA testing and outcomes in women with breast cancer. Breast Cancer Research and Treatment, 2021, 186, 839-850.	2.5	5
2325	Screening for mutations in BRCA1 and BRCA2 genes and related perspectives for the healthcare system. Visnik Ukrains Kogo Tovarstva Genetikiv I Selekcjoneriv, 2021, 18, 44-57.	0.2	0
2326	Chemopreventive and Therapeutic Potential of Natural Agents and Their Combinations for Breast Cancer. , 2021, , 231-281.		1
2327	Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility. International Journal of Cancer, 2021, 148, 1895-1909.	5.1	5
2328	Genetics and Public Health. , 2021, , 630-646.		0
2329	BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients. International Journal of Pharmaceutical Research and Allied Sciences, 2021, 10, 33-49.	0.9	1

#	ARTICLE	IF	CITATIONS
2330	Epithelial Ovarian Cancer. , 2021, , 633-641.		0
2331	<i>BRCA</i> mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees. Cancer Biology and Medicine, 2021, 18, 470-476.	3.0	3
2332	Cancer and genomic instability. , 2021, , 495-519.		1
2333	Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. Journal of Genetic Counseling, 2021, 30, 342-360.	1.6	18
2334	Breast cancer risk after age 60 among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	2.5	5
2335	Insights Into the Impacts of <i>BRCA</i> Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 574813.	2.8	13
2336	DNA double-strand break repair in cancer: A path to achieving precision medicine. International Review of Cell and Molecular Biology, 2021, 364, 111-137.	3.2	17
2337	Genetic Predispositions and Prophylactic Mastectomy in Breast Cancer Patients. , 2021, , 61-75.		0
2338	Evolutionary demographic models reveal the strength of purifying selection on susceptibility alleles to late-onset diseases. Nature Ecology and Evolution, 2021, 5, 392-400.	7.8	11
2339	Prepectoral breast reconstruction: an ideal approach to bilateral risk-reducing mastectomy. Gland Surgery, 2021, 10, 2997-3006.	1.1	11
2340	Histopathological Findings in Prophylactic Surgical Specimens. , 2021, , 279-299.		0
2341	Prophylactic Surgery for Genetic Predisposition of Female Organs. , 2021, , 301-311.		1
2342	Present Options in the Prevention of Breast Cancer. , 2021, , 117-127.		0
2343	Associations of one-carbon metabolism-related gene polymorphisms with breast cancer risk are modulated by diet, being higher when adherence to the Mediterranean dietary pattern is low. Breast Cancer Research and Treatment, 2021, 187, 793-804.	2.5	7
2344	Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer. Frontiers in Oncology, 2020, 10, 591739.	2.8	15
2345	Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. Journal of Personalized Medicine, 2021, 11, 149.	2.5	16
2346	Local Laboratory Testing of Germline <i>BRCA</i> Mutations vs. Myriad: A Single-Institution Experience in Korea. Diagnostics, 2021, 11, 370.	2.6	2
2347	Characteristics of <i>BRCA</i> -associated breast cancer in the population of the Russian Federation. Bulletin of Russian State Medical University, 2021, , 24-29.	0.2	1

#	ARTICLE	IF	CITATIONS
2348	Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. Journal of Breast Imaging, 2021, 3, 144-155.	1.3	47
2349	Hereditary Breast Ovarian Cancer Syndrome: One Case, Multiple Lessons. Journal of Gynecology and Womens Health, 2021, 21, .	0.1	0
2350	Breast Cancer Risk Genes â€™ Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
2351	A Phase I doseâ€™escalation study of two cycles carboplatinâ€™olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer, 2021, 148, 3041-3050.	5.1	5
2352	Precursor fractions of neurotensin and enkephalin might point to molecular mechanisms of cancer risk modulation during a lifestyle-intervention in germline BRCA1/2 gene mutation carriers. Breast Cancer Research and Treatment, 2021, 186, 741-752.	2.5	2
2353	The Role of PBK as a Potential Prognostic and Diagnostic Biomarker in Ovarian Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2021, , .	1.0	0
2354	Population-Based Estimates of the Age-Specific Cumulative Risk of Breast Cancer for Pathogenic Variants in CHEK2: Findings from the Australian Breast Cancer Family Registry. Cancers, 2021, 13, 1378.	3.7	5
2355	Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia. Journal of Translational Medicine, 2021, 19, 108.	4.4	14
2356	The BRCA1 c.788Gâ€™â€™T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought. Molecular Biology Reports, 2021, 48, 2985-2992.	2.3	1
2358	Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome. Cancers, 2021, 13, 1417.	3.7	4
2359	Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies. Nucleic Acids Research, 2021, 49, 4239-4257.	14.5	42
2360	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47.	2.8	81
2361	Correlation between family history and characteristics of breast cancer. Scientific Reports, 2021, 11, 6360.	3.3	19
2362	Fertility preservation in patients with BRCA mutations or Lynch syndrome. International Journal of Gynecological Cancer, 2021, 31, 332-338.	2.5	15
2363	Endocrine-Disrupting Chemicals and Vitamin D Deficiency in the Pathogenesis of Uterine Fibroids. Journal of Advanced Pharmacy Research, 2021, 5, 248-263.	0.3	5
2365	BRCA1 degradation in response to mitochondrial damage in breast cancer cells. Scientific Reports, 2021, 11, 8735.	3.3	10
2366	Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females. Journal of Community Genetics, 2021, 12, 431-438.	1.2	3
2367	Association of Vitamin D Receptor and Vitamin D-Binding Protein Polymorphisms with Familial Breast Cancer Prognosis in a Mono-Institutional Cohort. Nutrients, 2021, 13, 1208.	4.1	6

#	ARTICLE	IF	CITATIONS
2368	Controversies in Hereditary Cancer Management. <i>Obstetrics and Gynecology</i> , 2021, 137, 941-955.	2.4	4
2370	Clinico-radio-pathological Features and Biological Behavior of Breast Cancer in Young Indian Women: A Prospective Study. <i>Indian Journal of Radiology and Imaging</i> , 2021, 31, 323-332.	0.8	0
2371	BRCA1/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing. <i>Genes</i> , 2021, 12, 519.	2.4	13
2372	More reliable breast cancer risk assessment for every woman. <i>Cancer Cell</i> , 2021, 39, 457-459.	16.8	2
2373	HER2-positive breast cancer in a germline BRCA1 gene large deletion carrier. <i>International Cancer Conference Journal</i> , 2021, 10, 181-185.	0.5	1
2375	Combined breast conservation therapy versus mastectomy for BRCA mutation carriers – A systematic review and meta-analysis. <i>Breast</i> , 2021, 56, 26-34.	2.2	27
2376	Clinical significance of mutations in DNA repair genes in patients with metastatic prostate cancer. <i>Onkourologiya</i> , 2021, 17, 82-88.	0.3	0
2377	A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study. <i>Cancers</i> , 2021, 13, 2729.	3.7	8
2378	Penetrance of Breast Cancer Susceptibility Genes from the eMERGE III Network. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab044.	2.9	14
2379	Triple-negative breast cancer: A run-through of features, classification and current therapies (Review). <i>Oncology Letters</i> , 2021, 22, 512.	1.8	52
2380	Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance. <i>Nucleic Acids Research</i> , 2021, 49, 5588-5604.	14.5	20
2381	Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 655709.	2.8	4
2382	A narrative review on the interaction between genes and the treatment of hypertension and breast cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 894-894.	1.7	8
2383	Management of patients with BRCA mutation from the point of view of a breast surgeon. <i>Annals of Medicine and Surgery</i> , 2021, 65, 102311.	1.1	3
2384	A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study. <i>Cancers</i> , 2021, 13, 2192.	3.7	4
2385	Fanconi anemia pathway and its relationship with cancer. <i>Genome Instability & Disease</i> , 2021, 2, 175-183.	1.1	4
2386	Feasibility of Velocity-Selective Arterial Spin Labeling in Breast Cancer Patients for Noncontrast-Enhanced Perfusion Imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1282-1291.	3.4	8
2387	Diagnosis, Prognosis, Management, Treatment, Research and Advances in Canine Dilated Cardiomyopathy. , 0, , .		0

#	ARTICLE	IF	CITATIONS
2388	Collaborative digital platform France â€“ Cuba: oncorehabilitation in reproductive and sexual health. BMC Medical Education, 2021, 21, 337.	2.4	3
2389	Genetic Mutations Associated with Hormone-Positive Breast Cancer in a Small Cohort of Ethiopian Women. Annals of Biomedical Engineering, 2021, 49, 1900-1908.	2.5	2
2390	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). Gynecologic Oncology, 2021, 161, 755-761.	1.4	9
2391	Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients. Biology, 2021, 10, 566.	2.8	2
2392	Community research collaboration to develop a promotores-based hereditary breast cancer education program for Spanish-speaking Latinas. Health Education Research, 2021, 36, 319-336.	1.9	10
2393	RASSF1A Suppression as a Potential Regulator of Mechano-Pathobiology Associated with Mammographic Density in BRCA Mutation Carriers. Cancers, 2021, 13, 3251.	3.7	1
2394	Fertility preservation in women with malignant and borderline ovarian tumors: Experience of the French ESGO-certified center and pregnancy-associated cancer network (CALG). Gynecologic Oncology, 2021, 161, 817-824.	1.4	7
2395	No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families. Genes, 2021, 12, 1100.	2.4	1
2396	Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors. World Journal of Clinical Oncology, 2021, 12, 544-556.	2.3	7
2397	Can Morphological Markers of Chromosomal Instability in Fine-Needle Aspiration Cytology Aid in Cytological Grading of Breast Cancer. Indian Journal of Gynecologic Oncology, 2021, 19, 1.	0.3	0
2398	BRCA mutations and gastrointestinal cancers: When to expect the unexpected?. World Journal of Clinical Oncology, 2021, 12, 565-580.	2.3	10
2399	DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations. EBioMedicine, 2021, 69, 103446.	6.1	4
2400	How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?. Annals of Surgical Oncology, 2021, 28, 5657-5662.	1.5	15
2401	Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system. Gynecologic Oncology, 2021, 163, 134-141.	1.4	1
2402	Prediction of BRCA Gene Mutation in Breast Cancer Based on Deep Learning and Histopathology Images. Frontiers in Genetics, 2021, 12, 661109.	2.3	31
2403	rs73092672 allele T is significantly associated with the higher risk of breast cancer incidence. Nucleosides, Nucleotides and Nucleic Acids, 2021, 40, 779-789.	1.1	1
2404	Decision aids for female BRCA mutation carriers: a scoping review protocol. BMJ Open, 2021, 11, e045075.	1.9	0
2405	Development and pilot testing of a training for bilingual community education professionals about hereditary breast and ovarian cancer among Latinas: <i>ÂRBOLES Familiares</i>. Translational Behavioral Medicine, 2022, 12, .	2.4	10

#	ARTICLE	IF	CITATIONS
2406	Horizon Scanning in Cancer Genomics: How Advances in Genomic Medicine Will Change Cancer Care Over the Next Decade. <i>Current Genetic Medicine Reports</i> , 2021, 9, 37-46.	1.9	1
2407	Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers. <i>Aesthetic Plastic Surgery</i> , 2022, 46, 706-711.	0.9	7
2408	Changes in Immune Cell Types with Age in Breast are Consistent with a Decline in Immune Surveillance and Increased Immunosuppression. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2021, 26, 247-261.	2.7	9
2409	Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers. <i>Fertility and Sterility</i> , 2021, 116, 538-545.	1.0	8
2410	Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. <i>Cancer</i> , 2021, , .	4.1	5
2411	Experience in treating BRCA-associated breast cancer. The BRCA-history of a family. <i>Meditinskiy Sovet</i> , 2021, , 34-41.	0.5	1
2412	Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1900-1906.	1.0	2
2413	Surgical Management of Hereditary Breast Cancer. <i>Genes</i> , 2021, 12, 1371.	2.4	8
2414	Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives. <i>Breast</i> , 2021, 58, 121-129.	2.2	7
2415	Efficacy of risk-reducing salpingo-oophorectomy in BRCA1/2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC). <i>Gynecologic Oncology</i> , 2021, 163, 364-370.	1.4	11
2416	Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 674965.	2.8	4
2417	A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 847.	2.5	4
2418	Shared Genetics Between Age at Menopause, Early Menopause, POI and Other Traits. <i>Frontiers in Genetics</i> , 2021, 12, 676546.	2.3	12
2419	Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis. <i>Breast</i> , 2021, 60, 155-162.	2.2	8
2420	A complex of BRCA2 and PP2A-B56 is required for DNA repair by homologous recombination. <i>Nature Communications</i> , 2021, 12, 5748.	12.8	24
2421	Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian Cancer. <i>Healthcare (Switzerland)</i> , 2021, 9, 1145.	2.0	0
2422	A narrative review of biomarkers in advanced triple negative breast cancer. <i>Precision Cancer Medicine</i> , 0, 4, 24-24.	1.8	1
2423	Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudinal observational study. <i>Gynecologic Oncology</i> , 2021, 162, 715-719.	1.4	3

#	ARTICLE	IF	CITATIONS
2424	Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers. <i>Frontiers in Oncology</i> , 2021, 11, 700853.	2.8	6
2425	The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 265, 7-17.	1.1	10
2426	Anti-müllerian hormone levels and antral follicle count in women with a BRCA1 or BRCA2 germline pathogenic variant: A retrospective cohort study. <i>Breast</i> , 2021, 59, 239-247.	2.2	2
2427	Evaluation of a Targeted Next-generation Sequencing Assay for BRCA Mutation Screening in Clinical Samples. <i>Laboratory Medicine Online</i> , 2021, 11, 283-289.	0.2	0
2428	Do we know properly young age breast cancer patients: a double centre study. <i>Journal of Biochemical and Clinical Genetics</i> , 0, , 35-41.	0.1	1
2429	Supplemental Screening for Patients at Intermediate and High Risk for Breast Cancer. <i>Radiologic Clinics of North America</i> , 2021, 59, 67-83.	1.8	9
2430	Magnetic Resonance Imaging in Screening of Breast Cancer. <i>Radiologic Clinics of North America</i> , 2021, 59, 85-98.	1.8	29
2432	BRCA and Breast Cancer-Related High-Penetrance Genes. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1187, 473-490.	1.6	7
2433	Genomics in clinical care through precision medicine and personalized treatments. , 2021, , 49-58.		1
2434	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 77-102.	4.9	498
2435	Communication in Genetic Counselling for Breast/Ovarian Cancer. , 2006, 168, 23-36.		7
2436	Recent Advances in Breast Cancer Genetics. <i>Cancer Treatment and Research</i> , 2008, 141, 1-10.	0.5	14
2437	Risk Factors. , 2010, , 3-22.		5
2438	Genes, Environment, and Cancer Disparities. , 2009, , 49-82.		2
2439	Breast Cancer: Epidemiological Panorama and Opportunities for Prevention. , 2013, , 15-27.		1
2440	Diseases of the Fallopian Tube and Paratubal Region. , 2011, , 529-578.		16
2441	Fertility Communication and High-Risk Patients. , 2014, , 61-72.		2
2443	Multigenerational Information: The Example of the Icelandic Genealogy Database. <i>Methods in Molecular Biology</i> , 2011, 675, 221-229.	0.9	9

#	ARTICLE	IF	CITATIONS
2444	Epidemiology of Breast Cancer in Women. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 9-29.	1.6	212
2445	Health and Racial Disparity in Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 31-49.	1.6	245
2446	Ubiquitin-Regulated Cell Proliferation and Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1233, 3-28.	1.6	11
2447	Surveillance of Patients Following Primary Therapy. , 2016, , 447-454.		1
2448	Fertility Preservation in BRCA Carriers: Special Considerations. , 2017, , 171-186.		2
2449	FamiliÄres Mammakarzinom: Beratung, Gendiagnostik und Betreuung betroffener Familien. , 2006, , 97-109.		2
2450	Fertility Issues and Options in Young Women with Cancer. , 2008, 178, 203-224.		10
2451	Subsequent Pregnancy After Breast Cancer. , 2008, 178, 57-67.		18
2452	FamiliÄres Mammakarzinom â€” Beratung und Betreuung betroffener Familien. , 2010, , 31-40.		1
2453	The Hereditary Syndromes. , 2009, , 107-128.		2
2454	The success story of drug repurposing in breast cancer. , 2020, , 173-190.		4
2455	Genetic Factors: Hereditary Cancer Predisposition Syndromes. , 2008, , 171-191.		1
2456	Cancer of the Ovary. , 2010, , 1052-1066.		1
2459	Indications et efficacit© de la chirurgie prophylactique des cancers gyn©cologiques et digestifs avec pr©disposition g©n©tique. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 1237-1245.	0.0	1
2461	Decision making and decision support for hereditary breast-ovarian cancer susceptibility.. <i>Health Psychology</i> , 2005, 24, S78-S84.	1.6	56
2462	Telephone Genetic Counseling for High-Risk Women Undergoing<i>BRCA1</i>and<i>BRCA2</i>Testing: Rationale and Development of a Randomized Controlled Trial. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, .	1.7	1
2463	Uptake, Time Course, and Predictors of Risk-Reducing Surgeries inBRCACarriers. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, .	1.7	1
2464	Genetic Concepts and Methods in Epidemiologic Research. , 2006, , 89-98.		3

#	ARTICLE	IF	CITATIONS
2466	Attitudes about genetic testing and genetic testing intentions in African American women at increased risk for hereditary breast cancer. <i>Genetics in Medicine</i> , 2005, 7, 230-238.	2.4	51
2467	Cancer antigen 125 level after a bilateral salpingo-oophorectomy. <i>Menopause</i> , 2011, 18, 133-137.	2.0	9
2468	CA125 screening after risk-reducing salpingo-oophorectomy. <i>Menopause</i> , 2011, 18, 123-124.	2.0	1
2472	The risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers without a first-degree relative with breast cancer. <i>Clinical Genetics</i> , 2018, 93, 1063-1068.	2.0	14
2473	FSRH Guideline (January 2019, amended October 2023) Combined Hormonal Contraception. <i>BMJ Sexual and Reproductive Health</i> , 2019, 45, 1-93.	1.7	15
2474	Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1397-1403.	2.5	4
2475	Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians. <i>Cancer Prevention Research</i> , 2021, 14, 205-214.	1.5	4
2476	Genetic counselors: translating genomic science into clinical practice. <i>Journal of Clinical Investigation</i> , 2003, 112, 1274-1279.	8.2	55
2477	Breast cancer gene variants: separating the harmful from the harmless. <i>Journal of Clinical Investigation</i> , 2009, 119, 2895-2897.	8.2	8
2478	Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection. <i>BMC Cancer</i> , 2020, 20, 85.	2.6	12
2479	Ovarian Cancer: A Bioepidemiological Approach. , 2013, , 331-350.		1
2480	Feature selection for data integration with mixed multiview data. <i>Annals of Applied Statistics</i> , 2020, 14, .	1.1	11
2481	A new paradigm of genetic testing for hereditary breast/ovarian cancers. <i>Hong Kong Medical Journal</i> , 2016, 22, 171-7.	0.1	11
2483	Orchestrating Time in the Genomic Era: Timescape Perspective on the Changing Practice of Hereditary Breast Cancer Prevention. <i>Configurations</i> , 2005, 13, 421-434.	0.3	5
2484	Roles of <i>brca2</i> (<i>fancd1</i>) in Oocyte Nuclear Architecture, Gametogenesis, Gonad Tumors, and Genome Stability in Zebrafish. <i>PLoS Genetics</i> , 2011, 7, e1001357.	3.5	91
2485	Negative Selection on <i>BRCA1</i> Susceptibility Alleles Sheds Light on the Population Genetics of Late-Onset Diseases and Aging Theory. <i>PLoS ONE</i> , 2007, 2, e1206.	2.5	29
2486	Comprehensive Genomic Analysis of a <i>BRCA2</i> Deficient Human Pancreatic Cancer. <i>PLoS ONE</i> , 2011, 6, e21639.	2.5	17
2487	Metabotropic Glutamate Receptor 1 Expression and Its Polymorphic Variants Associate with Breast Cancer Phenotypes. <i>PLoS ONE</i> , 2013, 8, e69851.	2.5	22

#	ARTICLE	IF	CITATIONS
2488	Loss of the BRCA1-Interacting Helicase BRIP1 Results in Abnormal Mammary Acinar Morphogenesis. PLoS ONE, 2013, 8, e74013.	2.5	14
2489	Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection. PLoS ONE, 2016, 11, e0156661.	2.5	8
2490	Individual and Combined Expression of DNA Damage Response Molecules PARP1, γ H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients. PLoS ONE, 2016, 11, e0163193.	2.5	19
2491	Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability. PLoS ONE, 2017, 12, e0178450.	2.5	39
2492	How to manage BRCA mutation carriers?. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.7	6
2493	Multi gene panel testing for hereditary breast cancer - is it ready to be used?. Medicine and Pharmacy Reports, 2019, 92, 220-225.	0.4	26
2494	CDC Grand Rounds: Family History and Genomics as Tools for Cancer Prevention and Control. Morbidity and Mortality Weekly Report, 2016, 65, 1291-1294.	15.1	14
2495	BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integrative Cancer Science and Therapeutics, 2017, 4, .	0.1	111
2496	Screening for BRCA1 and BRCA2 mutations in breast cancer patients from mexico: the public health perspective. Salud Publica De Mexico, 2009, 51, s191-s196.	0.4	12
2497	Main risk factors for breast cancer and proposals for its prevention. Opuholi Zenskoj Reproktivnoy Sistemy, 2018, 14, 25-39.	0.4	5
2498	Aging is associated with an expansion of CD49fhi mammary stem cells that show a decline in function and increased transformation potential. Aging, 2016, 8, 2754-2776.	3.1	15
2499	BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget, 2016, 7, 70113-70127.	1.8	56
2500	The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?. Oncotarget, 2017, 8, 1957-1971.	1.8	38
2501	Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Oncotarget, 2016, 7, 86687-86694.	1.8	28
2502	BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget, 2017, 8, 97657-97670.	1.8	32
2503	A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy. Oncotarget, 2017, 8, 103327-103339.	1.8	5
2504	Premature ovarian aging in BRCA carriers: a prototype of systemic precocious aging?. Oncotarget, 2018, 9, 15931-15941.	1.8	32
2505	Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Oncotarget, 2019, 10, 2475-2483.	1.8	5

#	ARTICLE	IF	CITATIONS
2506	BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 2433-2454.	1.8	19
2507	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. <i>Oncotarget</i> , 2016, 7, 1076-1083.	1.8	68
2508	Molecular insights into the <i>OGG1</i> gene, a cancer risk modifier in <i>BRCA1</i> and <i>BRCA2</i> mutations carriers. <i>Oncotarget</i> , 2016, 7, 25815-25825.	1.8	16
2509	BRCA1/2 mutation spectrum in Chinese early-onset breast cancer. <i>Translational Cancer Research</i> , 2019, 8, 483-490.	1.0	6
2510	Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population. <i>Current Genomics</i> , 2018, 19, 395-410.	1.6	5
2511	Genetic Counseling for Hereditary Breast and Ovarian Cancer Among Puerto Rican Women Living in the United States. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 245-253.	0.8	13
2512	Influence of Genetic Factors on the Development of Breast Cancer in the Older Woman. <i>Current Aging Science</i> , 2012, 5, 140-147.	1.2	2
2513	At the Crossroads Between Neurodegeneration and Cancer: A Review of Overlapping Biology and Its Implications. <i>Current Aging Science</i> , 2019, 11, 77-89.	1.2	67
2514	Development of a Web-based Family Intervention for BRCA Carriers and Their Biological Relatives: Acceptability, Feasibility, and Usability Study. <i>JMIR Cancer</i> , 2018, 4, e7.	2.4	19
2515	Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e184.	1.0	30
2516	Hereditary ovarian cancers: state of the art. <i>Minerva Medica</i> , 2019, 110, 301-319.	0.9	15
2518	The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 605.	3.0	147
2519	Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. <i>Cancer Biology and Medicine</i> , 2016, 13, 55-67.	3.0	35
2520	Bioethics of Genetic Testing for Hereditary Breast Cancer. , 2007, , 35-51.		2
2522	Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1025-1029.	1.2	8
2523	<i>BRCA1/2</i> mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e24.	2.2	5
2524	Reclassification of <i>BRCA1</i> and <i>BRCA2</i> variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e83.	2.2	12
2525	Risk of Second Non Breast Malignancies (SNBM) in Relation to BRCA1 and BRCA2 Mutation Status Following Breast-Conserving Surgery and Radiotherapy. <i>American Journal of Immunology</i> , 2006, 2, 61-63.	0.1	3

#	ARTICLE	IF	CITATIONS
2527	Rare genetic variants: making the connection with breast cancer susceptibility. AIMS Genetics, 2015, 02, 281-292.	1.9	2
2528	Family history: Still relevant in the genomics era. Cleveland Clinic Journal of Medicine, 2012, 79, 331-336.	1.3	44
2529	Breast cancer in the young: role of the geneticist. Journal of Thoracic Disease, 2013, 5 Suppl 1, S19-26.	1.4	6
2530	Genetic causes of cancer predisposition in children and adolescents. Translational Pediatrics, 2015, 4, 67-75.	1.2	28
2531	Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surgery, 2015, 4, 467-75.	1.1	20
2532	Practice Patterns of Surgeons for the Management of Hereditary Breast Cancer in Korea. Journal of Breast Cancer, 2008, 11, 95.	1.9	14
2533	Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in <i>BRCA1/2</i> Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer. Journal of Breast Cancer, 2019, 22, 587.	1.9	9
2534	Prophylactic mastectomy for the prevention of breast cancer: Review of the literature. Avicenna Journal of Medicine, 2018, 8, 67-77.	0.8	41
2535	Mainstreaming genetic counseling for BRCA testing into oncology clinics – Indian perspective. Indian Journal of Cancer, 2019, 56, 38.	0.2	9
2536	A pragmatic approach to tackle the rising burden of breast cancer through prevention & early detection in countries 'in transition'. Indian Journal of Medical Research, 2020, 152, 343.	1.0	9
2537	Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients. Journal of Pathology and Translational Medicine, 2020, 54, 265-275.	1.1	15
2538	Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant. Cancer Research and Treatment, 2020, 52, 680-688.	3.0	7
2539	Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers. Hereditary Genetics: Current Research, 2012, 01, .	0.1	2
2540	Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status. Annals of Surgical Treatment and Research, 2019, 97, 113.	1.0	3
2541	Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?. Advances in Breast Cancer Research, 2015, 04, 87-99.	0.1	2
2542	Detection of Breast Cancer 1 (BRCA1) Gene Using an Electrochemical DNA Biosensor Based on Immobilized ZnO Nanowires. Open Journal of Applied Biosensor, 2014, 03, 9-17.	1.6	34
2543	Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review. World Journal of Gastrointestinal Oncology, 2020, 12, 228-236.	2.0	15
2545	Targeted therapy in breast cancer: what's new?. Swiss Medical Weekly, 2011, 141, w13231.	1.6	31

#	ARTICLE	IF	CITATIONS
2546	Korean Hereditary Breast Cancer. Journal of the Korean Medical Association, 2009, 52, 952.	0.3	3
2547	BRCA1 and BRCA2 sequence variations detected with next-generation sequencing in patients with premature ovarian insufficiency. Journal of the Turkish German Gynecology Association, 2016, 17, 77-82.	0.6	11
2548	Genetic interactions in translational research on cancer. World Journal of Medical Genetics, 2011, 1, 14.	1.0	3
2549	Synthetic Lethality in Anticancer Drug Discovery and Target Identification. Pharmacologia, 2012, 3, 352-361.	0.3	2
2550	Communication with Family Members about Positive BRCA1/2 Genetic Test Results in Korean Hereditary Breast Cancer Families. Journal of Genetic Medicine, 2011, 8, 105-112.	0.2	5
2551	Hereditary Breast Cancer in Korea. Journal of Genetic Medicine, 2012, 9, 1-10.	0.2	1
2552	Potential Tumor Biomarkers for Ovarian Cancer. , 0, , .		1
2553	The Role of Prophylactic Oophorectomy in the Management of Hereditary Breast & Ovarian Cancer Syndrome. , 0, , .		1
2554	Analysis of BRCA1/2 Mutations and Performance of Manchester Scoring System in High Risk Iranian Breast Cancer Patients: A Pilot Study. International Journal of Cancer Management, 2017, 10, .	0.4	4
2555	Fusion of FNA-cytology and Gene-expression Data Using Dempster-Shafer Theory of Evidence to Predict Breast Cancer Tumors. Bioinformation, 2006, 1, 170-175.	0.5	9
2556	What Made Her Give Up Her Breasts: a Qualitative Study on Decisional Considerations for Contralateral Prophylactic Mastectomy among Breast Cancer Survivors Undergoing BRCA1/2 Genetic Testing. Asian Pacific Journal of Cancer Prevention, 2012, 13, 2241-2247.	1.2	23
2557	Low Level of Consanguinity in Moroccan Families at High Risk of Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2013, 14, 723-726.	1.2	8
2558	Absence of 185delAG and 6174delT Mutations among Breast Cancer Patients of Eastern India. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7929-7933.	1.2	12
2559	The Spectrum of Genetic Mutations in Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 2177-2185.	1.2	58
2560	Taking Family History Seriously. Annals of Internal Medicine, 2005, 143, 388.	3.9	17
2561	Design and validation of a next generation sequencing assay for hereditary<i>BRCA1</i> and<i>BRCA2</i> mutation testing. PeerJ, 2016, 4, e2162.	2.0	17
2562	Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. Cureus, 2017, 9, e1517.	0.5	2
2563	Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. Frontiers in Oncology, 2021, 11, 662055.	2.8	12

#	ARTICLE	IF	CITATIONS
2564	High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma. Journal of Ovarian Research, 2021, 14, 131.	3.0	5
2565	<i>BRCA1/Trp53</i> heterozygosity and replication stress drive esophageal cancer development in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	5
2566	DNA methylation in genes associated with the evolution of ageing and disease: A critical review. Ageing Research Reviews, 2021, 72, 101488.	10.9	15
2567	The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriersK.A. Metcalfe, H.T. Lynch, P. Chadirian, N. Tung, I.A. Olivotto, W.D. Foulkes, E. Warner, O. Olopade, A. Eisen, B. Weber, et al. Gynecol Oncol 2005;96:222â€“26. Women's Oncology Review, 2005, 5, 163-164.	0.0	0
2570	Klinische genetica: erfelijkheidsadviesing en voorspellend genetisch onderzoek. , 2006, , 341-358.		0
2574	The Genetic Epidemiology of Hereditary Breast Cancer. , 2007, , 1-17.		0
2575	Genetic Disposition. Medical Radiology, 2008, , 311-328.	0.1	0
2576	Facteurs de risques g�n�tiques. , 2008, , 45-62.		1
2578	Models of Absolute Risk. , 2008, , 259-274.		0
2579	Genetic Risk Assessment for Hereditary Ovarian Cancer. , 2008, , 219-235.		0
2580	Risk-Reducing Salpingo-Oophorectomy for the Prevention of Inherited Breast and Ovarian Cancer. , 2008, , 79-91.		0
2581	Clinical Relevance of Hereditary Ovarian Cancer. , 2008, , 1-13.		0
2582	Management of BRCA Mutation-Negative Patients. , 2008, , 107-115.		0
2583	Sampling Distributions of Critical Illness Insurance Premium Rates: Breast and Ovarian Cancer. ASTIN Bulletin, 2008, 38, 527-542.	1.0	0
2585	13 Mammacarcinoom. , 2009, , 161-169.		1
2586	Clinical Implementation of Translational Genomics. , 2009, , 357-366.		0
2587	Heredit�res Ovariaalkarzinom. , 2009, , 125-131.		0
2588	NHG-Standaard Diagnostiek van mammacarcinoom. , 2009, , 606-623.		1

#	ARTICLE	IF	CITATIONS
2589	Genetic Modifiers of Risk of BRCA1- and BRCA2-Related Breast and Ovarian Cancers. , 2009, , 107-129.		0
2590	Identifying and Managing the High-Risk Patient. , 2009, , 101-122.		0
2591	The Genetics of Breast Cancer. , 2009, , 39-54.		0
2592	Inherited Predisposition: Familial Aggregation and High Risk Genes. , 2010, , 277-299.		0
2594	Prostate Cancer in Special Populations. , 2010, , 249-288.		0
2595	Genetic Testing for Cancer Susceptibility: How and When?. , 2009, , 931-939.		0
2596	Surgical Management of Inherited Susceptibility to Breast Cancer. , 2010, , 61-78.		0
2597	Management of Women at High Familial Risk of Breast and Ovarian Cancer. , 2009, , 941-967.		2
2598	Identification and Management of Women at High Familial Risk for Breast Cancer. , 2010, , 135-145.		0
2599	Ovarian Cancer Surgery. , 2010, , 109-142.		0
2600	Genetics of Hereditary Breast Cancer. , 2010, , 41-51.		0
2601	Surgical Management of Hereditary Breast and Ovarian Cancer. , 2010, , 53-62.		0
2602	Management of the Patient with a Genetic Predisposition for Breast Cancer. , 2010, , 551-568.		0
2603	Imaging of Ovarian Cancer. , 2010, , 63-85.		0
2604	The Biology of Breast Cancer. , 2010, , 83-96.		0
2605	Ovarian Cancer Family Syndromes and Genetic Testing. , 2010, , 33-50.		0
2606	Die VerflÄssigung der Norm: Selbstregierung und personalisierte Gesundheit. , 2010, , 39-53.		1
2607	Ovarialkarzinom. , 2010, , 887-902.		1

#	ARTICLE	IF	CITATIONS
2609	Ovarian Cancer Screening. , 2010, , 87-107.		0
2610	Screening for Ovarian Cancer: The Possible Improvement by 3D Ultrasound and 3D Power Doppler. Donald School Journal of Ultrasound in Obstetrics and Gynecology, 2010, 4, 299-319.	0.3	0
2611	Clinical characteristics and outcomes of <i>BRCA</i>-associated ovarian cancer (OC): Genotype and survival.. Journal of Clinical Oncology, 2010, 28, 5017-5017.	1.6	1
2612	Evaluation of Psychosocial Impact and Quality of Life in BRCA Mutation Family. Journal of Genetic Medicine, 2010, 7, 67-77.	0.2	3
2613	Hereditary Ovarian Cancer and Other Gynecologic Malignancies. , 2011, , 181-196.		1
2615	Hereditary Breast Cancer Syndromes. , 2011, , 51-104.		0
2617	NHG-Standaard Diagnostiek van mammacarcinoom. , 2011, , 1477-1494.		0
2619	Hormonal Contraception. , 2011, , 661-687.		0
2620	Cancers du sein familiaux. , 2011, , 43-52.		0
2621	Surface Epithelial Tumors: Clinical Introduction. , 2011, , 47-53.		1
2622	Magnetic Resonance Imaging (MRI) in the Screening of High-Risk Patients and in the Detection and Diagnosis of Early Breast Cancer. , 2011, , 45-55.		1
2624	BIOSYNTHESIS OF microRNAs AND THEIR ROLE IN GENE EXPRESSION PROFILING IN BREAST CANCER. Revista Da Universidade Vale Do Rio Verde, 2011, 9, 215-228.	0.1	0
2625	Inherited Diseases. , 2012, , 1239-1292.		0
2626	Cancer du sein : donnÃ©es Ã©pidÃ©miologiques Chiffres dâ€™incidence et de mortalitÃ©. , 2012, , 1-28.		1
2628	Preventive Strategies in Epithelial Ovarian Cancer. , 0, , .		0
2629	Epidemiology and Etiology of Ovarian Cancer. , 0, , .		1
2630	Management and Patient Selection for BRCA Genetic Testing to Identify Women at Increased Risk for Breast and Ovarian Cancers: A Review. Research Journal of Medical Sciences, 2012, 6, 83-86.	0.2	0
2631	On the Study of Risk Factors of Ca. Cervix and Ca. Breast: a Case Study in Assam. Bonfring International Journal of Data Mining, 2012, 2, 27-31.	0.5	0

#	ARTICLE	IF	CITATIONS
2632	Breast conserving surgery and radiation as a choice for patients with BRCA mutations. Journal of Solid Tumors, 2012, 2, .	0.1	0
2633	Identifying Women at High Risk of Breast Cancer: Understanding the Risk Models. , 2013, , 1-28.		0
2634	Risk Reduction Strategies: Surgical Perspective. , 2013, , 103-119.		0
2635	Management of Concomitant Risk. , 2013, , 141-154.		0
2636	Genetics and Gynecological Cancer. , 2013, , 107-122.		1
2637	Mastectomy to Prevent Breast Cancer: Psychosocial Aspects of Women's Decision-Making. , 2013, , 65-73.		0
2638	Epidemiology of Breast Cancer in Women. , 2013, , 19-34.		2
2639	Epidemiology and Etiology of Breast Cancer. , 2013, , 3-12.		0
2640	Metastatic Tumours of the Ovaries: Computed Tomography and Magnetic Resonance. , 2013, , 365-384.		0
2641	Nutrition and Genetic Factors in Carcinogenesis. , 2013, , 645-656.		0
2642	Mammakarzinom. , 2013, , 517-555.		0
2643	Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer. Advances in Breast Cancer Research, 2013, 02, 56-59.	0.1	1
2644	Polymorphic Repeat Length in the AIB1 Gene and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Meta-Analysis of Observational Studies. PLoS ONE, 2013, 8, e57781.	2.5	0
2647	Reproductive System. , 2014, , 89-136.		0
2648	BRCA1 and BRCA2 Testing in Inherited Breast Cancer. , 2014, , 167-189.		0
2649	Breast Cancer Prevention. , 2014, , 445-489.		1
2651	Genetic Risks of Ovarian Cancer. , 2014, , 23-31.		0
2652	Familial Gynecologic Cancers: Whom to Screen and How to Manage?. , 2014, , 247-261.		0

#	ARTICLE	IF	CITATIONS
2654	One Case of BRCA2 Germline Mutation Ovarian Cancer Mother and Carrier Daughter found by Genetic Counseling. Journal of Genetic Medicine, 2013, 10, 124-128.	0.2	0
2655	Genetic Factors. , 2014, , 169-187.e7.		4
2656	BRCA1/2 Mutation Frequency is HIGH in Japanese Triple-Negative Breast Cancer Patients. The Showa University Journal of Medical Sciences, 2014, 26, 219-227.	0.1	0
2657	Cancers Arising in the Ovary. , 2014, , 1592-1613.e6.		1
2658	The genetics of breast cancer, risk-reducing surgery and prevention. , 2014, , 127-145.		0
2662	Breast Cancer Genetics and Risk Assessment. , 2015, , 1-21.		0
2663	Genetically Based Breast Cancer: Risk Assessment, Counseling, and Testing. , 2015, , 137-159.		0
2665	Inherited Gene Mutations in Gynecological Oncology. , 2015, , 283-294.		0
2667	A Novel HRM Strategy for Detection of BRCA Mutations on Mexican Population. Journal of Carcinogenesis & Mutagenesis, 2015, 06, .	0.3	0
2668	Aetiology and Epidemiology of Breast Cancer. , 2015, , 17-25.		0
2670	Epigenetic BRCA2 Gene in Epithelial Ovarian Cancer. Gene, Cell and Tissue, 2015, 2, .	0.2	0
2671	Know Your Family Ancestry, Conditions, Traits, and Traditions (FACTs) DC: Increasing Genomic Awareness in Underserved Communities. Journal of Cancer Prevention & Current Research, 2015, 3, .	0.1	0
2672	Screening Women With Known or Suspected Cancer Gene Mutations. , 2016, , 265-298.		0
2673	Risk-Reducing Surgery for Breast Cancer Patients with BRCA Mutations. , 2016, , 3-20.		0
2674	Epidemiology, Risk Factors, and Prevention. , 2016, , 57-87.		1
2675	Expression of Oncodrivens HER-3 and C-MET during Breast Tumorigenesis in BRCA Mutation Carriers. Journal of Medical & Surgical Pathology, 2016, 01, .	0.2	0
2677	Molecular Detection of BRCA1 and BRCA2 Mutation in Breast Cancer Patients in Erbil Using PCR Techniques. Journal of Zankoy Sulaimani - Part A, 2016, 18, 37-52.	0.1	0
2678	Next-Generation Sequencing Based Testing for Breast Cancer. , 2016, , 299-328.		0

#	ARTICLE	IF	CITATIONS
2679	Follow Up of Patients with Germline Mutations in High Risk Predisposition Genes. , 2016, , 53-63.		0
2680	Epithelial Ovarian Cancers: On-Target is Better than Near-Target. Chemotherapy, 2016, 05, .	0.0	0
2681	Breast and Ovarian Cancer in Young Women of the Arabian Gulf Region: Relationship to Age. Open Journal of Epidemiology, 2016, 06, 173-182.	0.4	1
2682	Inherited Breast Cancer. , 2016, , 315-327.		0
2683	Management of the Patient with a Genetic Predisposition for Breast Cancer. , 2016, , 575-592.		0
2686	Imaging and clinicopathological characteristics of breast cancer among women under the age of 40 years. Journal of the Faculty of Medicine, Baghdad, 2016, 58, 20-25.	0.1	0
2688	Genetics of Ovarian Carcinomas. , 2017, , 13-31.		0
2689	Medical Management of Breast Cancer in BRCA Mutation Carriers. , 2017, , 135-150.		0
2690	Therapeutische Grundlagen in der gynÄkologischen Onkologie. , 2017, , 183-253.		0
2691	High-Risk Multimodality Screening. , 2017, , 329-335.		0
2692	Peking University - Juntendo University Joint Symposium on Cancer Research and Treatment. Juntendo Medical Journal, 2017, 63, 337-339.	0.1	0
2693	Cardiotoxicity During and After Breast Cancer Treatment. , 2017, , 117-126.		0
2695	Hereditary Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 15-35.	0.0	1
2696	The Methodology of Meta-Analyses and Its Potential Contribution to Patient Care. , 2017, , 905-913.		0
2697	Comparing Human Breast Cancer with Canine Mammary Cancer. , 2017, , 191-207.		0
2698	Diagnosing Hereditary Cancer Susceptibility Through Multigene Panel Testing. , 2017, , 123-153.		0
2699	Epidemiology of Breast Cancer in Young Women in the Southern part of the Mediterranean Area. Journal of Cancer Epidemiology & Treatment, 2017, 1, 1-7.	0.2	0
2700	Risk-reducing Salpingoâ€“Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. Anticancer Research, 2017, 37, 5241-5248.	1.1	11

#	ARTICLE	IF	CITATIONS
2701	Association of genetic polymorphism with the mutation status of the BRCA1/2 genes in spontaneous breast cancer. Biopolymers and Cell, 2017, 33, 393-400.	0.4	1
2704	Care for BRCA1 and BRCA2 gene carriers from the gynecologist's point of view. Onkologie (Czech) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	0
2705	Which Environment Makes Cancer?. Oncology Research and Reviews, 2018, 1, .	0.2	1
2706	Breast Cancer Detection and Diagnosis. Advances in Medical Diagnosis, Treatment, and Care, 2018, , 1-27.	0.1	1
2707	What Underlies the Observed Hospital Volume-Outcome Relationship?. SSRN Electronic Journal, 0, , .	0.4	0
2708	Hereditary breast and ovarian cancer genetics: Genetic testing in Serbia. Pirotski Zbornik, 2018, , 115-140.	0.2	0
2709	Risk-Reducing Surgery and Treatment of Menopausal Symptoms in BRCA Mutation Carriers (and Other) Tj ETQq0 0.0 rgBT /Overlock 10	0.2	0
2710	Morphological and Molecular Approaches to Breast Cancer Risk Assessment. , 2018, , 81-91.		0
2711	éřā/4œ€šā ¹³ ™Ĉāµā-Źĉ™Ĉā®ā-ā,Šæ%±ā,,. Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening	0.1	1
2712	Genetic Susceptibility to Breast cancer in East Azerbaijan, Iran. Biosciences, Biotechnology Research Asia, 2018, 15, 469-473.	0.5	0
2714	Association of E-selectin S128R polymorphism with hereditary breast carcinoma susceptibility in Turkish patients without <i>BRCA1/2</i> germline mutations. Balkan Journal of Medical Genetics, 2018, 21, 27-31.	0.5	3
2716	Evaluation and Management of Adnexal Masses in Postmenopausal Women. Current Women's Health Reviews, 2018, 15, 41-45.	0.2	0
2717	MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT. Problemy Radiatsiinoi Medytsyny Ta Radiobiolohii, 2019, 24, 455-464.	0.3	0
2718	Surveillance of Patients Following Primary Therapy. , 2019, , 387-392.		0
2719	Breast Cancer Prevention. , 2019, , 543-606.		0
2720	Whole-Breast Radiotherapy After Breast-Conserving Surgery. , 2019, , 195-203.		0
2721	Fertility in Women with BRCA1 and 2 Mutations - Do We Need to be Concerned?. Journal of Postgraduate Medicine Education and Research, 2019, 53, 0-0.	0.1	0
2722	Epidemiology, Risk Factors, and Prevention. , 2019, , 39-61.		1

#	ARTICLE	IF	CITATIONS
2723	Breast Cancer With Relevance for Heavy Metals, Mycotoxines, and Pesticides. Advances in Environmental Engineering and Green Technologies Book Series, 2019, , 152-192.	0.4	0
2724	Three Cases of Breast Cancer in a Family with Hereditary Breast and Ovarian Cancer Syndrome Undergoing Risk-reducing Salpingo-oophorectomy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1 1 0.784314mgBT /Ov	0.784314	0
2725	Genetics and Public Health. Advances in Bioinformatics and Biomedical Engineering Book Series, 2019, , 529-546.	0.4	1
2729	Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC). Methods in Molecular Biology, 2020, 2204, 75-89.	0.9	2
2730	Genetics and the Gynecologic Patient. Ochsner Journal, 2020, 20, 446-451.	1.1	3
2731	A Case of HBOC-Breast Cancer Successfully Treated with Chemotherapy after Ovarian Cancer Surgery. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 1059-1064.	0.0	0
2733	Evaluation of breast cancer regarding molecular and immunochemical markers. International Journal of Immunotherapy and Cancer Research, 2020, 6, 001-009.	0.4	1
2735	The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients “ Slovenian population based study. Radiology and Oncology, 2020, 54, 180-186.	1.7	4
2736	Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria. Ecancermedalscience, 2020, 14, 1078.	1.1	3
2737	Assessment of the Risk of Breast Cancer Development Applying NCI Tool among Iraqi Women. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3121-3126.	1.2	0
2738	Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer, 2021, 21, 1154.	2.6	35
2739	Genetics, Epigenetics, and Environmental Interactions. , 2020, , 21-38.		0
2742	Cost Effectiveness of Whole Population BRCA Genetic Screening for Cancer Prevention in Israel. Cancer Prevention Research, 2021, 14, 455-462.	1.5	14
2743	BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic review of the literature. Minerva Ginecologica, 2020, 72, 339-348.	0.8	2
2744	Epidemiology of Breast Cancer (BC) and Its Early Identification via Evolving Machine Learning Classification Tools (MLCT)“A Study. Learning and Analytics in Intelligent Systems, 2020, , 109-119.	0.6	0
2745	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, , .	1.3	0
2746	Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. Journal of Pharmacy and Nutrition Sciences (discontinued), 2020, 10, 46-59.	0.4	0
2747	Hereditary : BRCA and Other. , 2020, , 23-41.		0

#	ARTICLE	IF	CITATIONS
2749	Breast Cancer in Men: Oncology. , 2020, , 85-92.		0
2750	The Immune Landscape in Women Cancers. Cancer Treatment and Research, 2020, 180, 215-249.	0.5	3
2751	Basic Radiobiology and Radiation Physics Primer. , 2020, , 271-279.		0
2752	Cancer awareness at the gynecologist: BRCA mutation. Russian Journal of Human Reproduction, 2020, 26, 59.	0.3	0
2753	Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 9-14.	0.2	0
2754	RAD51C and RAD51D in the hereditary breast and ovarian cancer syndrome. Revista De Medicina De Laboratorio, 2020, , .	0.0	0
2755	Establishing a Program for Young Women at High Risk for Breast Cancer. , 2020, , 35-46.		0
2757	Intellectual Structure and Evolutionary Trends of Precision Medicine Research: Coword Analysis. JMIR Medical Informatics, 2020, 8, e11287.	2.6	4
2758	Evaluation of family history in terms of breast cancer in cases applying for breast ultrasonography. European Dental Research and Biomaterials Journal:, 2021, , .	0.1	0
2759	HEREDITARY BREAST CANCER CURRENT STATE OF PROBLEM. Journal of Clinical Practice, 0, , .	0.6	0
2760	PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations. JCO Precision Oncology, 2021, 5, 1639-1649.	3.0	7
2761	A Review of Breast Cancer Risk Factors in Adolescents and Young Adults. Cancers, 2021, 13, 5552.	3.7	7
2762	CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients. International Journal of General Medicine, 2021, Volume 14, 7647-7657.	1.8	16
2763	Primary multiple BRCA associated breast cancer and ovarian cancer (clinical case). Meditsinskiy Sovet, 2020, , 248-257.	0.5	0
2764	Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. Journal of Pharmacy and Nutrition Sciences (discontinued), 2020, 10, 155-168.	0.4	0
2765	High frequency of BRCA recurrent mutations in a consecutive series of unselected ovarian cancer patients. Romanian Journal of Laboratory Medicine, 2020, 28, 257-266.	0.2	2
2772	Ã©pidÃ©miologie, facteurs de risque, dÃ©pistage. , 2007, , 11-22.		2
2773	Facteurs de risque des cancers du sein familiaux. , 2007, , 23-36.		0

#	ARTICLE	IF	CITATIONS
2774	Mammectomie prophylactique et mutations des gènes BRCA1 ou BRCA2. , 2008, , 145-148.		0
2778	Meme kitle muayenesi: histopatolojik analiz. Online Türk SaĖil Bilimleri Dergisi, 0, , .	0.5	0
2780	AĖanakkale Ėlimizdeki Jinekolojik Kanserlerde Yeni Nesil DNA Dizi Analizi ile Saptanan Mutasyon Profilleri. UludaĖ Ėniversitesi Tıp Fakóltesi Dergisi, 0, , .	0.3	0
2781	Genetic epidemiology and primary care. British Journal of General Practice, 2006, 56, 214-21.	1.4	7
2783	BRCA phenocopies or ascertainment bias?. Journal of Medical Genetics, 2007, 44, e86; author reply e88.	3.2	8
2785	Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Medicine, 2007, 1, e92-8.	1.5	17
2786	Breast cancer prevention in women with a BRCA1 or BRCA2 mutation. Open Medicine, 2007, 1, e184-90.	1.5	3
2787	Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario. Canadian Family Physician, 2012, 58, e258-66.	0.4	7
2788	The CRM1 nuclear export protein in normal development and disease. International Journal of Biochemistry and Molecular Biology, 2012, 3, 137-51.	0.1	73
2789	Sequence Variants of BRCA1 and BRCA2 Genes in Four Iranian Families with Breast and Ovarian Cancer. Iranian Journal of Public Health, 2011, 40, 57-66.	0.5	9
2790	BRCA1 Gene Mutations in Breast Cancer Patients from Kerman Province, Iran. Iranian Journal of Cancer Prevention, 2012, 5, 210-5.	0.7	7
2792	Association between RAD51 polymorphism and breast cancer susceptibility: a meta analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 2326-33.	1.3	2
2793	Predictors for contralateral prophylactic mastectomy in breast cancer patients. International Journal of Clinical and Experimental Pathology, 2015, 8, 3748-64.	0.5	19
2795	FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer. International Journal of Clinical and Experimental Pathology, 2015, 8, 10192-203.	0.5	4
2796	Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications. Translational Cancer Research, 2015, 4, 3-13.	1.0	57
2798	Awareness of Risk Factors, Symptoms and Time to Seek Medical Help of Ovarian Cancer amongst Omani Women Attending Teaching Hospital in Muscat Governorate, Oman. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1833-1843.	1.2	6
2799	Ceramide synthase 6 predicts poor prognosis and activates the AKT/mTOR/4EBP1 pathway in high-grade serous ovarian cancer. American Journal of Translational Research (discontinued), 2020, 12, 5924-5939.	0.0	2
2800	Tumorigenesis-related key genes in adolescents and young adults with HR(+)/HER2(-) breast cancer. International Journal of Clinical and Experimental Pathology, 2020, 13, 2701-2709.	0.5	3

#	ARTICLE	IF	CITATIONS
2801	The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma. American Journal of Cancer Research, 2021, 11, 1754-1769.	1.4	4
2802	The acceptability of prophylactic mastectomy among lay people and health professionals: A pilot study. Revue Europeenne De Psychologie Appliquee, 2021, 71, 100714.	0.8	1
2803	Tubal histopathological abnormalities in <i>BRCA1/2</i> mutation carriers undergoing prophylactic salpingo-oophorectomy: a caseâ€control study. International Journal of Gynecological Cancer, 2022, 32, 41-47.	2.5	2
2804	High Poly(ADP-Ribose) Polymerase Expression Does Relate to Poor Survival in Solid Cancers: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 5594.	3.7	3
2805	Costâ€utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. European Journal of Health Economics, 2022, 23, 807-821.	2.8	9
2806	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. Genetics in Medicine, 2022, 24, 119-129.	2.4	10
2807	Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review. OncoTargets and Therapy, 2021, Volume 14, 5363-5372.	2.0	2
2808	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology, 2022, 33, 276-287.	1.2	68
2809	Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline <i>BRCA1/2</i> Mutation Carriers: A Retrospective Cohort Study. Yonsei Medical Journal, 2021, 62, 1090.	2.2	6
2810	Preventive population genomics: The model of BRCA related cancers. Advances in Genetics, 2021, 108, 1-33.	1.8	1
2811	Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic. Breast Cancer Research and Treatment, 2022, 192, 375-383.	2.5	5
2812	Ovarian cancer and KISS-1 gene expression: A consideration of the use of Kisspeptin plus Kisspeptin aptamers in diagnostics and therapy. European Journal of Pharmacology, 2022, 917, 174752.	3.5	2
2813	Inherited rare and common variants in PTCH1 and PTCH2 contributing to the predisposition to reproductive cancers. Gene, 2022, 814, 146157.	2.2	4
2815	Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. International Journal of Molecular Sciences, 2022, 23, 1205.	4.1	13
2816	What underlies the observed hospital volume-outcome relationship?. BMC Health Services Research, 2022, 22, 70.	2.2	2
2817	Schleichera oleosa Seed Extract Reduced the Proliferation of Breast Cancer by Regulating the BRCA1 and p16 Genes. Asian Pacific Journal of Cancer Prevention, 2022, 23, 151-160.	1.2	1
2818	Association of Hormonal Contraceptive Use With Adverse Health Outcomes. JAMA Network Open, 2022, 5, e2143730.	5.9	24
2819	Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. The Lancet Healthy Longevity, 2022, 3, e54-e66.	4.6	9

#	ARTICLE	IF	CITATIONS
2820	Perspectives on the role of breast cancer susceptibility gene in breast cancer. International Journal of Clinical Oncology, 2022, 27, 495-511.	2.2	1
2821	The Prevalence and Death Risk of Male Breast Cancer: A Study Based on the Surveillance, Epidemiology, and End Results Database. American Journal of Men's Health, 2022, 16, 155798832210748.	1.6	1
2822	Prophylactic mastectomy â€“ Correlation between skin flap thickness and residual glandular tissue evaluated postoperatively by imaging. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2022, , .	1.0	4
2823	Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer. Gynecologic Oncology, 2022, 164, 415-420.	1.4	2
2824	Feasibility of targeted cascade genetic testing in the family members ofÂBRCA1/2 geneÂpathogenic variant/likely pathogenic variant carriers. Scientific Reports, 2022, 12, 1842.	3.3	5
2825	Breast Cancer Risk Assessment and Management of the High-Risk Patient. Obstetrics and Gynecology Clinics of North America, 2022, 49, 87-116.	1.9	3
2826	Therapeutische Grundlagen in der gynÃkologischen Onkologie. , 2021, , 179-254.		0
2827	Hereditary breast cancer â€“ what we have learned in the last decade. Mastology, 0, 31, .	0.1	1
2828	A Web Screening on Training Initiatives in Cancer Genomics for Healthcare Professionals. Genes, 2022, 13, 430.	2.4	2
2829	Perspectives of Health Professionals Towards Neonatal Genetic Screening. Current Pharmacogenomics and Personalized Medicine, 2022, 19, .	0.2	0
2830	Breast Cancer in Black Women: Racial/Ethnic Disparities Affecting Survival. Journal of Women's Health, 2022, 31, 1255-1261.	3.3	1
2831	Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies. Frontiers in Pharmacology, 2022, 13, 823572.	3.5	9
2832	Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria. Scientific Reports, 2022, 12, 2507.	3.3	8
2833	Identification of Some Breast Cancer Related Genes by RAPD Technique in Maysan Province, Iraq. Revista Bionatura, 2022, 7, 1-8.	0.4	0
2834	Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology, 2022, , .	1.3	1
2835	Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant. Journal of Clinical Gastroenterology, 2023, 57, 317-323.	2.2	3
2836	Machine-learning of complex evolutionary signals improves classification of SNVs. NAR Genomics and Bioinformatics, 2022, 4, lqac025.	3.2	4
2837	Genetic variants associated with sepsis. PLoS ONE, 2022, 17, e0265052.	2.5	3

#	ARTICLE	IF	CITATIONS
2838	Combining Breast and Ovarian Operations Increases Complications. Plastic and Reconstructive Surgery, 2022, 149, 1050-1059.	1.4	0
2839	Habitat Analysis of Breast Cancer-Enhanced MRI Reflects BRCA1 Mutation Determined by Immunohistochemistry. BioMed Research International, 2022, 2022, 1-9.	1.9	2
2840	Needlescopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: peri-operative outcomes and psychological impact. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 273, 1-6.	1.1	2
2841	The surgical menopause. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 81, 111-118.	2.8	7
2842	Cancer Anxiety Mediates the Association Between Satisfaction With Medical Communication and Psychological Quality of Life After Prophylactic Bilateral Salpingo-Oophorectomy. Frontiers in Psychology, 2022, 13, 840931.	2.1	2
2843	Toward a better understanding of the experience of patients with moderate penetrance breast cancer gene pathogenic/likely pathogenic variants: A focus on <i>ATM</i> and <i>CHEK2</i> . Journal of Genetic Counseling, 2022, , .	1.6	3
2844	BRCA1: An Endocrine and Metabolic Regulator. Frontiers in Endocrinology, 2022, 13, 844575.	3.5	5
2846	Familial breast cancer, pregnancy and cardiotoxicity associated with the use of doxorubicin and reaction with trastuzumab. Journal of Oncology Pharmacy Practice, 2022, 28, 1893-1897.	0.9	1
2847	“It was a no-brainer” A qualitative study of factors driving previvors’ decision-making when considering risk-reducing salpingectomy with delayed oophorectomy. Gynecologic Oncology Reports, 2022, 40, 100948.	0.6	2
2848	The functional impact of BRCA1 BRCT domain variants using multiplexed DNA double-strand break repair assays. American Journal of Human Genetics, 2022, 109, 618-630.	6.2	8
2849	Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients. International Journal of Environmental Research and Public Health, 2022, 19, 4314.	2.6	5
2850	Genetics and Gynaecological Disease. , 2021, , 483-490.		0
2851	A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer. Frontiers in Genetics, 2021, 12, 742578.	2.3	9
2852	Peculiarities of BRCA1/2 testing in patients with advanced HER2-negative breast cancer in the Russian Federation (results of a survey of Russian oncologists). Malignant Tumours, 2021, 11, 38-44.	0.5	0
2853	Homologous Recombination Deficiencies and Hereditary Tumors. International Journal of Molecular Sciences, 2022, 23, 348.	4.1	27
2854	Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature). Klinicheskaya Laboratornaya Diagnostika, 2021, 66, 760-767.	0.5	2
2855	Current status of AYA-generation breast cancer: trends worldwide and in Japan. International Journal of Clinical Oncology, 2022, 27, 16-24.	2.2	3
2856	Oral contraceptives and risk of breast cancer and ovarian cancer in women with a <i>BRCA1</i> or <i>BRCA2</i> mutation: a meta-analysis of observational studies. Carcinogenesis, 2022, 43, 231-242.	2.8	8

#	ARTICLE	IF	CITATIONS
2857	Differences in age at diagnosis of ovarian cancer for each <i>BRCA</i> mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	7
2858	MRI Breast: Current Imaging Trends, Clinical Applications, and Future Research Directions. <i>Current Medical Imaging</i> , 2022, 18, 1347-1361.	0.8	6
2859	Common Variant in <i>ALDH2</i> Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in <i>BRCA2</i> . <i>JCO Precision Oncology</i> , 2022, 6, e2100450.	3.0	1
2870	Hereditary Ovarian and Endometrial Cancer. , 0, , 207-214.		0
2871	The Genetic Background of Hereditary Tumor Diseases. , 0, , 25-39.		0
2874	MicroRNA-199a-3p promotes drug sensitivity in triple negative breast cancer by down-regulation of .. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 2021-2036.	0.0	0
2876	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	2.5	3
2877	Deoxyribonucleic Acid Damage Response Defects. <i>Advances in Oncology</i> , 2022, 2, 195-211.	0.2	0
2878	Whole-Genome Sequencing Identifies <i>PPARGC1A</i> as a Putative Modifier of Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. <i>Cancers</i> , 2022, 14, 2350.	3.7	1
2879	The Landscape of Personalized Medicine in Gynecologic Cancer. <i>Advances in Oncology</i> , 2022, 2, 99-105.	0.2	1
2880	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, 64.	5.2	3
2884	Comparison of Outcomes Between <i>BRCA</i> Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 4706-4713.	1.5	9
2885	Mutations in exon 11 (11.1 and 11.2) of the <i>BRCA1</i> gene and risk factors for breast cancer in Burkina Faso. <i>Journal of Public Health in Africa</i> , 2022, 13, .	0.4	1
2886	Ovarian Masses in Patients With Breast Cancer. <i>Journal of Computer Assisted Tomography</i> , 0, Publish Ahead of Print, .	0.9	0
2887	Implementation of preventive and predictive <i>BRCA</i> testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
2888	Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	1.3	14
2889	Breast Cancer With Relevance for Heavy Metals, Mycotoxines, and Pesticides. , 2022, , 357-397.		0
2890	Olaparib Induces <i>RPL5/RPL11</i> -Dependent <i>p53</i> Activation via Nucleolar Stress. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	2

#	ARTICLE	IF	CITATIONS
2891	Making Biomarkers Relevant to Healthcare Innovation and Precision Medicine. Processes, 2022, 10, 1107.	2.8	6
2894	Mechanistic Effects of Estrogens on Breast Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 224-240.	2.0	8
2895	Genomic characterization of lymphomas in patients with inborn errors of immunity. Blood Advances, 2022, 6, 5403-5414.	5.2	12
2896	Association of <sc>BRCA1</sc> /2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis. Journal of Obstetrics and Gynaecology Research, 0, , .	1.3	2
2897	Founder &BRCA1& mutations in Nepalese population. Journal of Pathology and Translational Medicine, 2022, 56, 212-216.	1.1	2
2898	Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk Reducing Mastectomy and Breast Reconstruction. Plastic and Reconstructive Surgery, 0, Publish Ahead of Print, .	1.4	1
2899	PhenGenVar: A User-Friendly Genetic Variant Detection and Visualization Tool for Precision Medicine. Journal of Personalized Medicine, 2022, 12, 959.	2.5	3
2900	Experience with olaparib in a patient with luminal HER2-positive metastatic breast cancer. Meditsinskiy Sovet, 2022, , 179-184.	0.5	0
2901	Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine. Cancers, 2022, 14, 2860.	3.7	38
2902	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Cancers, 2022, 14, 2950.	3.7	9
2903	Modern Breast Cancer Surgery 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathology and Oncology Research, 0, 28, .	1.9	6
2904	Harnessing the DNA Repair Pathway in Breast Cancer: Germline Mutations/Polymorphisms in Breast Radiation. Seminars in Radiation Oncology, 2022, 32, 298-302.	2.2	1
2905	Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas. Clinical and Experimental Vaccine Research, 2022, 11, 163.	2.2	0
2906	The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo. Reports of Practical Oncology and Radiotherapy, 2022, 27, 303-309.	0.6	0
2907	Risk of pancreatic ductal adenocarcinoma associated with carriage of BRCA1 and/or BRCA2 mutation: A systematic review and meta-analysis. Journal of Surgical Oncology, 0, , .	1.7	1
2909	Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers. BMC Cancer, 2022, 22, .	2.6	6
2910	Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. International Journal of Environmental Research and Public Health, 2022, 19, 8113.	2.6	48
2911	From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. Cancers, 2022, 14, 3469.	3.7	5

#	ARTICLE	IF	CITATIONS
2912	Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value. <i>Frontiers in Cell and Developmental Biology</i> , 0, 9, .	3.7	6
2913	Prevalence of <i>BRCA1</i> Mutation Carriers among U.S. Non-Hispanic Whites. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 2078-2083.	2.5	104
2914	Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 98-107.	2.5	238
2915	Minority Recruitment in Hereditary Breast Cancer Research. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1146-1155.	2.5	36
2916	Genetics in Clinical Cancer Care: A Promise Unfulfilled among Minority Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1683-1686.	2.5	20
2917	Uptake of Offer to Receive Genetic Information about <i>BRCA1</i> and <i>BRCA2</i> Mutations in an Australian Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 2258-2263.	2.5	32
2919	The Identification by Exome Sequencing of Candidate Genes in BRCA-Negative Tunisian Patients at a High Risk of Hereditary Breast/Ovarian Cancer. <i>Genes</i> , 2022, 13, 1296.	2.4	2
2920	Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care. <i>JAMA Network Open</i> , 2022, 5, e2222092.	5.9	10
2921	Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants. <i>Journal of Human Genetics</i> , 0, , .	2.3	1
2922	Fertility Intentions Following Testing for a <i>BRCA1</i> Gene Mutation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 733-740.	2.5	43
2923	Functional Evaluation and Cancer Risk Assessment of BRCA2 Unclassified Variants. <i>Cancer Research</i> , 2005, 65, 417-426.	0.9	96
2924	Physical activity and sleep behaviour in women carrying BRCA1/2 mutations. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
2925	Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts. <i>Frontiers in Genetics</i> , 0, 13, .	2.3	67
2926	Rare germline <i>ATM</i> variants of uncertain significance in chronic lymphocytic leukaemia and other cancers. <i>British Journal of Haematology</i> , 0, , .	2.5	1
2927	What Causes Cancer in Women with a gBRCA Pathogenic Variant? Counselors' Causal Attributions and Associations with Perceived Control. <i>Genes</i> , 2022, 13, 1399.	2.4	2
2928	Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer. <i>Genes and Diseases</i> , 2023, 10, 1005-1018.	3.4	4
2929	Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. <i>Breast</i> , 2022, 65, 145-150.	2.2	6
2930	Ethnic predisposition, risk factors and breast cancer presentation; a 10-year data. Single centered prospective cohort study from Karachi. <i>Annals of Medicine and Surgery</i> , 2022, 82, .	1.1	2

#	ARTICLE	IF	CITATIONS
2931	Histopathological characterization of carcinoma breast with BRCA1/2 sequence variation in a Tertiary Care Center in Kerala, South India. Biomedical and Biotechnology Research Journal, 2022, 6, 117.	0.6	0
2932	An Integrated Clinico-Radiogenomic Screening Program for the Identification of BRCA 1/2 Carriers: A Cost-Effectiveness Analysis(e-PROBE Study). SSRN Electronic Journal, 0, , .	0.4	0
2934	Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients. Frontiers in Oncology, 0, 12, .	2.8	0
2935	Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution. BMC Medicine, 2022, 20, .	5.5	2
2936	Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study. PLoS ONE, 2022, 17, e0275015.	2.5	1
2937	Provider discussion of genetic counseling among high-risk Spanish-preferring Latina breast cancer survivors. Translational Behavioral Medicine, 2022, 12, 900-908.	2.4	2
2938	A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes. Medicine (United States), 2022, 101, e30576.	1.0	2
2939	Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients. Journal of Personalized Medicine, 2022, 12, 1467.	2.5	1
2940	<i>BRCA</i>-associated ovarian cancer: a review of the current literature. Pelvic Surgery and Oncology, 2022, 12, 56-62.	0.4	0
2941	Breastfeeding reduces the risk of breast cancer: A call for action in high-income countries with low rates of breastfeeding. Cancer Medicine, 2023, 12, 4616-4625.	2.8	19
2942	Gene-specific machine learning model to predict the pathogenicity of BRCA2 variants. Frontiers in Genetics, 0, 13, .	2.3	3
2943	Segregation analysis of 17,425 population-based breast cancer families: Evidence for genetic susceptibility and risk prediction. American Journal of Human Genetics, 2022, 109, 1777-1788.	6.2	12
2944	DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex. Cancers, 2022, 14, 5278.	3.7	15
2945	Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy. Molecular Genetics & Genomic Medicine, 0, , .	1.2	1
2946	Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2â€Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel. Breast, 2022, 66, 236-244.	2.2	1
2947	Effects of Exposure to an Entertainment-Based Genetic Testing Narrative on Genetic Testing Knowledge, Attitudes and Counseling Discussion Intentions. Journal of Health Communication, 2022, 27, 510-519.	2.4	0
2948	Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma. Cancer, 0, , .	4.1	3
2949	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. Current Women's Health Reviews, 2022, 19, .	0.2	0

#	ARTICLE	IF	CITATIONS
2952	Electrochemical biosensors for analysis of DNA point mutations in cancer research. Analytical and Bioanalytical Chemistry, 2023, 415, 1065-1085.	3.7	11
2953	Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways. Seminars in Cancer Biology, 2022, 86, 1186-1202.	9.6	8
2954	Genes and cancer: Genetic counselling and clinical management. , 2023, , 521-559.e6.		0
2955	Loss of Heterozygosity of <i>BRCA1/2</i> as a Predictive Marker for Talazoparib Response. Anticancer Research, 2022, 42, 5257-5263.	1.1	0
2956	Nucleic acid vaccination strategies for ovarian cancer. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	4
2957	Systematic mapping review of guidelines for <i>BRCA1/2</i> genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer. International Journal of Gynecological Cancer, 2023, 33, 250-256.	2.5	1
2958	Breast Cancer Pathology in the Era of Genomics. Hematology/Oncology Clinics of North America, 2023, 37, 33-50.	2.2	2
2959	BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy. Biomedicine and Pharmacotherapy, 2023, 158, 114090.	5.6	2
2960	Analyzing the effects of BRCA1/2 variants on mRNA splicing by minigene assay. Journal of Human Genetics, 0, , .	2.3	1
2962	Sensitive electrochemical detection of polymorphisms in IL6 and TGF β 1 genes from ovarian cancer DNA patients using EcoRI and DNA hairpin-modified gold electrodes. Mikrochimica Acta, 2023, 190, .	5.0	9
2963	Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1 α 2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients α ™ Satisfaction of Multiple Surgeries. Journal of Clinical Medicine, 2022, 11, 7502.	2.4	0
2964	Gene of the month: PALB2. Journal of Clinical Pathology, 0, , jcp-2022-208461.	2.0	1
2965	A global perspective on the ethnic-specific BRCA variation and its implication in clinical application. Journal of the National Cancer Center, 2022, , .	7.4	0
2966	The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows. International Journal of Molecular Sciences, 2023, 24, 764.	4.1	7
2967	A systematic review on the association between ovarian and prostate cancer with α BRCA1 α and α BRCA2 α gene. Siberian Journal of Oncology, 2023, 21, 145-155.	0.3	0
2968	Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p/BRCA1 axis. Frontiers in Pharmacology, 0, 13, .	3.5	3
2969	Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes. Scientific Reports, 2023, 13, .	3.3	0
2970	PROFLAKT α K SALP α NGO-OFOREKTOM α YAPILAN A α LEV α MEME VE OVER KANSER SENDROMLU HASTALARDA KL α N α K BULGULAR FARKLI MIDIR ?. Kocatepe T α p Dergisi, 2023, 24, 57-61.	0.1	0

#	ARTICLE	IF	CITATIONS
2971	Involvement of <i>ERCC1</i> (<i>rs3212986</i>) and <i>ERCC2</i> (<i>rs1799793</i> , <i>rs13181</i>) polymorphisms of DNA repair genes in breast cancer occurrence in Burkina Faso. <i>Molecular Genetics & Genomic Medicine</i> , 0, , .	1.2	1
2972	Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients. <i>Menopause</i> , 0, Publish Ahead of Print, .	2.0	2
2973	Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria. <i>Gynecologic Oncology</i> , 2023, 170, 32-37.	1.4	0
2974	Ovarian cancer onset across different <i>BRCA</i> mutation types: a view to a more tailored approach for <i>BRCA</i> mutated patients. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003893.	2.5	2
2975	Performance Evaluation of <i>BRCA1/2</i> Genetic Test Using Next-Generation Sequencing Based on Target Capture Method. , 2022, 44, 216-225.		0
2976	Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. <i>BMC Cancer</i> , 2022, 22, .	2.6	4
2977	Implications of BRCA1 and BRCA2 Mutations in Mexico. , 0, , .		0
2978	Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs. <i>Npj Precision Oncology</i> , 2023, 7, .	5.4	9
2979	Comparative analysis of the effectiveness of neoadjuvant systemic therapy and primary surgical treatment of patients with <i>BRCA</i> -associated triple-negative T1 breast cancer. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2023, 14, 33-42.	0.2	0
2980	Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2023, 62, 66-70.	1.3	5
2982	Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic. <i>Cancers</i> , 2023, 15, 1072.	3.7	0
2983	Breast Cancer Disease Exploitation to Recure a Healthy Lifestyle. , 2022, , 2617-2635.		0
2984	Bilateral prophylactic mastectomy: should we preserve the pectoral fascia? Protocol of a Dutch double blinded, prospective, randomised controlled pilot study with a within-subject design (PROFAS). <i>BMJ Open</i> , 2023, 13, e066728.	1.9	1
2985	Frequency and distribution of BRCA1/BRCA2 large genomic rearrangements in Turkish population with breast cancer. <i>Journal of Human Genetics</i> , 0, , .	2.3	2
2986	Epithelial Ovarian Cancer. , 2022, , 291-323.		1
2987	Functional Analyses of Rare Germline Missense BRCA1 Variants Located within and outside Protein Domains with Known Functions. <i>Genes</i> , 2023, 14, 262.	2.4	2
2988	Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 41-51.	3.1	1
2989	Hereditary Women's Cancer: Management and Risk-Reducing Surgery. <i>Medicina (Lithuania)</i> , 2023, 59, 300.	2.0	4

#	ARTICLE	IF	CITATIONS
2990	Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review. Journal of Clinical Medicine, 2023, 12, 1422.	2.4	4
2991	Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC). Journal of Clinical Medicine, 2023, 12, 1524.	2.4	11
2992	The necessity of incorporating non-genetic risk factors into polygenic risk score models. Scientific Reports, 2023, 13, .	3.3	3
2993	Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification. JCO Precision Oncology, 2023, , .	3.0	4
2994	Update of penetrance estimates in Birt-Hogg-Dubé syndrome. Journal of Medical Genetics, 2023, 60, 317-326.	3.2	5
2995	Imaging Recommendations for Diagnosis, Staging, and Management of Hereditary Malignancies. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.2	0
2996	BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations. Climacteric, 2023, 26, 154-160.	2.4	1
2997	Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers, 2023, 15, 1625.	3.7	4
2998	Renin Angiotensin System (RAS): The Common Thread Between Cancer and Heart Failure. , 2023, , 429-449.		0
2999	Prophylactic salpingectomy with delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in BRCA1/2 mutation carriers: women's point of view. Menopause, 0, Publish Ahead of Print, .	2.0	0
3001	Clinical case study meets population cohort: identification of a BRCA1 pathogenic founder variant in Orcadians. European Journal of Human Genetics, 2023, 31, 588-595.	2.8	1
3002	Clinical characteristics and survival of second primary breast carcinoma with extramammary malignancies. Frontiers in Oncology, 0, 13, .	2.8	0
3003	Other Syndromes and Genes Associated with Gastric Cancer Predisposition. , 2023, , 99-116.		0
3004	Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study. Swiss Medical Weekly, 2023, 153, 40055.	1.6	0
3005	Molecular Diagnostics of Oncological Disease: Prospects for the Development of a Reference Material for the HER2 gene Content. Reference Materials, 2023, 19, 5-17.	0.5	0
3007	Radiological Features of B3 Lesions in Mutation Carrier Patients: A Single-Center Retrospective Analysis. Applied Sciences (Switzerland), 2023, 13, 4994.	2.5	2
3008	Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells. ELife, 0, 12, .	6.0	1
3009	Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. British Journal of Cancer, 2023, 128, 2283-2294.	6.4	2

#	ARTICLE	IF	CITATIONS
3010	Décision et jugement médicaux en situation de forte incertitude: l'exemple de deux pratiques cliniques à l'épreuve de la génétique. Sciences Sociales Et Sante, 2008, Vol. 26, 33-66.	0.3	0
3011	An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series. Cureus, 2023, , .	0.5	1
3012	The Role of NQO1 in Ovarian Cancer. International Journal of Molecular Sciences, 2023, 24, 7839.	4.1	12
3013	The role of social support and stress coping strategies in genetic screening for cancer predisposition – BRCA testing as an example. Polish Annals of Medicine, 2023, 30, 15-24.	0.3	0
3014	Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer. Frontiers in Oncology, 0, 13, .	2.8	1
3015	Breast cancer screening in young women. Opuholi Zenskoj Reproktivnoj Sistemy, 2023, 18, 32-37.	0.4	0
3016	Targeting DNA damage repair precision medicine strategies in cancer. Current Opinion in Pharmacology, 2023, 70, 102381.	3.5	2
3017	Nontoxic Natural Products as Regulators of Tumor Suppressor Gene Function. , 2023, , 229-256.		0
3018	An overview of the research progress of BRCA gene mutations in breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188907.	7.4	4
3019	Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers. Menopause, 2023, 30, 732-737.	2.0	0
3020	Perspectives and possibilities of preserving reproductive function in patients receiving antitumor treatment. Clinical observation. , 2023, 3, 16-19.		0
3021	Mammary Glands of Women, Female Dogs and Female Rats: Similarities and Differences to Be Considered in Breast Cancer Research. Veterinary Sciences, 2023, 10, 379.	1.7	3
3022	Links between gender norms and the intergenerational transmission of health information in parents carrying BRCA1/2 pathogenic variants. Journal of Genetic Counseling, 0, , .	1.6	0
3023	“Earlier than Early”™ Detection of Breast Cancer in Israeli BRCA Mutation Carriers Applying AI-Based Analysis to Consecutive MRI Scans. Cancers, 2023, 15, 3120.	3.7	0
3024	Synchronous and Metachronous Breast and Ovarian Cancers: Experience from a Single Tertiary Care Cancer Centre in India. Indian Journal of Surgical Oncology, 2023, 14, 809-821.	0.7	0
3025	<i>BRCA1</i>-specific machine learning model predicts variant pathogenicity with high accuracy. Physiological Genomics, 2023, 55, 315-323.	2.3	1
3026	Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium. Breast Cancer Research, 2023, 25, .	5.0	0
3027	Role of Biomarkers in Cancer Prevention and Therapy. , 2023, , 179-195.		0

#	ARTICLE	IF	CITATIONS
3028	Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations. BMC Cancer, 2023, 23, .	2.6	1
3029	Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Frontiers in Oncology, 0, 13, .	2.8	3
3031	BRCT Domains: Structure, Functions, and Implications in Diseaseâ€”New Therapeutic Targets for Innovative Drug Discovery against Infections. Pharmaceuticals, 2023, 15, 1839.	4.5	4
3032	Evaluation des Nutzens. , 2023, , 37-179.		0
3033	Cuproptosis-related lncRNAs potentially predict prognosis and therapy sensitivity of breast cancer. Frontiers in Pharmacology, 0, 14, .	3.5	2
3034	miR-34a-FOXP1 Loop in Ovarian Cancer. ACS Omega, 0, , .	3.5	0
3035	Clinical Background of Breast Cancer. , 2023, , 1-6.		0
3036	Comparison of Survival Outcomes in Young Patients With Breast Cancer Receiving Contralateral Prophylactic Mastectomy Versus Unilateral Mastectomy. Clinical Breast Cancer, 2023, 23, 752-762.e7.	2.4	2
3037	Breast cancer screening in germline mutation carriers. A literature review. Opuholi Zenskoj Reproktivnoy Sistem, 2023, 19, 16-24.	0.4	1
3039	Molecular biomarkers for facilitating genomeâ€ directed precision medicine in gynecological cancer (Review). Oncology Letters, 2023, 26, .	1.8	0
3040	Predictive genetic testing in multifactorial disorders. , 2023, , 241-273.		0
3042	Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients. Breast Cancer Research and Treatment, 0, , .	2.5	0
3043	BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis. BMC Cancer, 2023, 23, .	2.6	1
3044	A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2. Human Mutation, 2023, 2023, 1-17.	2.5	0
3045	Mosaic<i>BRCA1</i> promoter methylation contribution in hereditary breast/ovarian cancer pedigrees. Journal of Medical Genetics, 0, , jmg-2023-109325.	3.2	2
3046	Polygenic scores in cancer. Nature Reviews Cancer, 2023, 23, 619-630.	28.4	7
3047	<i>Saccharomyces cerevisiae</i> as a research tool for <sc>RNA</sc>-mediated human disease. Wiley Interdisciplinary Reviews RNA, 2024, 15, .	6.4	1
3048	DNA repair function scores for 2172 variants in the BRCA1 amino-terminus. PLoS Genetics, 2023, 19, e1010739.	3.5	1

#	ARTICLE	IF	CITATIONS
3049	The preimplantation genetic testing for monogenic disorders strategy for blocking the transmission of hereditary cancers through haplotype linkage analysis by karyomapping. Journal of Assisted Reproduction and Genetics, 0, , .	2.5	0
3050	Assessment of medical knowledge toward genetic testing for individuals with hereditary breast and ovarian cancer syndrome in Brazil. Preventive Medicine Reports, 2023, 35, 102356.	1.8	1
3052	A bibliometric study of the top 100 most cited papers on aging and cancer. Medicine (United States), 2023, 102, e34428.	1.0	1
3053	Male Breast Cancer: Three Case Reports and a Literature Review. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 2154-2162.	1.7	1
3055	Educational Case: Hereditary breast and ovarian cancers. Academic Pathology, 2023, 10, 100091.	1.1	0
3056	Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls. Frontiers in Genetics, 0, 14, .	2.3	0
3057	October Breast Cancer Awareness Month: Emphasizing Equity in Access to Early Detection. Onco'zine, 0, , .	0.0	0
3058	Ascertainment Bias. , 2023, , 19-21.		0
3059	Emerging evidence on the role of breast microbiota on the development of breast cancer in high-risk patients. Carcinogenesis, 0, , .	2.8	0
3062	Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer. Uspehi Molekularnoj Onkologii, 2023, 10, 8-14.	0.3	0
3063	Clinical Significance of the TK1-Specific Activity in the Early Detection of Ovarian Cancer. Oncology, 2024, 102, 17-29.	1.9	0
3064	Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus. Breast Cancer Research and Treatment, 2024, 203, 307-315.	2.5	0
3066	The BRCA1 c.4096+1G>A Is a Founder Variant Which Originated in Ancient Times. International Journal of Molecular Sciences, 2023, 24, 15507.	4.1	0
3067	The incidence of risk factors for developing breast cancer. European Journal of Midwifery, 2023, 7, .	1.1	0
3068	Structural basis for stabilisation of the RAD51 nucleoprotein filament by BRCA2. Nature Communications, 2023, 14, .	12.8	3
3069	Genetic testing and management of prostate cancer patients with pathogenic germline variants. Memo - Magazine of European Medical Oncology, 2024, 17, 51-56.	0.5	0
3070	Counselling and management of women with genetic predisposition to gynaecological cancers. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2024, 294, 44-48.	1.1	0
3071	Concurrent uterine surgery and uptake of hormone therapy in patients undergoing bilateral salpingo-oophorectomy for risk-reducing or therapeutic indications. Gynecologic Oncology, 2023, 179, 131-137.	1.4	0

#	ARTICLE	IF	CITATIONS
3072	Multiplexed assay of variant effect reveals residues of functional importance in the BRCA1 coiled-coil and serine cluster domains. PLoS ONE, 2023, 18, e0293422.	2.5	0
3074	Breast Cancer Screening and Prevention. Annals of Internal Medicine, 2023, 176, ITC161-ITC176.	3.9	2
3076	Analysis of the indispensable RAD51 cofactor BRCA2 in <i>Naganishia liquefaciens</i> , a Basidiomycota yeast. Life Science Alliance, 2024, 7, e202302342.	2.8	0
3077	Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. British Journal of Cancer, 0, , .	6.4	0
3078	Comparing Prognosis for BRCA1, BRCA2, and Non-BRCA Breast Cancer. Cancers, 2023, 15, 5699.	3.7	0
3079	Role of biopsy techniques in breast cancer diagnosis: overview and update. Journal of Radiological Review, 2023, 10, .	0.1	0
3080	Optimal tactics of ovarian and metachronous breast cancer treatment in <i>BRCA</i> mutations carriers. , 2023, 3, 28-34.		0
3081	Male breast cancer: No evidence for mosaic BRCA1 promoter methylation involvement. Breast, 2024, 73, 103620.	2.2	0
3082	RADIATION DETECTION OF BREAST CANCER IN WOMEN WITH A GENETIC PREDISPOSITION OR FAMILY HISTORY (REVIEW). Russian Journal of Oncology, 2013, 18, 46-54.	0.1	1
3083	Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a BRCA1/2 Mutation. Cancers, 2024, 16, 28.	3.7	0
3084	Prophylactic Interventions for Hereditary Breast and Ovarian Cancer Risks and Mortality in BRCA1/2 Carriers. Cancers, 2024, 16, 103.	3.7	0
3085	Development and testing of patient-centered education about hormone replacement therapy for women at high genetic risk of breast and ovarian cancer. Gynecologic Oncology, 2024, 181, 91-98.	1.4	0
3086	Screening in Women With <i>BRCA</i> Mutations Revisited. Journal of Breast Imaging, 2024, 6, 4-13.	1.3	0
3087	Significance of Understanding HBOC for At-Risk Relatives in Prostate and Pancreatic Cancer Patients Who Tested Positive on the Germline BRCA1/2 Genetic Testing in the Current Japanese Healthcare System. , 2023, , 119-127.		0
3088	Implications of Highly Penetrant Genetic Variants on Breast Surgery. Clinical Breast Cancer, 2024, 24, 180-183.	2.4	0
3089	Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status. BMC Medicine, 2024, 22, .	5.5	0
3090	A cost-effectiveness analysis of an integrated clinical-radiogenomic screening program for the identification of BRCA 1/2 carriers (e-PROBE study). Scientific Reports, 2024, 14, .	3.3	0
3091	Male Breast Cancer: a Review on Diagnosis, Treatment, and Survivorship. Current Oncology Reports, 2024, 26, 34-45.	4.0	0

[illegible]